Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,1680635,clearance,The clearance of NNO averaged 7.5 ml/min/kg.,Disposition kinetics and metabolism of nicotine-1'-N-oxide in rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1680635/),[ml] / [kg·min],7.5,3388,DB00184,Nicotine
,1680635,half-life,The half-life averaged 42.6 min and VDss was 0.34 liter/kg.,Disposition kinetics and metabolism of nicotine-1'-N-oxide in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1680635/),min,42.6,3389,DB00184,Nicotine
,1680635,VDss,The half-life averaged 42.6 min and VDss was 0.34 liter/kg.,Disposition kinetics and metabolism of nicotine-1'-N-oxide in rabbits. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1680635/),[l] / [kg],0.34,3390,DB00184,Nicotine
,1680635,oral,"The oral and ip bioavailabilities were 15.1 and 79%, respectively.",Disposition kinetics and metabolism of nicotine-1'-N-oxide in rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1680635/),%,15.1,3391,DB00184,Nicotine
,1680635,bioavailabilities,"The oral and ip bioavailabilities were 15.1 and 79%, respectively.",Disposition kinetics and metabolism of nicotine-1'-N-oxide in rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1680635/),%,79,3392,DB00184,Nicotine
,9114908,mean input time (MIT),"2. The mean input time (MIT) and mean absorption time (MAT) for nicotine following application of NTS for 24 h were 7.7 and 4.2 h, respectively.",Bioavailability and absorption kinetics of nicotine following application of a transdermal system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9114908/),h,7.7,4581,DB00184,Nicotine
,9114908,mean absorption time (MAT),"2. The mean input time (MIT) and mean absorption time (MAT) for nicotine following application of NTS for 24 h were 7.7 and 4.2 h, respectively.",Bioavailability and absorption kinetics of nicotine following application of a transdermal system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9114908/),h,4.2,4582,DB00184,Nicotine
,9114908,apparent,"3. Following NTS removal, the mean apparent nicotine elimination half-life was 2.8 h, compared with 2.0 h following i.v. nicotine, reflecting continued absorption of nicotine following NTS removal.",Bioavailability and absorption kinetics of nicotine following application of a transdermal system. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9114908/),h,2.8,4583,DB00184,Nicotine
,9114908,apparent,"3. Following NTS removal, the mean apparent nicotine elimination half-life was 2.8 h, compared with 2.0 h following i.v. nicotine, reflecting continued absorption of nicotine following NTS removal.",Bioavailability and absorption kinetics of nicotine following application of a transdermal system. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9114908/),h,2.0,4584,DB00184,Nicotine
,9114908,amount,"4. The mean amount of nicotine absorbed from the NTS after the 24 h application was 20.9 mg, which represents about 68% of the amount released from the system; the remaining 32% was lost from the system during daily activities.",Bioavailability and absorption kinetics of nicotine following application of a transdermal system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9114908/),,20.9,4585,DB00184,Nicotine
,9114908,clearance,"6. Following i.v. administration, the mean nicotine clearance was 72 l h-1 (coefficient of variation 29%).",Bioavailability and absorption kinetics of nicotine following application of a transdermal system. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9114908/),[l] / [h],72,4586,DB00184,Nicotine
,8612383,peak plasma level,"Mean (+/- SD) peak plasma level of the last dosing interval was 32.0 +/- 8.7 ng/ml and 34.2 +/- 8.9 ng/ml for the buccal and the pulmonary technique, respectively, achieved after 0.33 and 0.50 (median) hour, respectively.",Dose released and absolute bioavailability of nicotine from a nicotine vapor inhaler. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8612383/),[ng] / [ml],32.0,9269,DB00184,Nicotine
,8612383,peak plasma level,"Mean (+/- SD) peak plasma level of the last dosing interval was 32.0 +/- 8.7 ng/ml and 34.2 +/- 8.9 ng/ml for the buccal and the pulmonary technique, respectively, achieved after 0.33 and 0.50 (median) hour, respectively.",Dose released and absolute bioavailability of nicotine from a nicotine vapor inhaler. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8612383/),[ng] / [ml],34.2,9270,DB00184,Nicotine
,8612383,absolute bioavailability,"The mean (95% confidence interval [CI]) absolute bioavailability of nicotine was 51 (95% CI, 40 to 65) and 56 (95% CI, 47 to 67) when the buccal and pulmonary techniques were used, respectively.",Dose released and absolute bioavailability of nicotine from a nicotine vapor inhaler. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8612383/),,51,9271,DB00184,Nicotine
,8612383,absolute bioavailability,"The mean (95% confidence interval [CI]) absolute bioavailability of nicotine was 51 (95% CI, 40 to 65) and 56 (95% CI, 47 to 67) when the buccal and pulmonary techniques were used, respectively.",Dose released and absolute bioavailability of nicotine from a nicotine vapor inhaler. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8612383/),,56,9272,DB00184,Nicotine
,27935787,Cmax,"In Study 1, Cmax (geometric mean (CV)) during a 5-minute puffing period (10 puffs, 30 seconds apart) was 13.4 (51.4) ng/ ml for a regular cigarette.",E-cigarette Nicotine Delivery: Data and Learnings from Pharmacokinetic Studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27935787/),[ng] / [ml],13.4,9516,DB00184,Nicotine
,27935787,Cmax,The e-cigarette Cmax was significantly lower (p .05) at 2.5 (67.8) ng/ml.,E-cigarette Nicotine Delivery: Data and Learnings from Pharmacokinetic Studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27935787/),[ng] / [ml],2.5,9517,DB00184,Nicotine
,27935787,Cmax,"In Study 2, during a 5-minute ad libitum puffing period, cigarette Cmax was 7.2 (130.8) ng/mL, and it was 7.8 (108.2) ng/mL for the e-cigarette.",E-cigarette Nicotine Delivery: Data and Learnings from Pharmacokinetic Studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27935787/),[ng] / [ml],7.2,9518,DB00184,Nicotine
,27935787,Cmax,"In Study 2, during a 5-minute ad libitum puffing period, cigarette Cmax was 7.2 (130.8) ng/mL, and it was 7.8 (108.2) ng/mL for the e-cigarette.",E-cigarette Nicotine Delivery: Data and Learnings from Pharmacokinetic Studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27935787/),[ng] / [ml],7.8,9519,DB00184,Nicotine
,21626790,t1/2alpha,"The fate of absorption and distribution was two compartment model and the values of t1/2alpha was 170.31 min, t1/2beta was 263.30 min and the AUC(0-infinity) was 2.75 x 10(5) microg x L(-1) min separately.",[Study of pharmacokinetics of nicotine in local brain by using microdialysis and stable labeled isotope]. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21626790/),min,170.31,9889,DB00184,Nicotine
,21626790,t1/2beta,"The fate of absorption and distribution was two compartment model and the values of t1/2alpha was 170.31 min, t1/2beta was 263.30 min and the AUC(0-infinity) was 2.75 x 10(5) microg x L(-1) min separately.",[Study of pharmacokinetics of nicotine in local brain by using microdialysis and stable labeled isotope]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21626790/),min,263.30,9890,DB00184,Nicotine
,21626790,AUC(0-infinity),"The fate of absorption and distribution was two compartment model and the values of t1/2alpha was 170.31 min, t1/2beta was 263.30 min and the AUC(0-infinity) was 2.75 x 10(5) microg x L(-1) min separately.",[Study of pharmacokinetics of nicotine in local brain by using microdialysis and stable labeled isotope]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21626790/),[min·μg] / [l],2.75 x 10(5),9891,DB00184,Nicotine
,7542589,tmax ratio,"The nasal vasoconstrictor, xylometazoline, normalised the extent of the bioavailability of nicotine, but further prolonged the time for absorption to almost twice that measured in the disease-free state, increasing the tmax ratio to 1.72.",Relative bioavailability of nicotine from a nasal spray in infectious rhinitis and after use of a topical decongestant. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7542589/),,1.72,13916,DB00184,Nicotine
,11014406,Nonrenal clearance,"Nonrenal clearance was 1303 mL/min and 661 mL/min in healthy subjects and patients with severe kidney failure, respectively.",Pharmacokinetics of nicotine in kidney failure. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11014406/),[ml] / [min],1303,16758,DB00184,Nicotine
,11014406,Nonrenal clearance,"Nonrenal clearance was 1303 mL/min and 661 mL/min in healthy subjects and patients with severe kidney failure, respectively.",Pharmacokinetics of nicotine in kidney failure. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11014406/),[ml] / [min],661,16759,DB00184,Nicotine
,2894940,half-life,"At the 3 doses of nicotine administered, plasma nicotine half-life ranged from 0.9 to 1.1 hr; total body clearance of nicotine ranged from 2.9 to 3.9 liters.",Pharmacokinetics of nicotine and 12 metabolites in the rat. Application of a new radiometric high performance liquid chromatography assay. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2894940/),h,0.9 to 1.1,16882,DB00184,Nicotine
,2894940,total body clearance,"At the 3 doses of nicotine administered, plasma nicotine half-life ranged from 0.9 to 1.1 hr; total body clearance of nicotine ranged from 2.9 to 3.9 liters.",Pharmacokinetics of nicotine and 12 metabolites in the rat. Application of a new radiometric high performance liquid chromatography assay. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2894940/),l,2.9 to 3.9,16883,DB00184,Nicotine
,2894940,apparent volume of distribution,hr-1.kg-1; and apparent volume of distribution of nicotine from 4.7 to 5.7 liters.,Pharmacokinetics of nicotine and 12 metabolites in the rat. Application of a new radiometric high performance liquid chromatography assay. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2894940/),l,4.7 to 5.7,16884,DB00184,Nicotine
,2894940,half-lives of urinary excretion,"Also at these 3 doses, mean half-lives of urinary excretion of cotinine, cotinine-N-oxide, and allohydroxydemethylcotinine ranged from 4.8 to 5.3 hr, from 7.9 to 8.2 hr, and from 9.9 to 11.0 hr, respectively.",Pharmacokinetics of nicotine and 12 metabolites in the rat. Application of a new radiometric high performance liquid chromatography assay. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2894940/),h,4.8 to 5.3,16885,DB00184,Nicotine
,2894940,half-lives of urinary excretion,"Also at these 3 doses, mean half-lives of urinary excretion of cotinine, cotinine-N-oxide, and allohydroxydemethylcotinine ranged from 4.8 to 5.3 hr, from 7.9 to 8.2 hr, and from 9.9 to 11.0 hr, respectively.",Pharmacokinetics of nicotine and 12 metabolites in the rat. Application of a new radiometric high performance liquid chromatography assay. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2894940/),h,7.9 to 8.2,16886,DB00184,Nicotine
,2894940,half-lives of urinary excretion,"Also at these 3 doses, mean half-lives of urinary excretion of cotinine, cotinine-N-oxide, and allohydroxydemethylcotinine ranged from 4.8 to 5.3 hr, from 7.9 to 8.2 hr, and from 9.9 to 11.0 hr, respectively.",Pharmacokinetics of nicotine and 12 metabolites in the rat. Application of a new radiometric high performance liquid chromatography assay. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2894940/),h,9.9 to 11.0,16887,DB00184,Nicotine
,10945316,renal clearance,"Steady-state plasma mecamylamine concentrations were twice as high (mean, 12.2 versus 6.3 ng/mL), consistent with lower renal clearance (2.1 versus 5.8 mL/min/kg) during alkaline compared with acidic urine conditions.",Nicotine-mecamylamine interactions. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10945316/),[ml] / [kg·min],2.1,21120,DB00184,Nicotine
,10945316,renal clearance,"Steady-state plasma mecamylamine concentrations were twice as high (mean, 12.2 versus 6.3 ng/mL), consistent with lower renal clearance (2.1 versus 5.8 mL/min/kg) during alkaline compared with acidic urine conditions.",Nicotine-mecamylamine interactions. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10945316/),[ml] / [kg·min],5.8,21121,DB00184,Nicotine
,7657849,tmax,The mean nicotine tmax value for the Nicoderm system was significantly shorter (P < .001) than that for Habitrol (2.7 versus 8.6 hours).,Comparison of the pharmacokinetics of two nicotine transdermal systems: nicoderm and habitrol. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7657849/),h,2.7,23306,DB00184,Nicotine
,7657849,tmax,The mean nicotine tmax value for the Nicoderm system was significantly shorter (P < .001) than that for Habitrol (2.7 versus 8.6 hours).,Comparison of the pharmacokinetics of two nicotine transdermal systems: nicoderm and habitrol. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7657849/),h,8.6,23307,DB00184,Nicotine
,3986082,half-lives,"Plasma nicotine concentrations declined in a biphasic manner, the half-lives of the initial and terminal phases averaging 9 min and 133 min respectively.",Nicotine pharmacokinetics and its application to intake from smoking. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3986082/),min,9,28710,DB00184,Nicotine
,3986082,half-lives,"Plasma nicotine concentrations declined in a biphasic manner, the half-lives of the initial and terminal phases averaging 9 min and 133 min respectively.",Nicotine pharmacokinetics and its application to intake from smoking. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3986082/),min,133,28711,DB00184,Nicotine
,3986082,plasma clearance,"The plasma clearance of nicotine and the volume of distribution were very high averaging 915 ml/min and 1731, respectively.",Nicotine pharmacokinetics and its application to intake from smoking. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3986082/),[ml] / [min],915,28712,DB00184,Nicotine
,3986082,volume of distribution,"The plasma clearance of nicotine and the volume of distribution were very high averaging 915 ml/min and 1731, respectively.",Nicotine pharmacokinetics and its application to intake from smoking. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3986082/),,1731,28713,DB00184,Nicotine
,8225689,elimination half-life,"Mean elimination half-life of nicotine after removal of the patches (3.5 +/- 1.8 h for the larger patch and 4.5 +/- 1.9 h for the smaller patch) was longer than reported values after i.v. administration, which was reported to vary between 40 and 120 min.",Transdermal nicotine substitution: pharmacokinetics of nicotine and cotinine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8225689/),h,3.5,32305,DB00184,Nicotine
,8225689,elimination half-life,"Mean elimination half-life of nicotine after removal of the patches (3.5 +/- 1.8 h for the larger patch and 4.5 +/- 1.9 h for the smaller patch) was longer than reported values after i.v. administration, which was reported to vary between 40 and 120 min.",Transdermal nicotine substitution: pharmacokinetics of nicotine and cotinine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8225689/),h,4.5,32306,DB00184,Nicotine
,8225689,elimination half-life,"Mean elimination half-life of nicotine after removal of the patches (3.5 +/- 1.8 h for the larger patch and 4.5 +/- 1.9 h for the smaller patch) was longer than reported values after i.v. administration, which was reported to vary between 40 and 120 min.",Transdermal nicotine substitution: pharmacokinetics of nicotine and cotinine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8225689/),min,40 and 120,32307,DB00184,Nicotine
,9378845,areas under the concentration-time curves from 0 to 24 hours (AUC0-24),"Mean areas under the concentration-time curves from 0 to 24 hours (AUC0-24) for nicotine were 453 +/- 120 ng.hr/mL (day 2), 489 +/- 143 ng.hr/mL (day 3), and 485 +/- 143 ng.hr/mL (day 4).",Plasma levels of nicotine and safety of smokers wearing transdermal delivery systems during multiple simultaneous intake of nicotine and during exercise. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9378845/),[h·ng] / [ml],453,34656,DB00184,Nicotine
,9378845,areas under the concentration-time curves from 0 to 24 hours (AUC0-24),"Mean areas under the concentration-time curves from 0 to 24 hours (AUC0-24) for nicotine were 453 +/- 120 ng.hr/mL (day 2), 489 +/- 143 ng.hr/mL (day 3), and 485 +/- 143 ng.hr/mL (day 4).",Plasma levels of nicotine and safety of smokers wearing transdermal delivery systems during multiple simultaneous intake of nicotine and during exercise. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9378845/),[h·ng] / [ml],489,34657,DB00184,Nicotine
,9378845,areas under the concentration-time curves from 0 to 24 hours (AUC0-24),"Mean areas under the concentration-time curves from 0 to 24 hours (AUC0-24) for nicotine were 453 +/- 120 ng.hr/mL (day 2), 489 +/- 143 ng.hr/mL (day 3), and 485 +/- 143 ng.hr/mL (day 4).",Plasma levels of nicotine and safety of smokers wearing transdermal delivery systems during multiple simultaneous intake of nicotine and during exercise. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9378845/),[h·ng] / [ml],485,34658,DB00184,Nicotine
less,3545615,oral bioavailability,"Based upon physicochemical and pharmacokinetic principles, the oral bioavailability of nicotine would be expected to be less than 20%.",Clinical pharmacokinetics of nicotine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3545615/),%,20,36027,DB00184,Nicotine
,3545615,volume of distribution,Nicotine distributes extensively into body tissues with a volume of distribution ranging from 1.0 to 3.0 L/kg.,Clinical pharmacokinetics of nicotine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3545615/),[l] / [kg],1.0 to 3.0,36028,DB00184,Nicotine
,3545615,Plasma protein binding,"Plasma protein binding is negligible, ranging from 4.9 to 20%.",Clinical pharmacokinetics of nicotine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3545615/),%,4.9 to 20,36029,DB00184,Nicotine
,3545615,Total plasma clearance,Total plasma clearance ranges from 0.92 to 2.43 L/min.,Clinical pharmacokinetics of nicotine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3545615/),[l] / [min],0.92 to 2.43,36030,DB00184,Nicotine
,3545615,renal clearance,"During urinary acidification, renal clearance averages 0.20 L/min.",Clinical pharmacokinetics of nicotine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3545615/),[l] / [min],0.20,36031,DB00184,Nicotine
,3545615,Non-renal blood clearance,"Non-renal blood clearance averages 1.2 L/min, indicating that nicotine elimination is dependent on hepatic blood flow.",Clinical pharmacokinetics of nicotine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3545615/),[l] / [min],1.2,36032,DB00184,Nicotine
,2237913,oral availability,"The oral availability of unchanged nicotine, derived by comparison of the respective areas under the concentration vs time curves (AUC), was 89%, indicating low hepatic extraction ratios of about 10%.",Increased hepatic nicotine elimination after phenobarbital induction in the conscious rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2237913/),%,89,36559,DB00184,Nicotine
,2237913,hepatic extraction ratios,"The oral availability of unchanged nicotine, derived by comparison of the respective areas under the concentration vs time curves (AUC), was 89%, indicating low hepatic extraction ratios of about 10%.",Increased hepatic nicotine elimination after phenobarbital induction in the conscious rat. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2237913/),%,10,36560,DB00184,Nicotine
,2237913,oral availability,The oral availability of unchanged nicotine in plasma dropped to 1.4% of the corresponding values obtained from PB-treated rats receiving nicotine iv.,Increased hepatic nicotine elimination after phenobarbital induction in the conscious rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2237913/),%,1.4,36561,DB00184,Nicotine
,1634647,maximum peak plasma concentration,"The mean nicotine maximum peak plasma concentration values for nicotine transdermal system application to the arm, back, and chest were equivalent (13.8, 14.6, and 13.2 ng/mL, respectively).",Comparison of plasma nicotine concentrations after application of nicoderm (nicotine transdermal system) to different skin sites. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1634647/),[ng] / [ml],13.8,39908,DB00184,Nicotine
,1634647,maximum peak plasma concentration,"The mean nicotine maximum peak plasma concentration values for nicotine transdermal system application to the arm, back, and chest were equivalent (13.8, 14.6, and 13.2 ng/mL, respectively).",Comparison of plasma nicotine concentrations after application of nicoderm (nicotine transdermal system) to different skin sites. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1634647/),[ng] / [ml],14.6,39909,DB00184,Nicotine
,1634647,maximum peak plasma concentration,"The mean nicotine maximum peak plasma concentration values for nicotine transdermal system application to the arm, back, and chest were equivalent (13.8, 14.6, and 13.2 ng/mL, respectively).",Comparison of plasma nicotine concentrations after application of nicoderm (nicotine transdermal system) to different skin sites. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1634647/),[ng] / [ml],13.2,39910,DB00184,Nicotine
,1634647,time to reach peak concentration (tmax),"The mean time to reach peak concentration (tmax) (3 to 6 hours), and area under the curve (168, 186, and 183 ng.h/mL) values for the arm, back, and chest, respectively, were not significantly different.",Comparison of plasma nicotine concentrations after application of nicoderm (nicotine transdermal system) to different skin sites. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1634647/),h,3 to 6,39911,DB00184,Nicotine
,1634647,area under the curve,"The mean time to reach peak concentration (tmax) (3 to 6 hours), and area under the curve (168, 186, and 183 ng.h/mL) values for the arm, back, and chest, respectively, were not significantly different.",Comparison of plasma nicotine concentrations after application of nicoderm (nicotine transdermal system) to different skin sites. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1634647/),[h·ng] / [ml],168,39912,DB00184,Nicotine
,1634647,area under the curve,"The mean time to reach peak concentration (tmax) (3 to 6 hours), and area under the curve (168, 186, and 183 ng.h/mL) values for the arm, back, and chest, respectively, were not significantly different.",Comparison of plasma nicotine concentrations after application of nicoderm (nicotine transdermal system) to different skin sites. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1634647/),[h·ng] / [ml],186,39913,DB00184,Nicotine
,1634647,area under the curve,"The mean time to reach peak concentration (tmax) (3 to 6 hours), and area under the curve (168, 186, and 183 ng.h/mL) values for the arm, back, and chest, respectively, were not significantly different.",Comparison of plasma nicotine concentrations after application of nicoderm (nicotine transdermal system) to different skin sites. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1634647/),[h·ng] / [ml],183,39914,DB00184,Nicotine
,34180227,limit of detection,An NMR limit of detection of 0.1 μM and a limit of quantitation of 0.7 μM is achieved in a practical pharmacokinetics scenario where precise quantitative and qualitative analysis is desired.,Developing Analytical Applications for Parahydrogen Hyperpolarization: Urinary Elimination Pharmacokinetics of Nicotine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34180227/),μM,0.1,41741,DB00184,Nicotine
,34180227,limit of quantitation,An NMR limit of detection of 0.1 μM and a limit of quantitation of 0.7 μM is achieved in a practical pharmacokinetics scenario where precise quantitative and qualitative analysis is desired.,Developing Analytical Applications for Parahydrogen Hyperpolarization: Urinary Elimination Pharmacokinetics of Nicotine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34180227/),μ,0.7,41742,DB00184,Nicotine
,17206524,t(1/2),"Additionally, the delay in the appearance of COT-d(2) in the blood was modeled as a time delay (t(1/2) = 12 min) in its release from the liver following NIC-d(2) administration.",Population pharmacokinetics of nicotine and its metabolites I. Model development. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17206524/),min,12,42028,DB00184,Nicotine
,11167665,total plasma clearance,"The total plasma clearance of 3-HC averaged 1.3 ml x min(-1) x kg(-1), of which 63% was renal excretion of unchanged drug.","Trans-3'-hydroxycotinine: disposition kinetics, effects and plasma levels during cigarette smoking. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11167665/),[ml] / [kg·min],1.3,43819,DB00184,Nicotine
,33354734,initial,"Disposition of intravenous nicotine was best described by a three-compartment model with initial and terminal half-lives of 7 min and 4.5 h, respectively, and the absorption of single oral doses was best described with a first-order absorption rate constant of 1.55 h-1.","Nicotine Population Pharmacokinetics in Healthy Smokers After Intravenous, Oral, Buccal and Transdermal Administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33354734/),min,7,45206,DB00184,Nicotine
,33354734,terminal half-lives,"Disposition of intravenous nicotine was best described by a three-compartment model with initial and terminal half-lives of 7 min and 4.5 h, respectively, and the absorption of single oral doses was best described with a first-order absorption rate constant of 1.55 h-1.","Nicotine Population Pharmacokinetics in Healthy Smokers After Intravenous, Oral, Buccal and Transdermal Administration. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33354734/),h,4.5,45207,DB00184,Nicotine
,33354734,first-order absorption rate constant,"Disposition of intravenous nicotine was best described by a three-compartment model with initial and terminal half-lives of 7 min and 4.5 h, respectively, and the absorption of single oral doses was best described with a first-order absorption rate constant of 1.55 h-1.","Nicotine Population Pharmacokinetics in Healthy Smokers After Intravenous, Oral, Buccal and Transdermal Administration. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33354734/),1/[h],1.55,45208,DB00184,Nicotine
,33354734,clearance,"Key pharmacokinetic parameters were reliably estimated, with typical values for clearance (67 L/h for a 70-kg subject), volume of distribution (4.3 L/kg), oral bioavailability (40%) and transdermal bioavailability (76%) within expected ranges.","Nicotine Population Pharmacokinetics in Healthy Smokers After Intravenous, Oral, Buccal and Transdermal Administration. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33354734/),[l] / [h],67,45209,DB00184,Nicotine
,33354734,volume of distribution,"Key pharmacokinetic parameters were reliably estimated, with typical values for clearance (67 L/h for a 70-kg subject), volume of distribution (4.3 L/kg), oral bioavailability (40%) and transdermal bioavailability (76%) within expected ranges.","Nicotine Population Pharmacokinetics in Healthy Smokers After Intravenous, Oral, Buccal and Transdermal Administration. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33354734/),[l] / [kg],4.3,45210,DB00184,Nicotine
,33354734,oral bioavailability,"Key pharmacokinetic parameters were reliably estimated, with typical values for clearance (67 L/h for a 70-kg subject), volume of distribution (4.3 L/kg), oral bioavailability (40%) and transdermal bioavailability (76%) within expected ranges.","Nicotine Population Pharmacokinetics in Healthy Smokers After Intravenous, Oral, Buccal and Transdermal Administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33354734/),%,40,45211,DB00184,Nicotine
,33354734,transdermal bioavailability,"Key pharmacokinetic parameters were reliably estimated, with typical values for clearance (67 L/h for a 70-kg subject), volume of distribution (4.3 L/kg), oral bioavailability (40%) and transdermal bioavailability (76%) within expected ranges.","Nicotine Population Pharmacokinetics in Healthy Smokers After Intravenous, Oral, Buccal and Transdermal Administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33354734/),%,76,45212,DB00184,Nicotine
,27927703,clearance,Mecamylamine's estimated clearance was 0.28 ± 0.015 L min-1.,Pharmacokinetics and pharmacodynamics of oral mecamylamine - development of a nicotinic acetylcholine receptor antagonist cognitive challenge test using modelling and simulation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27927703/),[l] / [min],0.28,45860,DB00184,Nicotine
,27927703,peripheral volume of distribution,The peripheral volume of distribution (291 ± 5.15 L) was directly related to total body weight.,Pharmacokinetics and pharmacodynamics of oral mecamylamine - development of a nicotinic acetylcholine receptor antagonist cognitive challenge test using modelling and simulation. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27927703/),l,291,45861,DB00184,Nicotine
,27927703,EC50,"On the other hand, mecamylamine induced a decrease in performance of tests evaluating visual and fine motor coordination at higher plasma concentrations (EC50 97 μg L-1).",Pharmacokinetics and pharmacodynamics of oral mecamylamine - development of a nicotinic acetylcholine receptor antagonist cognitive challenge test using modelling and simulation. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27927703/),[μg] / [l],97,45862,DB00184,Nicotine
,11094866,peak serum nicotine concentration,A peak serum nicotine concentration of 4.71 +/- 3.16 ng/mL occurred 10 minutes after drug administration.,Pharmacokinetics and pharmacodynamic effects of nicotine nasal spray devices on cardiovascular and pulmonary function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11094866/),[ng] / [ml],4.71,46634,DB00184,Nicotine
,15385840,flow rate,A flow rate of 0.2 mL/min resulted in a total analysis time of 5 minutes per sample.,The measurement of nicotine in human plasma by high-performance liquid chromatography-electrospray-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15385840/),[ml] / [min],0.2,47101,DB00184,Nicotine
,15385840,total analysis time,A flow rate of 0.2 mL/min resulted in a total analysis time of 5 minutes per sample.,The measurement of nicotine in human plasma by high-performance liquid chromatography-electrospray-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15385840/),[min] / [sample],5,47102,DB00184,Nicotine
,15385840,m/z,Mass spectrometric detection was by selected reactant monitoring (nicotine m/z 163.2 --> 130.2; IS m/z 166.2 --> 87.2).,The measurement of nicotine in human plasma by high-performance liquid chromatography-electrospray-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15385840/),,163.2,47103,DB00184,Nicotine
,15385840,m/z,Mass spectrometric detection was by selected reactant monitoring (nicotine m/z 163.2 --> 130.2; IS m/z 166.2 --> 87.2).,The measurement of nicotine in human plasma by high-performance liquid chromatography-electrospray-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15385840/),,130.2,47104,DB00184,Nicotine
,15385840,m/z,Mass spectrometric detection was by selected reactant monitoring (nicotine m/z 163.2 --> 130.2; IS m/z 166.2 --> 87.2).,The measurement of nicotine in human plasma by high-performance liquid chromatography-electrospray-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15385840/),,166.2,47105,DB00184,Nicotine
,27023159,flow rate,"Isocratic elution was performed using acetonitrile:100mM ammonium formate buffer (pH=3.2) (90:10, v/v) as the mobile phase, at a flow rate of 0.4 mL/min.",A fully validated LC-MS/MS method for simultaneous determination of nicotine and its metabolite cotinine in human serum and its application to a pharmacokinetic study after using nicotine transdermal delivery systems with standard heat application in adult smokers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27023159/),[ml] / [min],0.4,48717,DB00184,Nicotine
,23891672,relative bioavailability,"The relative bioavailability of nicotine for PNCIT compared to CC was 0.92 ± 0.32, indicating similar nicotine bioavailability for both forms.",Pharmacokinetic analysis of nicotine when using non-combustion inhaler type of tobacco product in Japanese adult male smokers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23891672/),,0.92,50682,DB00184,Nicotine
≥,33270145,AUC0,"Juul EU delivered less nicotine than OBC (t(13) = -4.64 p < .001) and than Juul US (t(13) = -6.40, p < .001): AUC0 ≥ 30 77.3, 324.8 and 355.9, respectively.","Nicotine delivery and user reactions to Juul EU (20 mg/ml) compared with Juul US (59 mg/ml), cigarettes and other e-cigarette products. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33270145/),,30,51106,DB00184,Nicotine
≥,33270145,AUC0,"Juul EU delivered less nicotine than OBC (t(13) = -4.64 p < .001) and than Juul US (t(13) = -6.40, p < .001): AUC0 ≥ 30 77.3, 324.8 and 355.9, respectively.","Nicotine delivery and user reactions to Juul EU (20 mg/ml) compared with Juul US (59 mg/ml), cigarettes and other e-cigarette products. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33270145/),,77.3,51107,DB00184,Nicotine
≥,33270145,AUC0,"Juul EU delivered less nicotine than OBC (t(13) = -4.64 p < .001) and than Juul US (t(13) = -6.40, p < .001): AUC0 ≥ 30 77.3, 324.8 and 355.9, respectively.","Nicotine delivery and user reactions to Juul EU (20 mg/ml) compared with Juul US (59 mg/ml), cigarettes and other e-cigarette products. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33270145/),,324.8,51108,DB00184,Nicotine
≥,33270145,AUC0,"Juul EU delivered less nicotine than OBC (t(13) = -4.64 p < .001) and than Juul US (t(13) = -6.40, p < .001): AUC0 ≥ 30 77.3, 324.8 and 355.9, respectively.","Nicotine delivery and user reactions to Juul EU (20 mg/ml) compared with Juul US (59 mg/ml), cigarettes and other e-cigarette products. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33270145/),,355.9,51109,DB00184,Nicotine
,33270145,Cmax,"Maximum nicotine concentration (Cmax) was also much lower for Juul EU than Juul US (z = -3.59, p < .001): Cmax 3.8 ng/ml vs 21.1 ng/ml, respectively.","Nicotine delivery and user reactions to Juul EU (20 mg/ml) compared with Juul US (59 mg/ml), cigarettes and other e-cigarette products. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33270145/),[ng] / [ml],3.8,51110,DB00184,Nicotine
,33270145,Cmax,"Maximum nicotine concentration (Cmax) was also much lower for Juul EU than Juul US (z = -3.59, p < .001): Cmax 3.8 ng/ml vs 21.1 ng/ml, respectively.","Nicotine delivery and user reactions to Juul EU (20 mg/ml) compared with Juul US (59 mg/ml), cigarettes and other e-cigarette products. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33270145/),[ng] / [ml],21.1,51111,DB00184,Nicotine
,34432106,Cmax,Nicotine Cmax values ranged from 9.0 to 11.5 ng/mL for the NPs and 16.3 ng/mL for OBCs.,Nicotine pharmacokinetics and subjective response among adult smokers using different flavors of on!® nicotine pouches compared to combustible cigarettes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34432106/),[ng] / [ml],9.0 to 11.5,52882,DB00184,Nicotine
,34432106,Cmax,Nicotine Cmax values ranged from 9.0 to 11.5 ng/mL for the NPs and 16.3 ng/mL for OBCs.,Nicotine pharmacokinetics and subjective response among adult smokers using different flavors of on!® nicotine pouches compared to combustible cigarettes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34432106/),[ng] / [ml],16.3,52883,DB00184,Nicotine
,34432106,tmax,The tmax ranged from 30.1 to 34.9 min for ONPs and 7.5 min for OBCs.,Nicotine pharmacokinetics and subjective response among adult smokers using different flavors of on!® nicotine pouches compared to combustible cigarettes. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34432106/),min,30.1 to 34.9,52884,DB00184,Nicotine
,34432106,tmax,The tmax ranged from 30.1 to 34.9 min for ONPs and 7.5 min for OBCs.,Nicotine pharmacokinetics and subjective response among adult smokers using different flavors of on!® nicotine pouches compared to combustible cigarettes. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34432106/),min,7.5,52885,DB00184,Nicotine
,15179444,half-life,Its pharmacokinetic (PK) profile (half-life of 2 h) contrasts with the long lasting improvement in working memory (18 h) demonstrating that cognitive improvement extends beyond the lifetime of the compound.,"TC-1734: an orally active neuronal nicotinic acetylcholine receptor modulator with antidepressant, neuroprotective and long-lasting cognitive effects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15179444/),h,2,53603,DB00184,Nicotine
,1410168,peak increase,"Absorption was particularly rapid during the first 2.5 min, the average rise in blood nicotine concentrations during this time being 8.6 ng/ml for the two products, followed by a small further rise to an average peak increase of 10.5 ng/ml 5 min after the dose of 2 mg nicotine base (mean 27.8 micrograms/kg).",Nasal nicotine spray: a rapid nicotine delivery system. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1410168/),[ng] / [ml],10.5,53623,DB00184,Nicotine
,20637967,AUC(0-infinity),"The AUC(0-infinity) was significantly higher for the 21-mg patch worn for 24 hours than for the 25-mg patch worn for 16 hours (382.36 vs 243.69 ng/mL . h, respectively; geometric mean ratio: 156.90%; 90% CI, 148.10%-166.23%; P < 0.001).","Pharmacokinetic comparison of two nicotine transdermal systems, a 21-mg/24-hour patch and a 25-mg/16-hour patch: a randomized, open-label, single-dose, two-way crossover study in adult smokers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20637967/),[ng] / [h·ml],382.36,57693,DB00184,Nicotine
,20637967,AUC(0-infinity),"The AUC(0-infinity) was significantly higher for the 21-mg patch worn for 24 hours than for the 25-mg patch worn for 16 hours (382.36 vs 243.69 ng/mL . h, respectively; geometric mean ratio: 156.90%; 90% CI, 148.10%-166.23%; P < 0.001).","Pharmacokinetic comparison of two nicotine transdermal systems, a 21-mg/24-hour patch and a 25-mg/16-hour patch: a randomized, open-label, single-dose, two-way crossover study in adult smokers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20637967/),[ng] / [h·ml],243.69,57694,DB00184,Nicotine
,20637967,T(max),T(max) was reached significantly sooner with the 21-mg patch than with the 25-mg patch (6.0 vs 12.0 hours; P < 0.001).,"Pharmacokinetic comparison of two nicotine transdermal systems, a 21-mg/24-hour patch and a 25-mg/16-hour patch: a randomized, open-label, single-dose, two-way crossover study in adult smokers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20637967/),h,6.0,57695,DB00184,Nicotine
,20637967,T(max),T(max) was reached significantly sooner with the 21-mg patch than with the 25-mg patch (6.0 vs 12.0 hours; P < 0.001).,"Pharmacokinetic comparison of two nicotine transdermal systems, a 21-mg/24-hour patch and a 25-mg/16-hour patch: a randomized, open-label, single-dose, two-way crossover study in adult smokers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20637967/),h,12.0,57696,DB00184,Nicotine
,20637967,C(max),"C(max) was significantly higher for the 21-mg patch compared with the 25-mg patch (18.34 vs 16.56 ng/mL; geometric mean ratio: 110.72%; 90% CI, 104.82%-116.94%; P < 0.01).","Pharmacokinetic comparison of two nicotine transdermal systems, a 21-mg/24-hour patch and a 25-mg/16-hour patch: a randomized, open-label, single-dose, two-way crossover study in adult smokers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20637967/),[ng] / [ml],18.34,57697,DB00184,Nicotine
,20637967,C(max),"C(max) was significantly higher for the 21-mg patch compared with the 25-mg patch (18.34 vs 16.56 ng/mL; geometric mean ratio: 110.72%; 90% CI, 104.82%-116.94%; P < 0.01).","Pharmacokinetic comparison of two nicotine transdermal systems, a 21-mg/24-hour patch and a 25-mg/16-hour patch: a randomized, open-label, single-dose, two-way crossover study in adult smokers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20637967/),[ng] / [ml],16.56,57698,DB00184,Nicotine
,3369603,Half-lives,Half-lives for cotinine averaged 16-19 hours in the different body fluids (range 10 to 27 hours between subjects).,Elimination of cotinine from body fluids: implications for noninvasive measurement of tobacco smoke exposure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3369603/),h,16-19,58333,DB00184,Nicotine
,3369603,Half-lives,Half-lives for cotinine averaged 16-19 hours in the different body fluids (range 10 to 27 hours between subjects).,Elimination of cotinine from body fluids: implications for noninvasive measurement of tobacco smoke exposure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3369603/),h,10 to 27,58334,DB00184,Nicotine
,9342586,amount,"With a 15 l air volume, the average amount of nicotine released was 1.44, 3.49, 4.80 and 6.99 mg at 10 degrees C, 22 degrees C, 29 degrees C and 40 degrees C, respectively.",Temperature dependency of the release and bioavailability of nicotine from a nicotine vapour inhaler; in vitro/in vivo correlation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9342586/),mg,1.44,59524,DB00184,Nicotine
,9342586,amount,"With a 15 l air volume, the average amount of nicotine released was 1.44, 3.49, 4.80 and 6.99 mg at 10 degrees C, 22 degrees C, 29 degrees C and 40 degrees C, respectively.",Temperature dependency of the release and bioavailability of nicotine from a nicotine vapour inhaler; in vitro/in vivo correlation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9342586/),mg,3.49,59525,DB00184,Nicotine
,9342586,amount,"With a 15 l air volume, the average amount of nicotine released was 1.44, 3.49, 4.80 and 6.99 mg at 10 degrees C, 22 degrees C, 29 degrees C and 40 degrees C, respectively.",Temperature dependency of the release and bioavailability of nicotine from a nicotine vapour inhaler; in vitro/in vivo correlation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9342586/),mg,4.80,59526,DB00184,Nicotine
,9342586,amount,"With a 15 l air volume, the average amount of nicotine released was 1.44, 3.49, 4.80 and 6.99 mg at 10 degrees C, 22 degrees C, 29 degrees C and 40 degrees C, respectively.",Temperature dependency of the release and bioavailability of nicotine from a nicotine vapour inhaler; in vitro/in vivo correlation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9342586/),mg,6.99,59527,DB00184,Nicotine
,9342586,peak plasma levels,In vivo peak plasma levels obtained at 30 degrees and 40 degrees C were 29.7 and 34.0 ng.,Temperature dependency of the release and bioavailability of nicotine from a nicotine vapour inhaler; in vitro/in vivo correlation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9342586/),ng,29.7,59528,DB00184,Nicotine
,9342586,peak plasma levels,In vivo peak plasma levels obtained at 30 degrees and 40 degrees C were 29.7 and 34.0 ng.,Temperature dependency of the release and bioavailability of nicotine from a nicotine vapour inhaler; in vitro/in vivo correlation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9342586/),ng,34.0,59529,DB00184,Nicotine
,9342586,area under the plasma concentration-time curve (AUC),"At 20 degrees C, the area under the plasma concentration-time curve (AUC) of the last dosing interval was 20.5 ng.",Temperature dependency of the release and bioavailability of nicotine from a nicotine vapour inhaler; in vitro/in vivo correlation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9342586/),ng,20.5,59530,DB00184,Nicotine
,9342586,AUCs,"At 30 degrees C and 40 degrees C, the AUCs were 26.5 and 30.3 ng.",Temperature dependency of the release and bioavailability of nicotine from a nicotine vapour inhaler; in vitro/in vivo correlation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9342586/),ng,26.5,59531,DB00184,Nicotine
,9342586,AUCs,"At 30 degrees C and 40 degrees C, the AUCs were 26.5 and 30.3 ng.",Temperature dependency of the release and bioavailability of nicotine from a nicotine vapour inhaler; in vitro/in vivo correlation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9342586/),ng,30.3,59532,DB00184,Nicotine
,27063714,retention time,The retention time of dopamine was about 11.32 min.,Quantification of Dopamine in Brain Microdialysates with High-Performance Liquid Chromatography-Tandem Mass Spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27063714/),min,11.32,59607,DB00184,Nicotine
,27063714,limit of detection (LOD),"The limit of detection (LOD) and the limit of qualification (LOQ) were 5 and 20 pg/mL, respectively.",Quantification of Dopamine in Brain Microdialysates with High-Performance Liquid Chromatography-Tandem Mass Spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27063714/),[pg] / [ml],5,59608,DB00184,Nicotine
,27063714,limit of qualification (LOQ),"The limit of detection (LOD) and the limit of qualification (LOQ) were 5 and 20 pg/mL, respectively.",Quantification of Dopamine in Brain Microdialysates with High-Performance Liquid Chromatography-Tandem Mass Spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27063714/),[pg] / [ml],20,59609,DB00184,Nicotine
,27063714,recovery,"The recovery ranged from 98.2 to 109.0%, and both the intra-RSD and inter-RSD were below <9%, respectively.",Quantification of Dopamine in Brain Microdialysates with High-Performance Liquid Chromatography-Tandem Mass Spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27063714/),%,98.2 to 109.0,59610,DB00184,Nicotine
,27063714,probe recovery,The probe recovery for dopamine in this brain microdialysis experiment was about 25%.,Quantification of Dopamine in Brain Microdialysates with High-Performance Liquid Chromatography-Tandem Mass Spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27063714/),%,25,59611,DB00184,Nicotine
,1475232,transdermal clearance,"The transdermal clearance of nicotine, 1351 ml/min, coincided with reported values following intravenous nicotine administration; however, the terminal-phase half-life, 5.0 hr, did not.",Pharmacokinetic disposition of multiple-dose transdermal nicotine in healthy adult smokers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1475232/),[ml] / [min],1351,61994,DB00184,Nicotine
,1475232,terminal-phase half-life,"The transdermal clearance of nicotine, 1351 ml/min, coincided with reported values following intravenous nicotine administration; however, the terminal-phase half-life, 5.0 hr, did not.",Pharmacokinetic disposition of multiple-dose transdermal nicotine in healthy adult smokers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1475232/),h,5.0,61995,DB00184,Nicotine
,10583017,Cmax,"Cmax nicotine values were 2.2 and 5 ng ml-1, obtained 7 h after the ingestion of 6 and 15 mg, respectively, of the formulation.",An oral formulation of nicotine for release and absorption in the colon: its development and pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10583017/),[ng] / [ml],2.2,67692,DB00184,Nicotine
,10583017,Cmax,"Cmax nicotine values were 2.2 and 5 ng ml-1, obtained 7 h after the ingestion of 6 and 15 mg, respectively, of the formulation.",An oral formulation of nicotine for release and absorption in the colon: its development and pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10583017/),[ng] / [ml],5,67693,DB00184,Nicotine
,10583017,Cmax,"The corresponding Cmax values for cotinine were 37 and 94.4 ng ml-1, occurring after 9-10 h.",An oral formulation of nicotine for release and absorption in the colon: its development and pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10583017/),[ng] / [ml],37,67694,DB00184,Nicotine
,10583017,Cmax,"The corresponding Cmax values for cotinine were 37 and 94.4 ng ml-1, occurring after 9-10 h.",An oral formulation of nicotine for release and absorption in the colon: its development and pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10583017/),[ng] / [ml],94.4,67695,DB00184,Nicotine
,10583017,elimination half-lives,"The mean for elimination half-lives in the 24 studies, including the 6 and 15 mg doses, for nicotine were 4.3+/-2.7 h and for cotinine 16.8+/-7.5 h.",An oral formulation of nicotine for release and absorption in the colon: its development and pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10583017/),h,4.3,67696,DB00184,Nicotine
,10583017,elimination half-lives,"The mean for elimination half-lives in the 24 studies, including the 6 and 15 mg doses, for nicotine were 4.3+/-2.7 h and for cotinine 16.8+/-7.5 h.",An oral formulation of nicotine for release and absorption in the colon: its development and pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10583017/),h,16.8,67697,DB00184,Nicotine
,28482017,maximum plasma nicotine concentration (Cmax),"Geometric least-squares means for maximum plasma nicotine concentration (Cmax), generated by the mixed-effect model for exposure comparison, were 9.7, 11.2, and 9.8 ng/mL for the 50, 80, and 150 µg/puff P3L variants, respectively, compared to 6.1 ng/mL after Nicorette inhalator use.",Evaluation of Nicotine Pharmacokinetics and Subjective Effects following Use of a Novel Nicotine Delivery System. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28482017/),[ng] / [ml],9.7,69042,DB00184,Nicotine
,28482017,maximum plasma nicotine concentration (Cmax),"Geometric least-squares means for maximum plasma nicotine concentration (Cmax), generated by the mixed-effect model for exposure comparison, were 9.7, 11.2, and 9.8 ng/mL for the 50, 80, and 150 µg/puff P3L variants, respectively, compared to 6.1 ng/mL after Nicorette inhalator use.",Evaluation of Nicotine Pharmacokinetics and Subjective Effects following Use of a Novel Nicotine Delivery System. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28482017/),[ng] / [ml],11.2,69043,DB00184,Nicotine
,28482017,maximum plasma nicotine concentration (Cmax),"Geometric least-squares means for maximum plasma nicotine concentration (Cmax), generated by the mixed-effect model for exposure comparison, were 9.7, 11.2, and 9.8 ng/mL for the 50, 80, and 150 µg/puff P3L variants, respectively, compared to 6.1 ng/mL after Nicorette inhalator use.",Evaluation of Nicotine Pharmacokinetics and Subjective Effects following Use of a Novel Nicotine Delivery System. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28482017/),[ng] / [ml],9.8,69044,DB00184,Nicotine
,28482017,maximum plasma nicotine concentration (Cmax),"Geometric least-squares means for maximum plasma nicotine concentration (Cmax), generated by the mixed-effect model for exposure comparison, were 9.7, 11.2, and 9.8 ng/mL for the 50, 80, and 150 µg/puff P3L variants, respectively, compared to 6.1 ng/mL after Nicorette inhalator use.",Evaluation of Nicotine Pharmacokinetics and Subjective Effects following Use of a Novel Nicotine Delivery System. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28482017/),[ng] / [ml],6.1,69045,DB00184,Nicotine
,28482017,time from,"Median time from product use start to Cmax was 7.0 minutes for all P3L, compared to 30.0 minutes for the Nicorette inhalator.",Evaluation of Nicotine Pharmacokinetics and Subjective Effects following Use of a Novel Nicotine Delivery System. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28482017/),min,7.0,69046,DB00184,Nicotine
,28482017,time from,"Median time from product use start to Cmax was 7.0 minutes for all P3L, compared to 30.0 minutes for the Nicorette inhalator.",Evaluation of Nicotine Pharmacokinetics and Subjective Effects following Use of a Novel Nicotine Delivery System. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28482017/),min,30.0,69047,DB00184,Nicotine
,9156375,bioavailabilities,"The mean (+/-SD) bioavailabilities of nicotine after administration in the liquid enema formulations (hydrophilic acidic 17 +/- 18%, hydrophilic basic 16 +/- 16%, hydrophobic acidic 25 +/- 17%, hydrophobic basic 15 +/- 12%) were similar to the bioavailability of nicotine after administration by oral solution (20 +/- 25%).","Pharmacokinetics of nicotine tartrate after single-dose liquid enema, oral, and intravenous administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9156375/),%,17,69919,DB00184,Nicotine
,9156375,bioavailabilities,"The mean (+/-SD) bioavailabilities of nicotine after administration in the liquid enema formulations (hydrophilic acidic 17 +/- 18%, hydrophilic basic 16 +/- 16%, hydrophobic acidic 25 +/- 17%, hydrophobic basic 15 +/- 12%) were similar to the bioavailability of nicotine after administration by oral solution (20 +/- 25%).","Pharmacokinetics of nicotine tartrate after single-dose liquid enema, oral, and intravenous administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9156375/),%,16,69920,DB00184,Nicotine
,9156375,bioavailabilities,"The mean (+/-SD) bioavailabilities of nicotine after administration in the liquid enema formulations (hydrophilic acidic 17 +/- 18%, hydrophilic basic 16 +/- 16%, hydrophobic acidic 25 +/- 17%, hydrophobic basic 15 +/- 12%) were similar to the bioavailability of nicotine after administration by oral solution (20 +/- 25%).","Pharmacokinetics of nicotine tartrate after single-dose liquid enema, oral, and intravenous administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9156375/),%,25,69921,DB00184,Nicotine
,9156375,bioavailabilities,"The mean (+/-SD) bioavailabilities of nicotine after administration in the liquid enema formulations (hydrophilic acidic 17 +/- 18%, hydrophilic basic 16 +/- 16%, hydrophobic acidic 25 +/- 17%, hydrophobic basic 15 +/- 12%) were similar to the bioavailability of nicotine after administration by oral solution (20 +/- 25%).","Pharmacokinetics of nicotine tartrate after single-dose liquid enema, oral, and intravenous administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9156375/),%,15,69922,DB00184,Nicotine
,9156375,bioavailability,"The mean (+/-SD) bioavailabilities of nicotine after administration in the liquid enema formulations (hydrophilic acidic 17 +/- 18%, hydrophilic basic 16 +/- 16%, hydrophobic acidic 25 +/- 17%, hydrophobic basic 15 +/- 12%) were similar to the bioavailability of nicotine after administration by oral solution (20 +/- 25%).","Pharmacokinetics of nicotine tartrate after single-dose liquid enema, oral, and intravenous administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9156375/),%,20,69923,DB00184,Nicotine
,9156375,bioavailabilities,The bioavailabilities of nicotine for all five nonintravenous formulations were significantly less than for intravenous nicotine (100%).,"Pharmacokinetics of nicotine tartrate after single-dose liquid enema, oral, and intravenous administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9156375/),%,100,69924,DB00184,Nicotine
,9669788,total,"The total and nonrenal clearances of nicotine were not significantly different, respectively, in blacks (17.7 and 17.2 mL x min(-1) x kg(-1)) compared with whites (19.6 and 18.9 mL x min(-1) x kg(-1)) (P=.11 and .20).",Nicotine metabolism and intake in black and white smokers. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9669788/),[ml] / [kg·min],17.7,70663,DB00184,Nicotine
,9669788,total,"The total and nonrenal clearances of nicotine were not significantly different, respectively, in blacks (17.7 and 17.2 mL x min(-1) x kg(-1)) compared with whites (19.6 and 18.9 mL x min(-1) x kg(-1)) (P=.11 and .20).",Nicotine metabolism and intake in black and white smokers. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9669788/),[ml] / [kg·min],19.6,70664,DB00184,Nicotine
,9669788,nonrenal clearances,"The total and nonrenal clearances of nicotine were not significantly different, respectively, in blacks (17.7 and 17.2 mL x min(-1) x kg(-1)) compared with whites (19.6 and 18.9 mL x min(-1) x kg(-1)) (P=.11 and .20).",Nicotine metabolism and intake in black and white smokers. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9669788/),[ml] / [kg·min],17.2,70665,DB00184,Nicotine
,9669788,nonrenal clearances,"The total and nonrenal clearances of nicotine were not significantly different, respectively, in blacks (17.7 and 17.2 mL x min(-1) x kg(-1)) compared with whites (19.6 and 18.9 mL x min(-1) x kg(-1)) (P=.11 and .20).",Nicotine metabolism and intake in black and white smokers. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9669788/),[ml] / [kg·min],18.9,70666,DB00184,Nicotine
,9669788,total,"However, the total and nonrenal clearances of cotinine were significantly lower, respectively, in blacks (0.56 and 0.47 mL x min(-1) x kg(-1)) than in whites (0.68 vs 0.61 mL x min(-1) x kg(-1); P=.009 for each comparison).",Nicotine metabolism and intake in black and white smokers. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9669788/),[ml] / [kg·min],0.56,70667,DB00184,Nicotine
,9669788,total,"However, the total and nonrenal clearances of cotinine were significantly lower, respectively, in blacks (0.56 and 0.47 mL x min(-1) x kg(-1)) than in whites (0.68 vs 0.61 mL x min(-1) x kg(-1); P=.009 for each comparison).",Nicotine metabolism and intake in black and white smokers. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9669788/),[ml] / [kg·min],0.68,70668,DB00184,Nicotine
,9669788,nonrenal clearances,"However, the total and nonrenal clearances of cotinine were significantly lower, respectively, in blacks (0.56 and 0.47 mL x min(-1) x kg(-1)) than in whites (0.68 vs 0.61 mL x min(-1) x kg(-1); P=.009 for each comparison).",Nicotine metabolism and intake in black and white smokers. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9669788/),[ml] / [kg·min],0.47,70669,DB00184,Nicotine
,9669788,nonrenal clearances,"However, the total and nonrenal clearances of cotinine were significantly lower, respectively, in blacks (0.56 and 0.47 mL x min(-1) x kg(-1)) than in whites (0.68 vs 0.61 mL x min(-1) x kg(-1); P=.009 for each comparison).",Nicotine metabolism and intake in black and white smokers. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9669788/),[ml] / [kg·min],0.61,70670,DB00184,Nicotine
,9669788,half-life,"Volume of distribution did not differ for the 2 groups, but cotinine half-life was higher in blacks than in whites (1064 vs 950 minutes, respectively; P = .07).",Nicotine metabolism and intake in black and white smokers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9669788/),min,1064,70671,DB00184,Nicotine
,9669788,half-life,"Volume of distribution did not differ for the 2 groups, but cotinine half-life was higher in blacks than in whites (1064 vs 950 minutes, respectively; P = .07).",Nicotine metabolism and intake in black and white smokers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9669788/),min,950,70672,DB00184,Nicotine
,10824624,elimination half-life,"The elimination half-life for nicotine was 11.2 hours (95% confidence interval [CI], 8.0 to 18.9) based on blood data and 9.0 hours (95% CI, 7.0 to 12.4) based on urine data.",Nicotine metabolism and elimination kinetics in newborns. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10824624/),h,11.2,76119,DB00184,Nicotine
,10824624,elimination half-life,"The elimination half-life for nicotine was 11.2 hours (95% confidence interval [CI], 8.0 to 18.9) based on blood data and 9.0 hours (95% CI, 7.0 to 12.4) based on urine data.",Nicotine metabolism and elimination kinetics in newborns. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10824624/),h,9.0,76120,DB00184,Nicotine
,10824624,elimination half-life,"The elimination half-life for cotinine was 16.3 hours (95% CI, 12.4 to 23.9) based on blood data and was 22.8 hours (95% CI, 19.5 to 25.8) based on urine data.",Nicotine metabolism and elimination kinetics in newborns. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10824624/),h,16.3,76121,DB00184,Nicotine
,10824624,elimination half-life,"The elimination half-life for cotinine was 16.3 hours (95% CI, 12.4 to 23.9) based on blood data and was 22.8 hours (95% CI, 19.5 to 25.8) based on urine data.",Nicotine metabolism and elimination kinetics in newborns. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10824624/),h,22.8,76122,DB00184,Nicotine
,10824624,elimination half-lives,The elimination half-lives for the other metabolites were 13 hours for conjugated nicotine; 19.8 hours for conjugated cotinine; 18.8 hours for 3'-hydroxycotinine; and 19.4 hours for conjugated 3'-hydroxycotinine.,Nicotine metabolism and elimination kinetics in newborns. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10824624/),h,13,76123,DB00184,Nicotine
,10824624,elimination half-lives,The elimination half-lives for the other metabolites were 13 hours for conjugated nicotine; 19.8 hours for conjugated cotinine; 18.8 hours for 3'-hydroxycotinine; and 19.4 hours for conjugated 3'-hydroxycotinine.,Nicotine metabolism and elimination kinetics in newborns. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10824624/),h,19.8,76124,DB00184,Nicotine
,10824624,elimination half-lives,The elimination half-lives for the other metabolites were 13 hours for conjugated nicotine; 19.8 hours for conjugated cotinine; 18.8 hours for 3'-hydroxycotinine; and 19.4 hours for conjugated 3'-hydroxycotinine.,Nicotine metabolism and elimination kinetics in newborns. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10824624/),h,18.8,76125,DB00184,Nicotine
,10824624,elimination half-lives,The elimination half-lives for the other metabolites were 13 hours for conjugated nicotine; 19.8 hours for conjugated cotinine; 18.8 hours for 3'-hydroxycotinine; and 19.4 hours for conjugated 3'-hydroxycotinine.,Nicotine metabolism and elimination kinetics in newborns. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10824624/),h,19.4,76126,DB00184,Nicotine
,23530019,half-life of nicotine elimination,"The half-life of nicotine elimination was 33 minutes, and levels were undetectable by 4 hours.",Nicotine kinetics in zebra finches in vivo and in vitro. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23530019/),min,33,77530,DB00184,Nicotine
,23530019,brain levels,Nicotine brain levels were 30 and 14 ng/g 1 and 2 hours after treatment.,Nicotine kinetics in zebra finches in vivo and in vitro. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23530019/),[ng] / [g],30,77531,DB00184,Nicotine
,23530019,brain levels,Nicotine brain levels were 30 and 14 ng/g 1 and 2 hours after treatment.,Nicotine kinetics in zebra finches in vivo and in vitro. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23530019/),[ng] / [g],14,77532,DB00184,Nicotine
,23530019,Michaelis-Menten constant (K(m)),Nicotine was metabolized to cotinine with a Michaelis-Menten constant (K(m)) of 96 µM and a V(max) of 56 pmol/min per milligram.,Nicotine kinetics in zebra finches in vivo and in vitro. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23530019/),μM,96,77533,DB00184,Nicotine
,23530019,V(max),Nicotine was metabolized to cotinine with a Michaelis-Menten constant (K(m)) of 96 µM and a V(max) of 56 pmol/min per milligram.,Nicotine kinetics in zebra finches in vivo and in vitro. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23530019/),[pM] / [milligram·min],56,77534,DB00184,Nicotine
,15906589,C(max),"C(max) values between groups with C(max) values of 16.4 +/- 9.5 ng/ml and 16.0 +/- 10.7 ng/ml at rest (p < 0.919, NS) and 10.05 +/- 6.8 ng/ml and 10.2 +/- 6.9 ng/ml (p < 0.959, NS) during exercise did not differ significantly.",Effect of exercise on transdermal nicotine release in healthy habitual smokers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15906589/),[ng] / [ml],16.4,77667,DB00184,Nicotine
,15906589,C(max),"C(max) values between groups with C(max) values of 16.4 +/- 9.5 ng/ml and 16.0 +/- 10.7 ng/ml at rest (p < 0.919, NS) and 10.05 +/- 6.8 ng/ml and 10.2 +/- 6.9 ng/ml (p < 0.959, NS) during exercise did not differ significantly.",Effect of exercise on transdermal nicotine release in healthy habitual smokers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15906589/),[ng] / [ml],16.0,77668,DB00184,Nicotine
,15906589,C(max),"C(max) values between groups with C(max) values of 16.4 +/- 9.5 ng/ml and 16.0 +/- 10.7 ng/ml at rest (p < 0.919, NS) and 10.05 +/- 6.8 ng/ml and 10.2 +/- 6.9 ng/ml (p < 0.959, NS) during exercise did not differ significantly.",Effect of exercise on transdermal nicotine release in healthy habitual smokers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15906589/),[ng] / [ml],10.05,77669,DB00184,Nicotine
,15906589,C(max),"C(max) values between groups with C(max) values of 16.4 +/- 9.5 ng/ml and 16.0 +/- 10.7 ng/ml at rest (p < 0.919, NS) and 10.05 +/- 6.8 ng/ml and 10.2 +/- 6.9 ng/ml (p < 0.959, NS) during exercise did not differ significantly.",Effect of exercise on transdermal nicotine release in healthy habitual smokers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15906589/),[ng] / [ml],10.2,77670,DB00184,Nicotine
,2007322,elimination half-life,"Analysis of disposition kinetics in 10 healthy men revealed a multiexponential decline after the end of an infusion, with an elimination half-life averaging 203 minutes.",Stable isotope studies of nicotine kinetics and bioavailability. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2007322/),min,203,79946,DB00184,Nicotine
,2007322,Plasma clearance,Plasma clearance averaged 14.6 ml/min/kg.,Stable isotope studies of nicotine kinetics and bioavailability. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2007322/),[ml] / [kg·min],14.6,79947,DB00184,Nicotine
,2007322,oral bioavailability,The oral bioavailability of nicotine averaged 44%.,Stable isotope studies of nicotine kinetics and bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2007322/),%,44,79948,DB00184,Nicotine
,31361999,maximum nicotine level,Nicotine and cotinine levels showed a circadian variation as they increased with time up to the maximum nicotine level of 21.8 ± 7.1 ng/mL during the daily intermittent E-cig exposure in the 12-h dark phase and then declined during the light phase when there was no E-cig delivery.,A mouse model for chronic intermittent electronic cigarette exposure exhibits nicotine pharmacokinetics resembling human vapers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31361999/),[ng] / [ml],21.8,80043,DB00184,Nicotine
,25824453,half-lives,"Pharmacokinetic results showed that the mean half-lives of nicotine, cotinine, nornicotine, norcotinine, nicotine-N'-oxide, cotinine-N'-oxide, trans-3'-hydroxy-cotinine, nicotine-N-glucuronide, cotinine-N-glucuronide, and trans-3'-hydroxy-cotinine-O-glucuronide in rat plasma were 63, 291, 175, 440, 251, 451, 322, 341, 488, and 516 min, respectively.",Simultaneous determination of nicotine and its nine metabolites in rat blood utilizing microdialysis coupled with UPLC-tandem mass spectrometry for pharmacokinetic application. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25824453/),min,63,81230,DB00184,Nicotine
,25824453,half-lives,"Pharmacokinetic results showed that the mean half-lives of nicotine, cotinine, nornicotine, norcotinine, nicotine-N'-oxide, cotinine-N'-oxide, trans-3'-hydroxy-cotinine, nicotine-N-glucuronide, cotinine-N-glucuronide, and trans-3'-hydroxy-cotinine-O-glucuronide in rat plasma were 63, 291, 175, 440, 251, 451, 322, 341, 488, and 516 min, respectively.",Simultaneous determination of nicotine and its nine metabolites in rat blood utilizing microdialysis coupled with UPLC-tandem mass spectrometry for pharmacokinetic application. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25824453/),min,291,81231,DB00184,Nicotine
,25824453,half-lives,"Pharmacokinetic results showed that the mean half-lives of nicotine, cotinine, nornicotine, norcotinine, nicotine-N'-oxide, cotinine-N'-oxide, trans-3'-hydroxy-cotinine, nicotine-N-glucuronide, cotinine-N-glucuronide, and trans-3'-hydroxy-cotinine-O-glucuronide in rat plasma were 63, 291, 175, 440, 251, 451, 322, 341, 488, and 516 min, respectively.",Simultaneous determination of nicotine and its nine metabolites in rat blood utilizing microdialysis coupled with UPLC-tandem mass spectrometry for pharmacokinetic application. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25824453/),min,175,81232,DB00184,Nicotine
,25824453,half-lives,"Pharmacokinetic results showed that the mean half-lives of nicotine, cotinine, nornicotine, norcotinine, nicotine-N'-oxide, cotinine-N'-oxide, trans-3'-hydroxy-cotinine, nicotine-N-glucuronide, cotinine-N-glucuronide, and trans-3'-hydroxy-cotinine-O-glucuronide in rat plasma were 63, 291, 175, 440, 251, 451, 322, 341, 488, and 516 min, respectively.",Simultaneous determination of nicotine and its nine metabolites in rat blood utilizing microdialysis coupled with UPLC-tandem mass spectrometry for pharmacokinetic application. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25824453/),min,440,81233,DB00184,Nicotine
,25824453,half-lives,"Pharmacokinetic results showed that the mean half-lives of nicotine, cotinine, nornicotine, norcotinine, nicotine-N'-oxide, cotinine-N'-oxide, trans-3'-hydroxy-cotinine, nicotine-N-glucuronide, cotinine-N-glucuronide, and trans-3'-hydroxy-cotinine-O-glucuronide in rat plasma were 63, 291, 175, 440, 251, 451, 322, 341, 488, and 516 min, respectively.",Simultaneous determination of nicotine and its nine metabolites in rat blood utilizing microdialysis coupled with UPLC-tandem mass spectrometry for pharmacokinetic application. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25824453/),min,251,81234,DB00184,Nicotine
,25824453,half-lives,"Pharmacokinetic results showed that the mean half-lives of nicotine, cotinine, nornicotine, norcotinine, nicotine-N'-oxide, cotinine-N'-oxide, trans-3'-hydroxy-cotinine, nicotine-N-glucuronide, cotinine-N-glucuronide, and trans-3'-hydroxy-cotinine-O-glucuronide in rat plasma were 63, 291, 175, 440, 251, 451, 322, 341, 488, and 516 min, respectively.",Simultaneous determination of nicotine and its nine metabolites in rat blood utilizing microdialysis coupled with UPLC-tandem mass spectrometry for pharmacokinetic application. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25824453/),min,451,81235,DB00184,Nicotine
,25824453,half-lives,"Pharmacokinetic results showed that the mean half-lives of nicotine, cotinine, nornicotine, norcotinine, nicotine-N'-oxide, cotinine-N'-oxide, trans-3'-hydroxy-cotinine, nicotine-N-glucuronide, cotinine-N-glucuronide, and trans-3'-hydroxy-cotinine-O-glucuronide in rat plasma were 63, 291, 175, 440, 251, 451, 322, 341, 488, and 516 min, respectively.",Simultaneous determination of nicotine and its nine metabolites in rat blood utilizing microdialysis coupled with UPLC-tandem mass spectrometry for pharmacokinetic application. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25824453/),min,322,81236,DB00184,Nicotine
,25824453,half-lives,"Pharmacokinetic results showed that the mean half-lives of nicotine, cotinine, nornicotine, norcotinine, nicotine-N'-oxide, cotinine-N'-oxide, trans-3'-hydroxy-cotinine, nicotine-N-glucuronide, cotinine-N-glucuronide, and trans-3'-hydroxy-cotinine-O-glucuronide in rat plasma were 63, 291, 175, 440, 251, 451, 322, 341, 488, and 516 min, respectively.",Simultaneous determination of nicotine and its nine metabolites in rat blood utilizing microdialysis coupled with UPLC-tandem mass spectrometry for pharmacokinetic application. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25824453/),min,341,81237,DB00184,Nicotine
,25824453,half-lives,"Pharmacokinetic results showed that the mean half-lives of nicotine, cotinine, nornicotine, norcotinine, nicotine-N'-oxide, cotinine-N'-oxide, trans-3'-hydroxy-cotinine, nicotine-N-glucuronide, cotinine-N-glucuronide, and trans-3'-hydroxy-cotinine-O-glucuronide in rat plasma were 63, 291, 175, 440, 251, 451, 322, 341, 488, and 516 min, respectively.",Simultaneous determination of nicotine and its nine metabolites in rat blood utilizing microdialysis coupled with UPLC-tandem mass spectrometry for pharmacokinetic application. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25824453/),min,488,81238,DB00184,Nicotine
,25824453,half-lives,"Pharmacokinetic results showed that the mean half-lives of nicotine, cotinine, nornicotine, norcotinine, nicotine-N'-oxide, cotinine-N'-oxide, trans-3'-hydroxy-cotinine, nicotine-N-glucuronide, cotinine-N-glucuronide, and trans-3'-hydroxy-cotinine-O-glucuronide in rat plasma were 63, 291, 175, 440, 251, 451, 322, 341, 488, and 516 min, respectively.",Simultaneous determination of nicotine and its nine metabolites in rat blood utilizing microdialysis coupled with UPLC-tandem mass spectrometry for pharmacokinetic application. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25824453/),min,516,81239,DB00184,Nicotine
,22585541,area under the plasma concentration-time curve (AUC),"The area under the plasma concentration-time curve (AUC) and maximum plasma concentration (C(max)) of nicotine ranged from 26.9 to 13.1 ng.h/ml and 17.9 to 9.1 ng.h/ml, respectively across all the products.",Determination of nicotine absorption from multiple tobacco products and nicotine gum. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22585541/),[h·ng] / [ml],26.9 to 13.1,82369,DB00184,Nicotine
,22585541,maximum plasma concentration (C(max)),"The area under the plasma concentration-time curve (AUC) and maximum plasma concentration (C(max)) of nicotine ranged from 26.9 to 13.1 ng.h/ml and 17.9 to 9.1 ng.h/ml, respectively across all the products.",Determination of nicotine absorption from multiple tobacco products and nicotine gum. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22585541/),[h·ng] / [ml],17.9 to 9.1,82370,DB00184,Nicotine
,22585541,AUC,Nicotine was absorbed more rapidly from the cigarette but systemic exposure was within the range of the smokeless tobacco products (AUC = 14.8 ng.h/ml; C(max) = 12.8 ng.h/ml).,Determination of nicotine absorption from multiple tobacco products and nicotine gum. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22585541/),[h·ng] / [ml],14.8,82371,DB00184,Nicotine
,22585541,C(max),Nicotine was absorbed more rapidly from the cigarette but systemic exposure was within the range of the smokeless tobacco products (AUC = 14.8 ng.h/ml; C(max) = 12.8 ng.h/ml).,Determination of nicotine absorption from multiple tobacco products and nicotine gum. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22585541/),[h·ng] / [ml],12.8,82372,DB00184,Nicotine
,1447703,Peak of nicotine concentrations,Peak of nicotine concentrations in plasma were significantly lower after instillation at the trachea (11.5 +/- 4.4 ng/mL) and the subsegmental bronchus (18.2 +/- 5.0 ng/mL) than after an iv dose (30.3 +/- 10.7 ng/mL); p < 0.05 for each comparison.,Nicotine absorption after pulmonary instillation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1447703/),[ng] / [ml],11.5,83730,DB00184,Nicotine
,1447703,Peak of nicotine concentrations,Peak of nicotine concentrations in plasma were significantly lower after instillation at the trachea (11.5 +/- 4.4 ng/mL) and the subsegmental bronchus (18.2 +/- 5.0 ng/mL) than after an iv dose (30.3 +/- 10.7 ng/mL); p < 0.05 for each comparison.,Nicotine absorption after pulmonary instillation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1447703/),[ng] / [ml],18.2,83731,DB00184,Nicotine
,1447703,Peak of nicotine concentrations,Peak of nicotine concentrations in plasma were significantly lower after instillation at the trachea (11.5 +/- 4.4 ng/mL) and the subsegmental bronchus (18.2 +/- 5.0 ng/mL) than after an iv dose (30.3 +/- 10.7 ng/mL); p < 0.05 for each comparison.,Nicotine absorption after pulmonary instillation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1447703/),[ng] / [ml],30.3,83732,DB00184,Nicotine
,1447703,peak concentration,"In addition, the peak concentration after instillation at the trachea was significantly lower than that after instillation at the distal site (22.1 +/- 6.2 ng/mL, p < 0.05).",Nicotine absorption after pulmonary instillation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1447703/),[ng] / [ml],22.1,83733,DB00184,Nicotine
,1447703,Time to peak concentration,Time to peak concentration was significantly longer after tracheal instillation (5.3 +/- 3.0 min) than after subsegmental instillation (2.0 +/- 0.0 min) or iv infusion (2.0 +/- 0.0 min); p < 0.05 for each comparison.,Nicotine absorption after pulmonary instillation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1447703/),min,5.3,83734,DB00184,Nicotine
,1447703,Time to peak concentration,Time to peak concentration was significantly longer after tracheal instillation (5.3 +/- 3.0 min) than after subsegmental instillation (2.0 +/- 0.0 min) or iv infusion (2.0 +/- 0.0 min); p < 0.05 for each comparison.,Nicotine absorption after pulmonary instillation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1447703/),min,2.0,83735,DB00184,Nicotine
,27924817,Jss,Average Jss (μg/cm2/h) from formulations were: nicotine in PG (24 mg/ml): 3.97; commercial e-liquid containing menthol (25 mg/ml nicotine): 10.2; commercial e-liquid containing limonene (25 mg/ml nicotine): 23.7; neat nicotine: 175.,In vitro human epidermal permeation of nicotine from electronic cigarette refill liquids and implications for dermal exposure assessment. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27924817/),[μg] / [cm2·h],3.97,85314,DB00184,Nicotine
,27924817,Jss,Average Jss (μg/cm2/h) from formulations were: nicotine in PG (24 mg/ml): 3.97; commercial e-liquid containing menthol (25 mg/ml nicotine): 10.2; commercial e-liquid containing limonene (25 mg/ml nicotine): 23.7; neat nicotine: 175.,In vitro human epidermal permeation of nicotine from electronic cigarette refill liquids and implications for dermal exposure assessment. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27924817/),[μg] / [cm2·h],10.2,85315,DB00184,Nicotine
,27924817,Jss,Average Jss (μg/cm2/h) from formulations were: nicotine in PG (24 mg/ml): 3.97; commercial e-liquid containing menthol (25 mg/ml nicotine): 10.2; commercial e-liquid containing limonene (25 mg/ml nicotine): 23.7; neat nicotine: 175.,In vitro human epidermal permeation of nicotine from electronic cigarette refill liquids and implications for dermal exposure assessment. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27924817/),[μg] / [cm2·h],23.7,85316,DB00184,Nicotine
,27924817,Jss,Average Jss (μg/cm2/h) from formulations were: nicotine in PG (24 mg/ml): 3.97; commercial e-liquid containing menthol (25 mg/ml nicotine): 10.2; commercial e-liquid containing limonene (25 mg/ml nicotine): 23.7; neat nicotine: 175.,In vitro human epidermal permeation of nicotine from electronic cigarette refill liquids and implications for dermal exposure assessment. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27924817/),[μg] / [cm2·h],175,85317,DB00184,Nicotine
,27924817,lag times,E-liquid lag times ranged from 5 to 10 h.,In vitro human epidermal permeation of nicotine from electronic cigarette refill liquids and implications for dermal exposure assessment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27924817/),h,5 to 10,85318,DB00184,Nicotine
≈,27924817,Absorbed fraction,Absorbed fraction of nicotine from finite doses was ≈0.3 at 48 h.,In vitro human epidermal permeation of nicotine from electronic cigarette refill liquids and implications for dermal exposure assessment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27924817/),,0.3,85319,DB00184,Nicotine
less,20068013,elimination half-life,"The elimination half-life of nicotine seems to be short, that is, less than 1 hour.",Nicotine poisoning due to intravenous injection of cigarette soakage. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20068013/),h,1,85580,DB00184,Nicotine
,30916845,AUC0-6,"The geometric mean AUC0-6 (90% confidence interval) of melatonin, bupropion, repaglinide, chlorzoxazone and midazolam after LRYGB was 27 (19%-41%), 54 (43%-67%), 44 (29%-66%), 160 (129%-197%) and 74 (62%-90%) of the pre-surgery values, respectively.","Laparoscopic Roux-en-Y gastric bypass surgery influenced pharmacokinetics of several drugs given as a cocktail with the highest impact observed for CYP1A2, CYP2C8 and CYP2E1 substrates. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30916845/),,27,85677,DB00184,Nicotine
,30916845,AUC0-6,"The geometric mean AUC0-6 (90% confidence interval) of melatonin, bupropion, repaglinide, chlorzoxazone and midazolam after LRYGB was 27 (19%-41%), 54 (43%-67%), 44 (29%-66%), 160 (129%-197%) and 74 (62%-90%) of the pre-surgery values, respectively.","Laparoscopic Roux-en-Y gastric bypass surgery influenced pharmacokinetics of several drugs given as a cocktail with the highest impact observed for CYP1A2, CYP2C8 and CYP2E1 substrates. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30916845/),,54,85678,DB00184,Nicotine
,30916845,AUC0-6,"The geometric mean AUC0-6 (90% confidence interval) of melatonin, bupropion, repaglinide, chlorzoxazone and midazolam after LRYGB was 27 (19%-41%), 54 (43%-67%), 44 (29%-66%), 160 (129%-197%) and 74 (62%-90%) of the pre-surgery values, respectively.","Laparoscopic Roux-en-Y gastric bypass surgery influenced pharmacokinetics of several drugs given as a cocktail with the highest impact observed for CYP1A2, CYP2C8 and CYP2E1 substrates. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30916845/),,44,85679,DB00184,Nicotine
,30916845,AUC0-6,"The geometric mean AUC0-6 (90% confidence interval) of melatonin, bupropion, repaglinide, chlorzoxazone and midazolam after LRYGB was 27 (19%-41%), 54 (43%-67%), 44 (29%-66%), 160 (129%-197%) and 74 (62%-90%) of the pre-surgery values, respectively.","Laparoscopic Roux-en-Y gastric bypass surgery influenced pharmacokinetics of several drugs given as a cocktail with the highest impact observed for CYP1A2, CYP2C8 and CYP2E1 substrates. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30916845/),,160,85680,DB00184,Nicotine
,30916845,AUC0-6,"The geometric mean AUC0-6 (90% confidence interval) of melatonin, bupropion, repaglinide, chlorzoxazone and midazolam after LRYGB was 27 (19%-41%), 54 (43%-67%), 44 (29%-66%), 160 (129%-197%) and 74 (62%-90%) of the pre-surgery values, respectively.","Laparoscopic Roux-en-Y gastric bypass surgery influenced pharmacokinetics of several drugs given as a cocktail with the highest impact observed for CYP1A2, CYP2C8 and CYP2E1 substrates. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30916845/),,74,85681,DB00184,Nicotine
,22318754,AUC ratios,"However, among menthol smokers, the AUC ratios of metabolite/bupropion were lower in the nonsmoking phase compared with the smoking phase (hydro/bup = 31.49 ± 18.84 vs. 22.95 ± 13.27, p = .04; erythro/bup = 1.99 ± 1.02 vs. 1.76 ± 0.75, p = .016; threo/bup = 11.77 ± 8.90 vs. 10.44 ± 5.63, p = .034).",Effects of menthol on the pharmacokinetics of bupropion among Black smokers. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22318754/),,31.49,85825,DB00184,Nicotine
,22318754,AUC ratios,"However, among menthol smokers, the AUC ratios of metabolite/bupropion were lower in the nonsmoking phase compared with the smoking phase (hydro/bup = 31.49 ± 18.84 vs. 22.95 ± 13.27, p = .04; erythro/bup = 1.99 ± 1.02 vs. 1.76 ± 0.75, p = .016; threo/bup = 11.77 ± 8.90 vs. 10.44 ± 5.63, p = .034).",Effects of menthol on the pharmacokinetics of bupropion among Black smokers. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22318754/),,22.95,85826,DB00184,Nicotine
,22318754,AUC ratios,"However, among menthol smokers, the AUC ratios of metabolite/bupropion were lower in the nonsmoking phase compared with the smoking phase (hydro/bup = 31.49 ± 18.84 vs. 22.95 ± 13.27, p = .04; erythro/bup = 1.99 ± 1.02 vs. 1.76 ± 0.75, p = .016; threo/bup = 11.77 ± 8.90 vs. 10.44 ± 5.63, p = .034).",Effects of menthol on the pharmacokinetics of bupropion among Black smokers. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22318754/),,1.99,85827,DB00184,Nicotine
,22318754,AUC ratios,"However, among menthol smokers, the AUC ratios of metabolite/bupropion were lower in the nonsmoking phase compared with the smoking phase (hydro/bup = 31.49 ± 18.84 vs. 22.95 ± 13.27, p = .04; erythro/bup = 1.99 ± 1.02 vs. 1.76 ± 0.75, p = .016; threo/bup = 11.77 ± 8.90 vs. 10.44 ± 5.63, p = .034).",Effects of menthol on the pharmacokinetics of bupropion among Black smokers. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22318754/),,1.76,85828,DB00184,Nicotine
,22318754,AUC ratios,"However, among menthol smokers, the AUC ratios of metabolite/bupropion were lower in the nonsmoking phase compared with the smoking phase (hydro/bup = 31.49 ± 18.84 vs. 22.95 ± 13.27, p = .04; erythro/bup = 1.99 ± 1.02 vs. 1.76 ± 0.75, p = .016; threo/bup = 11.77 ± 8.90 vs. 10.44 ± 5.63, p = .034).",Effects of menthol on the pharmacokinetics of bupropion among Black smokers. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22318754/),,11.77,85829,DB00184,Nicotine
,22318754,AUC ratios,"However, among menthol smokers, the AUC ratios of metabolite/bupropion were lower in the nonsmoking phase compared with the smoking phase (hydro/bup = 31.49 ± 18.84 vs. 22.95 ± 13.27, p = .04; erythro/bup = 1.99 ± 1.02 vs. 1.76 ± 0.75, p = .016; threo/bup = 11.77 ± 8.90 vs. 10.44 ± 5.63, p = .034).",Effects of menthol on the pharmacokinetics of bupropion among Black smokers. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22318754/),,10.44,85830,DB00184,Nicotine
,1382940,a,"Clinical trials have shown that abstinence rates of 30 to 41% can be achieved during the first 6 weeks of application of transdermal nicotine systems, compared with 4 to 21% with placebo systems.","Transdermal Nicotine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy as an aid to smoking cessation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1382940/),,30 to 41,86537,DB00184,Nicotine
,1382940,a,"Clinical trials have shown that abstinence rates of 30 to 41% can be achieved during the first 6 weeks of application of transdermal nicotine systems, compared with 4 to 21% with placebo systems.","Transdermal Nicotine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy as an aid to smoking cessation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1382940/),,4,86538,DB00184,Nicotine
,8491235,Peak plasma nicotine concentration,"Peak plasma nicotine concentration correlated well with the dose, averaging 2.8 to 14.8 ng/ml, 19 to 25 min after injection of the 0.4 mg and 2.4 mg doses, respectively.",A clinical pharmacological study of subcutaneous nicotine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8491235/),[ng] / [ml],2.8 to 14.8,92238,DB00184,Nicotine
,8491235,plasma clearance over bioavailability ratio (CL/f),"The plasma clearance over bioavailability ratio (CL/f) averaged 12 to 13 ml.min-1.kg-1, similar to the clearance reported previously for intravenously administered nicotine.",A clinical pharmacological study of subcutaneous nicotine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8491235/),[ml] / [kg·min],12 to 13,92239,DB00184,Nicotine
,8491235,bioavailability,"Thus, bioavailability appears to be approximately 100%.",A clinical pharmacological study of subcutaneous nicotine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8491235/),%,100,92240,DB00184,Nicotine
,25082830,T max,"In Part B, the novel device 0.45 and 0.67 mg produced significantly lower C max, AUClast, and AUCall than Nicorette® (all p ≤ .05), higher AUC0-10 and significantly shorter T max (18.7 and 19.2 min vs. 38.0 min, respectively, p ≤ .05).",Evaluation of a novel nicotine inhaler device: part 2--effect on craving and smoking urges. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25082830/),min,18.7,93404,DB00184,Nicotine
,25082830,T max,"In Part B, the novel device 0.45 and 0.67 mg produced significantly lower C max, AUClast, and AUCall than Nicorette® (all p ≤ .05), higher AUC0-10 and significantly shorter T max (18.7 and 19.2 min vs. 38.0 min, respectively, p ≤ .05).",Evaluation of a novel nicotine inhaler device: part 2--effect on craving and smoking urges. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25082830/),min,19.2,93405,DB00184,Nicotine
,25082830,T max,"In Part B, the novel device 0.45 and 0.67 mg produced significantly lower C max, AUClast, and AUCall than Nicorette® (all p ≤ .05), higher AUC0-10 and significantly shorter T max (18.7 and 19.2 min vs. 38.0 min, respectively, p ≤ .05).",Evaluation of a novel nicotine inhaler device: part 2--effect on craving and smoking urges. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25082830/),min,38.0,93406,DB00184,Nicotine
,25082830,Craving score,"Craving score AUC was lower for the novel device 0.45 mg than for Nicorette® in Part B (1356.3 vs. 1566.3, p = .029) and approached statistical significance in Part D (1208.5 vs. 1402.3 [p = .059]).",Evaluation of a novel nicotine inhaler device: part 2--effect on craving and smoking urges. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25082830/),,1356.3,93407,DB00184,Nicotine
,25082830,Craving score,"Craving score AUC was lower for the novel device 0.45 mg than for Nicorette® in Part B (1356.3 vs. 1566.3, p = .029) and approached statistical significance in Part D (1208.5 vs. 1402.3 [p = .059]).",Evaluation of a novel nicotine inhaler device: part 2--effect on craving and smoking urges. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25082830/),,1566.3,93408,DB00184,Nicotine
,25082830,Craving score,"Craving score AUC was lower for the novel device 0.45 mg than for Nicorette® in Part B (1356.3 vs. 1566.3, p = .029) and approached statistical significance in Part D (1208.5 vs. 1402.3 [p = .059]).",Evaluation of a novel nicotine inhaler device: part 2--effect on craving and smoking urges. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25082830/),,1402.3,93409,DB00184,Nicotine
,25082830,AUC,"Craving score AUC was lower for the novel device 0.45 mg than for Nicorette® in Part B (1356.3 vs. 1566.3, p = .029) and approached statistical significance in Part D (1208.5 vs. 1402.3 [p = .059]).",Evaluation of a novel nicotine inhaler device: part 2--effect on craving and smoking urges. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25082830/),,1356.3,93410,DB00184,Nicotine
,25082830,AUC,"Craving score AUC was lower for the novel device 0.45 mg than for Nicorette® in Part B (1356.3 vs. 1566.3, p = .029) and approached statistical significance in Part D (1208.5 vs. 1402.3 [p = .059]).",Evaluation of a novel nicotine inhaler device: part 2--effect on craving and smoking urges. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25082830/),,1566.3,93411,DB00184,Nicotine
,25082830,AUC,"Craving score AUC was lower for the novel device 0.45 mg than for Nicorette® in Part B (1356.3 vs. 1566.3, p = .029) and approached statistical significance in Part D (1208.5 vs. 1402.3 [p = .059]).",Evaluation of a novel nicotine inhaler device: part 2--effect on craving and smoking urges. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25082830/),,1208.5,93412,DB00184,Nicotine
,25082830,AUC,"Craving score AUC was lower for the novel device 0.45 mg than for Nicorette® in Part B (1356.3 vs. 1566.3, p = .029) and approached statistical significance in Part D (1208.5 vs. 1402.3 [p = .059]).",Evaluation of a novel nicotine inhaler device: part 2--effect on craving and smoking urges. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25082830/),,1402.3,93413,DB00184,Nicotine
,16085507,bioavailable dose,The approximate bioavailable dose of nicotine from snus was 40%-60% of the extracted dose.,Steady-state nicotine plasma levels following use of four different types of Swedish snus compared with 2-mg Nicorette chewing gum: a crossover study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16085507/),%,40,93693,DB00184,Nicotine
,26686829,flow rate,A gradient program was used at a flow rate of 0.2mL/min.,"Development of a hydrophilic interaction liquid chromatography-tandem mass spectrometric method for the determination of kinsenoside, an antihyperlipidemic candidate, in rat plasma and its application to pharmacokinetic studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26686829/),[ml] / [min],0.2,94362,DB00184,Nicotine
,26686829,m/z,"For mass spectrometric detection, the multiple reaction monitoring mode was used; the MRM transitions were m/z 265.2→m/z 102.9 for kinsenoside and m/z 163.3→m/z 132.1 for the internal standard (IS) nicotine in the positive ionization mode.","Development of a hydrophilic interaction liquid chromatography-tandem mass spectrometric method for the determination of kinsenoside, an antihyperlipidemic candidate, in rat plasma and its application to pharmacokinetic studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26686829/),,265.2,94363,DB00184,Nicotine
,26686829,m/z,"For mass spectrometric detection, the multiple reaction monitoring mode was used; the MRM transitions were m/z 265.2→m/z 102.9 for kinsenoside and m/z 163.3→m/z 132.1 for the internal standard (IS) nicotine in the positive ionization mode.","Development of a hydrophilic interaction liquid chromatography-tandem mass spectrometric method for the determination of kinsenoside, an antihyperlipidemic candidate, in rat plasma and its application to pharmacokinetic studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26686829/),→,163.3,94364,DB00184,Nicotine
,11294371,Cmax,"The plasma nicotine profiles were similar following repeated administration of the sublingual tablet and the 2-mg nicotine chewing gum (mean Cmax 13.2 versus 14.4 ng/ml, median tmax 20 versus 20 min, mean AUC11-12 12.4 versus 13.5 ng/ml per hour) with no statistically significant difference between the two treatments.",Pharmacokinetic investigation of a nicotine sublingual tablet. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294371/),[ng] / [ml],13.2,95470,DB00184,Nicotine
,11294371,Cmax,"The plasma nicotine profiles were similar following repeated administration of the sublingual tablet and the 2-mg nicotine chewing gum (mean Cmax 13.2 versus 14.4 ng/ml, median tmax 20 versus 20 min, mean AUC11-12 12.4 versus 13.5 ng/ml per hour) with no statistically significant difference between the two treatments.",Pharmacokinetic investigation of a nicotine sublingual tablet. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294371/),[ng] / [ml],14.4,95471,DB00184,Nicotine
,11294371,tmax,"The plasma nicotine profiles were similar following repeated administration of the sublingual tablet and the 2-mg nicotine chewing gum (mean Cmax 13.2 versus 14.4 ng/ml, median tmax 20 versus 20 min, mean AUC11-12 12.4 versus 13.5 ng/ml per hour) with no statistically significant difference between the two treatments.",Pharmacokinetic investigation of a nicotine sublingual tablet. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294371/),min,20,95472,DB00184,Nicotine
,11294371,AUC11-12,"The plasma nicotine profiles were similar following repeated administration of the sublingual tablet and the 2-mg nicotine chewing gum (mean Cmax 13.2 versus 14.4 ng/ml, median tmax 20 versus 20 min, mean AUC11-12 12.4 versus 13.5 ng/ml per hour) with no statistically significant difference between the two treatments.",Pharmacokinetic investigation of a nicotine sublingual tablet. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294371/),[ng] / [h·ml],12.4,95473,DB00184,Nicotine
,11294371,AUC11-12,"The plasma nicotine profiles were similar following repeated administration of the sublingual tablet and the 2-mg nicotine chewing gum (mean Cmax 13.2 versus 14.4 ng/ml, median tmax 20 versus 20 min, mean AUC11-12 12.4 versus 13.5 ng/ml per hour) with no statistically significant difference between the two treatments.",Pharmacokinetic investigation of a nicotine sublingual tablet. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294371/),[ng] / [h·ml],13.5,95474,DB00184,Nicotine
,11294371,Cmax,"The mean Cmax for the 2-, 4- and 6-mg dose was 3.8 +/- 1.0, 6.8 +/- 2. 1, and 9.0 +/- 3.3 ng/ml, respectively, and in terms of dose proportionality the relative bioavailability of the 4- and 6-mg dose was 0.82 and 0.71, respectively.",Pharmacokinetic investigation of a nicotine sublingual tablet. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294371/),[ng] / [ml],3.8,95475,DB00184,Nicotine
,11294371,Cmax,"The mean Cmax for the 2-, 4- and 6-mg dose was 3.8 +/- 1.0, 6.8 +/- 2. 1, and 9.0 +/- 3.3 ng/ml, respectively, and in terms of dose proportionality the relative bioavailability of the 4- and 6-mg dose was 0.82 and 0.71, respectively.",Pharmacokinetic investigation of a nicotine sublingual tablet. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294371/),[ng] / [ml],6.8,95476,DB00184,Nicotine
,11294371,Cmax,"The mean Cmax for the 2-, 4- and 6-mg dose was 3.8 +/- 1.0, 6.8 +/- 2. 1, and 9.0 +/- 3.3 ng/ml, respectively, and in terms of dose proportionality the relative bioavailability of the 4- and 6-mg dose was 0.82 and 0.71, respectively.",Pharmacokinetic investigation of a nicotine sublingual tablet. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294371/),[ng] / [ml],9.0,95477,DB00184,Nicotine
,11294371,relative bioavailability,"The mean Cmax for the 2-, 4- and 6-mg dose was 3.8 +/- 1.0, 6.8 +/- 2. 1, and 9.0 +/- 3.3 ng/ml, respectively, and in terms of dose proportionality the relative bioavailability of the 4- and 6-mg dose was 0.82 and 0.71, respectively.",Pharmacokinetic investigation of a nicotine sublingual tablet. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294371/),,0.82,95478,DB00184,Nicotine
,11294371,relative bioavailability,"The mean Cmax for the 2-, 4- and 6-mg dose was 3.8 +/- 1.0, 6.8 +/- 2. 1, and 9.0 +/- 3.3 ng/ml, respectively, and in terms of dose proportionality the relative bioavailability of the 4- and 6-mg dose was 0.82 and 0.71, respectively.",Pharmacokinetic investigation of a nicotine sublingual tablet. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294371/),,0.71,95479,DB00184,Nicotine
,11294371,Cmax,"Mean Cmax was 12.1 ng/ml (correct use), 10.3 ng/ml (chewing and immediate swallowing), and 12.1 ng/ml (chewing and delayed swallowing).",Pharmacokinetic investigation of a nicotine sublingual tablet. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294371/),[ng] / [ml],12.1,95480,DB00184,Nicotine
,11294371,Cmax,"Mean Cmax was 12.1 ng/ml (correct use), 10.3 ng/ml (chewing and immediate swallowing), and 12.1 ng/ml (chewing and delayed swallowing).",Pharmacokinetic investigation of a nicotine sublingual tablet. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294371/),[ng] / [ml],10.3,95481,DB00184,Nicotine
,11294371,AUC9-10,"Corresponding mean values for AUC9-10 were 11.6, 9.6 and 11.2 ng/ml per hour.",Pharmacokinetic investigation of a nicotine sublingual tablet. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294371/),[ng] / [h·ml],11.6,95482,DB00184,Nicotine
,11294371,AUC9-10,"Corresponding mean values for AUC9-10 were 11.6, 9.6 and 11.2 ng/ml per hour.",Pharmacokinetic investigation of a nicotine sublingual tablet. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294371/),[ng] / [h·ml],9.6,95483,DB00184,Nicotine
,11294371,AUC9-10,"Corresponding mean values for AUC9-10 were 11.6, 9.6 and 11.2 ng/ml per hour.",Pharmacokinetic investigation of a nicotine sublingual tablet. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294371/),[ng] / [h·ml],11.2,95484,DB00184,Nicotine
,11294371,Cmax,"There were no significant differences between 'alkaline mouth' versus control, 'acidic mouth' versus control or 'alkaline stomach' versus control, but the rate of nicotine absorption was increased at alkaline compared to acidic oral pH (mean Cmax 6.1 versus 4.9 ng/l ml, P = 0.003; median tmax 60 versus 90 min, P= 0.0002).",Pharmacokinetic investigation of a nicotine sublingual tablet. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294371/),[ng] / [l·ml],6.1,95485,DB00184,Nicotine
,11294371,Cmax,"There were no significant differences between 'alkaline mouth' versus control, 'acidic mouth' versus control or 'alkaline stomach' versus control, but the rate of nicotine absorption was increased at alkaline compared to acidic oral pH (mean Cmax 6.1 versus 4.9 ng/l ml, P = 0.003; median tmax 60 versus 90 min, P= 0.0002).",Pharmacokinetic investigation of a nicotine sublingual tablet. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294371/),[ng] / [l·ml],4.9,95486,DB00184,Nicotine
,11294371,tmax,"There were no significant differences between 'alkaline mouth' versus control, 'acidic mouth' versus control or 'alkaline stomach' versus control, but the rate of nicotine absorption was increased at alkaline compared to acidic oral pH (mean Cmax 6.1 versus 4.9 ng/l ml, P = 0.003; median tmax 60 versus 90 min, P= 0.0002).",Pharmacokinetic investigation of a nicotine sublingual tablet. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294371/),min,60,95487,DB00184,Nicotine
,11294371,tmax,"There were no significant differences between 'alkaline mouth' versus control, 'acidic mouth' versus control or 'alkaline stomach' versus control, but the rate of nicotine absorption was increased at alkaline compared to acidic oral pH (mean Cmax 6.1 versus 4.9 ng/l ml, P = 0.003; median tmax 60 versus 90 min, P= 0.0002).",Pharmacokinetic investigation of a nicotine sublingual tablet. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294371/),min,90,95488,DB00184,Nicotine
,3830243,half-life,"Intravenous administration was characterized by a dose-independent half-life of 12.2 h, mean residence time of 15.9 h, total clearance of 3.64 l h-1 and a volume of distribution of 56.5 l.",Kinetics of cotinine after oral and intravenous administration to man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3830243/),h,12.2,99023,DB00184,Nicotine
,3830243,mean residence time,"Intravenous administration was characterized by a dose-independent half-life of 12.2 h, mean residence time of 15.9 h, total clearance of 3.64 l h-1 and a volume of distribution of 56.5 l.",Kinetics of cotinine after oral and intravenous administration to man. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3830243/),h,15.9,99024,DB00184,Nicotine
,3830243,total clearance,"Intravenous administration was characterized by a dose-independent half-life of 12.2 h, mean residence time of 15.9 h, total clearance of 3.64 l h-1 and a volume of distribution of 56.5 l.",Kinetics of cotinine after oral and intravenous administration to man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3830243/),[l] / [h],3.64,99025,DB00184,Nicotine
,3830243,volume of distribution,"Intravenous administration was characterized by a dose-independent half-life of 12.2 h, mean residence time of 15.9 h, total clearance of 3.64 l h-1 and a volume of distribution of 56.5 l.",Kinetics of cotinine after oral and intravenous administration to man. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3830243/),l,56.5,99026,DB00184,Nicotine
,3830243,Renal clearance,Renal clearance was 0.46 l h-1 and approximately 12.0% of the dose was excreted unchanged in the urine.,Kinetics of cotinine after oral and intravenous administration to man. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3830243/),[l] / [h],0.46,99027,DB00184,Nicotine
,3830243,mean absorption time,"The mean absorption time after oral dosing ranged between 1 and 3 h, the peak concentration was reached within 45 min and the mean elimination half-lives were 12.9 and 11.7 h, respectively, after the 10 and 20 mg doses.",Kinetics of cotinine after oral and intravenous administration to man. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3830243/),h,1 and 3,99028,DB00184,Nicotine
,3830243,elimination half-lives,"The mean absorption time after oral dosing ranged between 1 and 3 h, the peak concentration was reached within 45 min and the mean elimination half-lives were 12.9 and 11.7 h, respectively, after the 10 and 20 mg doses.",Kinetics of cotinine after oral and intravenous administration to man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3830243/),h,12.9,99029,DB00184,Nicotine
,3830243,elimination half-lives,"The mean absorption time after oral dosing ranged between 1 and 3 h, the peak concentration was reached within 45 min and the mean elimination half-lives were 12.9 and 11.7 h, respectively, after the 10 and 20 mg doses.",Kinetics of cotinine after oral and intravenous administration to man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3830243/),h,11.7,99030,DB00184,Nicotine
,3830243,Systemic bioavailability,Systemic bioavailability ranged between 0.84 and 1.11 following 10 mg and between 0.97 and 1.03 following the 20 mg dose.,Kinetics of cotinine after oral and intravenous administration to man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3830243/),,0.84 and 1.11,99031,DB00184,Nicotine
,3830243,Systemic bioavailability,Systemic bioavailability ranged between 0.84 and 1.11 following 10 mg and between 0.97 and 1.03 following the 20 mg dose.,Kinetics of cotinine after oral and intravenous administration to man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3830243/),,0.97 and 1.03,99032,DB00184,Nicotine
,1257606,biologic half-life (t1/2),"Plasma nicotine concentration was characterized by a biexponential decay with a mean biologic half-life (t1/2) of 0.96 hrs, a large apparent volume of distribution (5.67 L/kg) and total body clearance (4.04 L/hr/kg).",Disposition of nicotine in the rat after intravenous administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1257606/),h,0.96,99200,DB00184,Nicotine
,1257606,apparent volume of distribution,"Plasma nicotine concentration was characterized by a biexponential decay with a mean biologic half-life (t1/2) of 0.96 hrs, a large apparent volume of distribution (5.67 L/kg) and total body clearance (4.04 L/hr/kg).",Disposition of nicotine in the rat after intravenous administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1257606/),[l] / [kg],5.67,99201,DB00184,Nicotine
,1257606,total body clearance,"Plasma nicotine concentration was characterized by a biexponential decay with a mean biologic half-life (t1/2) of 0.96 hrs, a large apparent volume of distribution (5.67 L/kg) and total body clearance (4.04 L/hr/kg).",Disposition of nicotine in the rat after intravenous administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1257606/),[l] / [h·kg],4.04,99202,DB00184,Nicotine
,1257606,t1/2,"Maximum plasma concentration of cotinine was reached within 1 1/2 hrs post-nicotine administration, followed by a monoexponential decline with a mean t1/2 of 6.4 hrs.",Disposition of nicotine in the rat after intravenous administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1257606/),h,6.4,99203,DB00184,Nicotine
,1257606,t1/2,The plasma concentrations of origin activity rose to maximum levels within 30 minutes and declined slowly in a biexponential fashion with a mean t1/2 of 23.2 hrs.,Disposition of nicotine in the rat after intravenous administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1257606/),h,23.2,99204,DB00184,Nicotine
,7768082,clearance,"The clearance of nicotine was unusually low (6.5 ml/min/kg versus 17.2 ml/min/kg), and the half-life of nicotine significantly longer (348 minutes versus 138 minutes) in the index case subject compared with the control subjects.",Deficient C-oxidation of nicotine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7768082/),[ml] / [kg·min],6.5,99563,DB00184,Nicotine
,7768082,clearance,"The clearance of nicotine was unusually low (6.5 ml/min/kg versus 17.2 ml/min/kg), and the half-life of nicotine significantly longer (348 minutes versus 138 minutes) in the index case subject compared with the control subjects.",Deficient C-oxidation of nicotine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7768082/),[ml] / [kg·min],17.2,99564,DB00184,Nicotine
,7768082,half-life,"The clearance of nicotine was unusually low (6.5 ml/min/kg versus 17.2 ml/min/kg), and the half-life of nicotine significantly longer (348 minutes versus 138 minutes) in the index case subject compared with the control subjects.",Deficient C-oxidation of nicotine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7768082/),min,348,99565,DB00184,Nicotine
,7768082,half-life,"The clearance of nicotine was unusually low (6.5 ml/min/kg versus 17.2 ml/min/kg), and the half-life of nicotine significantly longer (348 minutes versus 138 minutes) in the index case subject compared with the control subjects.",Deficient C-oxidation of nicotine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7768082/),min,138,99566,DB00184,Nicotine
,21454913,Extracted dose,"Extracted dose from the NP gum averaged 2.56 mg compared with 2.12 and 2.18 mg, respectively, for Swedish portion snus.",Nicotine delivery and subjective effects of Swedish portion snus compared with 4 mg nicotine polacrilex chewing gum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21454913/),mg,2.56,100647,DB00184,Nicotine
,21454913,Extracted dose,"Extracted dose from the NP gum averaged 2.56 mg compared with 2.12 and 2.18 mg, respectively, for Swedish portion snus.",Nicotine delivery and subjective effects of Swedish portion snus compared with 4 mg nicotine polacrilex chewing gum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21454913/),mg,2.12,100648,DB00184,Nicotine
,21454913,Extracted dose,"Extracted dose from the NP gum averaged 2.56 mg compared with 2.12 and 2.18 mg, respectively, for Swedish portion snus.",Nicotine delivery and subjective effects of Swedish portion snus compared with 4 mg nicotine polacrilex chewing gum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21454913/),mg,2.18,100649,DB00184,Nicotine
,21454913,T(max),"Median T(max) was shorter, 30 min for snus compared with 45 min for the NP gum.",Nicotine delivery and subjective effects of Swedish portion snus compared with 4 mg nicotine polacrilex chewing gum. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21454913/),min,30,100650,DB00184,Nicotine
,21454913,T(max),"Median T(max) was shorter, 30 min for snus compared with 45 min for the NP gum.",Nicotine delivery and subjective effects of Swedish portion snus compared with 4 mg nicotine polacrilex chewing gum. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21454913/),min,45,100651,DB00184,Nicotine
,17112808,area under the plasma cotinine concentration-time curve from 0 to 8 hours,"Grapefruit juice inhibited the formation of cotinine from nicotine (area under the plasma cotinine concentration-time curve from 0 to 8 hours of 6807 min.ng/mL, 7805 min.ng/mL, and 8007 min.ng/mL for full-strength grapefruit juice, half-strength grapefruit juice, and water, respectively; repeated-measures ANOVA, P=.009).",Effect of grapefruit juice on cytochrome P450 2A6 and nicotine renal clearance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17112808/),[min·ng] / [ml],6807,103177,DB00184,Nicotine
,17112808,area under the plasma cotinine concentration-time curve from 0 to 8 hours,"Grapefruit juice inhibited the formation of cotinine from nicotine (area under the plasma cotinine concentration-time curve from 0 to 8 hours of 6807 min.ng/mL, 7805 min.ng/mL, and 8007 min.ng/mL for full-strength grapefruit juice, half-strength grapefruit juice, and water, respectively; repeated-measures ANOVA, P=.009).",Effect of grapefruit juice on cytochrome P450 2A6 and nicotine renal clearance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17112808/),[min·ng] / [ml],7805,103178,DB00184,Nicotine
,17112808,area under the plasma cotinine concentration-time curve from 0 to 8 hours,"Grapefruit juice inhibited the formation of cotinine from nicotine (area under the plasma cotinine concentration-time curve from 0 to 8 hours of 6807 min.ng/mL, 7805 min.ng/mL, and 8007 min.ng/mL for full-strength grapefruit juice, half-strength grapefruit juice, and water, respectively; repeated-measures ANOVA, P=.009).",Effect of grapefruit juice on cytochrome P450 2A6 and nicotine renal clearance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17112808/),[min·ng] / [ml],8007,103179,DB00184,Nicotine
,17112808,time to peak plasma concentration,"The time to peak plasma concentration of cotinine was delayed (216 minutes, 159 minutes, and 147 minutes, respectively; ANOVA, P=.011), and the peak plasma concentration was lower with grapefruit juice compared with water (18 ng/mL, 21 ng/mL, and 22 ng/mL, respectively; ANOVA, P=.010).",Effect of grapefruit juice on cytochrome P450 2A6 and nicotine renal clearance. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17112808/),min,216,103180,DB00184,Nicotine
,17112808,time to peak plasma concentration,"The time to peak plasma concentration of cotinine was delayed (216 minutes, 159 minutes, and 147 minutes, respectively; ANOVA, P=.011), and the peak plasma concentration was lower with grapefruit juice compared with water (18 ng/mL, 21 ng/mL, and 22 ng/mL, respectively; ANOVA, P=.010).",Effect of grapefruit juice on cytochrome P450 2A6 and nicotine renal clearance. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17112808/),min,159,103181,DB00184,Nicotine
,17112808,time to peak plasma concentration,"The time to peak plasma concentration of cotinine was delayed (216 minutes, 159 minutes, and 147 minutes, respectively; ANOVA, P=.011), and the peak plasma concentration was lower with grapefruit juice compared with water (18 ng/mL, 21 ng/mL, and 22 ng/mL, respectively; ANOVA, P=.010).",Effect of grapefruit juice on cytochrome P450 2A6 and nicotine renal clearance. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17112808/),min,147,103182,DB00184,Nicotine
,17112808,peak plasma concentration,"The time to peak plasma concentration of cotinine was delayed (216 minutes, 159 minutes, and 147 minutes, respectively; ANOVA, P=.011), and the peak plasma concentration was lower with grapefruit juice compared with water (18 ng/mL, 21 ng/mL, and 22 ng/mL, respectively; ANOVA, P=.010).",Effect of grapefruit juice on cytochrome P450 2A6 and nicotine renal clearance. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17112808/),[ng] / [ml],18,103183,DB00184,Nicotine
,17112808,peak plasma concentration,"The time to peak plasma concentration of cotinine was delayed (216 minutes, 159 minutes, and 147 minutes, respectively; ANOVA, P=.011), and the peak plasma concentration was lower with grapefruit juice compared with water (18 ng/mL, 21 ng/mL, and 22 ng/mL, respectively; ANOVA, P=.010).",Effect of grapefruit juice on cytochrome P450 2A6 and nicotine renal clearance. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17112808/),[ng] / [ml],21,103184,DB00184,Nicotine
,17112808,peak plasma concentration,"The time to peak plasma concentration of cotinine was delayed (216 minutes, 159 minutes, and 147 minutes, respectively; ANOVA, P=.011), and the peak plasma concentration was lower with grapefruit juice compared with water (18 ng/mL, 21 ng/mL, and 22 ng/mL, respectively; ANOVA, P=.010).",Effect of grapefruit juice on cytochrome P450 2A6 and nicotine renal clearance. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17112808/),[ng] / [ml],22,103185,DB00184,Nicotine
,17112808,renal clearance,"Grapefruit juice increased the renal clearance of nicotine (231 mL/min, 219 mL/min, and 123 mL/min, respectively; ANOVA, P=.045) and cotinine (19 mL/min, 14 mL/min, and 16 mL/min, respectively; ANOVA, P=.002).",Effect of grapefruit juice on cytochrome P450 2A6 and nicotine renal clearance. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17112808/),[ml] / [min],231,103186,DB00184,Nicotine
,17112808,renal clearance,"Grapefruit juice increased the renal clearance of nicotine (231 mL/min, 219 mL/min, and 123 mL/min, respectively; ANOVA, P=.045) and cotinine (19 mL/min, 14 mL/min, and 16 mL/min, respectively; ANOVA, P=.002).",Effect of grapefruit juice on cytochrome P450 2A6 and nicotine renal clearance. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17112808/),[ml] / [min],219,103187,DB00184,Nicotine
,17112808,renal clearance,"Grapefruit juice increased the renal clearance of nicotine (231 mL/min, 219 mL/min, and 123 mL/min, respectively; ANOVA, P=.045) and cotinine (19 mL/min, 14 mL/min, and 16 mL/min, respectively; ANOVA, P=.002).",Effect of grapefruit juice on cytochrome P450 2A6 and nicotine renal clearance. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17112808/),[ml] / [min],123,103188,DB00184,Nicotine
,17112808,renal clearance,"Grapefruit juice increased the renal clearance of nicotine (231 mL/min, 219 mL/min, and 123 mL/min, respectively; ANOVA, P=.045) and cotinine (19 mL/min, 14 mL/min, and 16 mL/min, respectively; ANOVA, P=.002).",Effect of grapefruit juice on cytochrome P450 2A6 and nicotine renal clearance. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17112808/),[ml] / [min],19,103189,DB00184,Nicotine
,17112808,renal clearance,"Grapefruit juice increased the renal clearance of nicotine (231 mL/min, 219 mL/min, and 123 mL/min, respectively; ANOVA, P=.045) and cotinine (19 mL/min, 14 mL/min, and 16 mL/min, respectively; ANOVA, P=.002).",Effect of grapefruit juice on cytochrome P450 2A6 and nicotine renal clearance. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17112808/),[ml] / [min],14,103190,DB00184,Nicotine
,17112808,renal clearance,"Grapefruit juice increased the renal clearance of nicotine (231 mL/min, 219 mL/min, and 123 mL/min, respectively; ANOVA, P=.045) and cotinine (19 mL/min, 14 mL/min, and 16 mL/min, respectively; ANOVA, P=.002).",Effect of grapefruit juice on cytochrome P450 2A6 and nicotine renal clearance. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17112808/),[ml] / [min],16,103191,DB00184,Nicotine
,9759592,Cmax,"The revised enema formulation significantly reduced Cmax for nicotine from 8.3 +/- 2.7 to 6.6 +/- 2.1, p = 0.03 with some reduction in nicotine absorption and improved tolerance.",Nicotine carbomer enemas--pharmacokinetics of a revised formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9759592/),,8.3,107109,DB00184,Nicotine
,9759592,Cmax,"The revised enema formulation significantly reduced Cmax for nicotine from 8.3 +/- 2.7 to 6.6 +/- 2.1, p = 0.03 with some reduction in nicotine absorption and improved tolerance.",Nicotine carbomer enemas--pharmacokinetics of a revised formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9759592/),,6.6,107110,DB00184,Nicotine
,31994254,maximum concentration (Cmax ),"Juul's PK profile was close to the PK profile of cigarettes [maximum concentration (Cmax ) = 20.4 versus 19.2 ng/ml; time to maximum concentration (Tmax ) = 4 versus 6 minutes; area under the curve (AUC): 307.9 versus 312.6, respectively].",Nicotine delivery and users' reactions to Juul compared with cigarettes and other e-cigarette products. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31994254/),[ng] / [ml],20.4,107528,DB00184,Nicotine
,31994254,maximum concentration (Cmax ),"Juul's PK profile was close to the PK profile of cigarettes [maximum concentration (Cmax ) = 20.4 versus 19.2 ng/ml; time to maximum concentration (Tmax ) = 4 versus 6 minutes; area under the curve (AUC): 307.9 versus 312.6, respectively].",Nicotine delivery and users' reactions to Juul compared with cigarettes and other e-cigarette products. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31994254/),[ng] / [ml],19.2,107529,DB00184,Nicotine
,31994254,time to maximum concentration (Tmax ),"Juul's PK profile was close to the PK profile of cigarettes [maximum concentration (Cmax ) = 20.4 versus 19.2 ng/ml; time to maximum concentration (Tmax ) = 4 versus 6 minutes; area under the curve (AUC): 307.9 versus 312.6, respectively].",Nicotine delivery and users' reactions to Juul compared with cigarettes and other e-cigarette products. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31994254/),min,4,107530,DB00184,Nicotine
,31994254,time to maximum concentration (Tmax ),"Juul's PK profile was close to the PK profile of cigarettes [maximum concentration (Cmax ) = 20.4 versus 19.2 ng/ml; time to maximum concentration (Tmax ) = 4 versus 6 minutes; area under the curve (AUC): 307.9 versus 312.6, respectively].",Nicotine delivery and users' reactions to Juul compared with cigarettes and other e-cigarette products. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31994254/),min,6,107531,DB00184,Nicotine
,31994254,area under the curve (AUC),"Juul's PK profile was close to the PK profile of cigarettes [maximum concentration (Cmax ) = 20.4 versus 19.2 ng/ml; time to maximum concentration (Tmax ) = 4 versus 6 minutes; area under the curve (AUC): 307.9 versus 312.6, respectively].",Nicotine delivery and users' reactions to Juul compared with cigarettes and other e-cigarette products. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31994254/),,307.9,107532,DB00184,Nicotine
,31994254,area under the curve (AUC),"Juul's PK profile was close to the PK profile of cigarettes [maximum concentration (Cmax ) = 20.4 versus 19.2 ng/ml; time to maximum concentration (Tmax ) = 4 versus 6 minutes; area under the curve (AUC): 307.9 versus 312.6, respectively].",Nicotine delivery and users' reactions to Juul compared with cigarettes and other e-cigarette products. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31994254/),,312.6,107533,DB00184,Nicotine
,31994254,Tmax,"Compared with other EC products, Juul had shorter Tmax [4 minutes, (IQR = 2.5-4.0) versus 6.3 minutes, (IQR = 4.7 - 8.1), P = 0.012] and higher Cmax (28.9 (SD = 15.6) versus 10.6 (SD = 5.5), P = 0.013) despite a lower number of puffs (12.5 (SD = 4.2) versus 17.0 (SD = 4.2), P = 0.084).",Nicotine delivery and users' reactions to Juul compared with cigarettes and other e-cigarette products. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31994254/),min,4,107534,DB00184,Nicotine
,31994254,Tmax,"Compared with other EC products, Juul had shorter Tmax [4 minutes, (IQR = 2.5-4.0) versus 6.3 minutes, (IQR = 4.7 - 8.1), P = 0.012] and higher Cmax (28.9 (SD = 15.6) versus 10.6 (SD = 5.5), P = 0.013) despite a lower number of puffs (12.5 (SD = 4.2) versus 17.0 (SD = 4.2), P = 0.084).",Nicotine delivery and users' reactions to Juul compared with cigarettes and other e-cigarette products. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31994254/),min,6.3,107535,DB00184,Nicotine
,31994254,Cmax,"Compared with other EC products, Juul had shorter Tmax [4 minutes, (IQR = 2.5-4.0) versus 6.3 minutes, (IQR = 4.7 - 8.1), P = 0.012] and higher Cmax (28.9 (SD = 15.6) versus 10.6 (SD = 5.5), P = 0.013) despite a lower number of puffs (12.5 (SD = 4.2) versus 17.0 (SD = 4.2), P = 0.084).",Nicotine delivery and users' reactions to Juul compared with cigarettes and other e-cigarette products. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31994254/),,28.9,107536,DB00184,Nicotine
,31994254,Cmax,"Compared with other EC products, Juul had shorter Tmax [4 minutes, (IQR = 2.5-4.0) versus 6.3 minutes, (IQR = 4.7 - 8.1), P = 0.012] and higher Cmax (28.9 (SD = 15.6) versus 10.6 (SD = 5.5), P = 0.013) despite a lower number of puffs (12.5 (SD = 4.2) versus 17.0 (SD = 4.2), P = 0.084).",Nicotine delivery and users' reactions to Juul compared with cigarettes and other e-cigarette products. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31994254/),,10.6,107537,DB00184,Nicotine
,31257625,run time,The gradient elution was performed at 0.4 mL/min with a run time of 3.6 min.,Simultaneous determination of plasma nicotine and cotinine by UHPLC-MS/MS in C57BL/6 mice and its application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31257625/),min,3.6,111173,DB00184,Nicotine
,31257625,m/z,"The quantitative ion transition was m/z 163.1 > 130.0 for nicotine, m/z 177.1 > 80.0 for cotinine and m/z 167.1 > 134.0 for nicotine-D4 (internal standard, IS).",Simultaneous determination of plasma nicotine and cotinine by UHPLC-MS/MS in C57BL/6 mice and its application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31257625/),,163.1,111174,DB00184,Nicotine
>,31257625,m/z,"The quantitative ion transition was m/z 163.1 > 130.0 for nicotine, m/z 177.1 > 80.0 for cotinine and m/z 167.1 > 134.0 for nicotine-D4 (internal standard, IS).",Simultaneous determination of plasma nicotine and cotinine by UHPLC-MS/MS in C57BL/6 mice and its application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31257625/),,130.0,111175,DB00184,Nicotine
,31257625,m/z,"The quantitative ion transition was m/z 163.1 > 130.0 for nicotine, m/z 177.1 > 80.0 for cotinine and m/z 167.1 > 134.0 for nicotine-D4 (internal standard, IS).",Simultaneous determination of plasma nicotine and cotinine by UHPLC-MS/MS in C57BL/6 mice and its application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31257625/),,177.1,111176,DB00184,Nicotine
>,31257625,m/z,"The quantitative ion transition was m/z 163.1 > 130.0 for nicotine, m/z 177.1 > 80.0 for cotinine and m/z 167.1 > 134.0 for nicotine-D4 (internal standard, IS).",Simultaneous determination of plasma nicotine and cotinine by UHPLC-MS/MS in C57BL/6 mice and its application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31257625/),,80.0,111177,DB00184,Nicotine
,31257625,m/z,"The quantitative ion transition was m/z 163.1 > 130.0 for nicotine, m/z 177.1 > 80.0 for cotinine and m/z 167.1 > 134.0 for nicotine-D4 (internal standard, IS).",Simultaneous determination of plasma nicotine and cotinine by UHPLC-MS/MS in C57BL/6 mice and its application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31257625/),,167.1,111178,DB00184,Nicotine
>,31257625,m/z,"The quantitative ion transition was m/z 163.1 > 130.0 for nicotine, m/z 177.1 > 80.0 for cotinine and m/z 167.1 > 134.0 for nicotine-D4 (internal standard, IS).",Simultaneous determination of plasma nicotine and cotinine by UHPLC-MS/MS in C57BL/6 mice and its application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31257625/),,134.0,111179,DB00184,Nicotine
,31257625,normalized recovery,"The IS normalized recovery was 90.62-98.95% for nicotine and 89.18-101.53% for cotinine, and the IS normalized matrix factor was 106.00-116.44% for nicotine and 100.34-109.85% for cotinine.",Simultaneous determination of plasma nicotine and cotinine by UHPLC-MS/MS in C57BL/6 mice and its application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31257625/),%,90.62-98.95,111180,DB00184,Nicotine
,31257625,normalized recovery,"The IS normalized recovery was 90.62-98.95% for nicotine and 89.18-101.53% for cotinine, and the IS normalized matrix factor was 106.00-116.44% for nicotine and 100.34-109.85% for cotinine.",Simultaneous determination of plasma nicotine and cotinine by UHPLC-MS/MS in C57BL/6 mice and its application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31257625/),%,89.18-101.53,111181,DB00184,Nicotine
,31257625,normal,"The IS normalized recovery was 90.62-98.95% for nicotine and 89.18-101.53% for cotinine, and the IS normalized matrix factor was 106.00-116.44% for nicotine and 100.34-109.85% for cotinine.",Simultaneous determination of plasma nicotine and cotinine by UHPLC-MS/MS in C57BL/6 mice and its application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31257625/),,106.00-116.44,111182,DB00184,Nicotine
,26696273,maximum plasma nicotine concentration (Cmax),"In Part 1, maximum plasma nicotine concentration (Cmax) for UF2.0%, FL2.0%, Nicorette(®) and CC was 3.6, 2.5, 2.5 and 21.2 ng/mL, respectively.","A randomised, crossover study on an electronic vapour product, a nicotine inhalator and a conventional cigarette. Part A: Pharmacokinetics. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26696273/),[ng] / [ml],3.6,111885,DB00184,Nicotine
,26696273,maximum plasma nicotine concentration (Cmax),"In Part 1, maximum plasma nicotine concentration (Cmax) for UF2.0%, FL2.0%, Nicorette(®) and CC was 3.6, 2.5, 2.5 and 21.2 ng/mL, respectively.","A randomised, crossover study on an electronic vapour product, a nicotine inhalator and a conventional cigarette. Part A: Pharmacokinetics. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26696273/),[ng] / [ml],2.5,111886,DB00184,Nicotine
,26696273,maximum plasma nicotine concentration (Cmax),"In Part 1, maximum plasma nicotine concentration (Cmax) for UF2.0%, FL2.0%, Nicorette(®) and CC was 3.6, 2.5, 2.5 and 21.2 ng/mL, respectively.","A randomised, crossover study on an electronic vapour product, a nicotine inhalator and a conventional cigarette. Part A: Pharmacokinetics. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26696273/),[ng] / [ml],21.2,111887,DB00184,Nicotine
,26696273,time to maximum plasma nicotine concentration (Tmax),"The time to maximum plasma nicotine concentration (Tmax) was longer for the EVP (UF2.0%, 9.0 min; FL2.0%, 10.0 min) and the nicotine inhalator (13.0 min) compared to CC (3.0 min).","A randomised, crossover study on an electronic vapour product, a nicotine inhalator and a conventional cigarette. Part A: Pharmacokinetics. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26696273/),%,2.,111888,DB00184,Nicotine
,26696273,time to maximum plasma nicotine concentration (Tmax),"The time to maximum plasma nicotine concentration (Tmax) was longer for the EVP (UF2.0%, 9.0 min; FL2.0%, 10.0 min) and the nicotine inhalator (13.0 min) compared to CC (3.0 min).","A randomised, crossover study on an electronic vapour product, a nicotine inhalator and a conventional cigarette. Part A: Pharmacokinetics. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26696273/),min,9.0,111889,DB00184,Nicotine
,26696273,time to maximum plasma nicotine concentration (Tmax),"The time to maximum plasma nicotine concentration (Tmax) was longer for the EVP (UF2.0%, 9.0 min; FL2.0%, 10.0 min) and the nicotine inhalator (13.0 min) compared to CC (3.0 min).","A randomised, crossover study on an electronic vapour product, a nicotine inhalator and a conventional cigarette. Part A: Pharmacokinetics. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26696273/),%,2.0,111890,DB00184,Nicotine
,26696273,time to maximum plasma nicotine concentration (Tmax),"The time to maximum plasma nicotine concentration (Tmax) was longer for the EVP (UF2.0%, 9.0 min; FL2.0%, 10.0 min) and the nicotine inhalator (13.0 min) compared to CC (3.0 min).","A randomised, crossover study on an electronic vapour product, a nicotine inhalator and a conventional cigarette. Part A: Pharmacokinetics. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26696273/),min,10.0,111891,DB00184,Nicotine
,26696273,time to maximum plasma nicotine concentration (Tmax),"The time to maximum plasma nicotine concentration (Tmax) was longer for the EVP (UF2.0%, 9.0 min; FL2.0%, 10.0 min) and the nicotine inhalator (13.0 min) compared to CC (3.0 min).","A randomised, crossover study on an electronic vapour product, a nicotine inhalator and a conventional cigarette. Part A: Pharmacokinetics. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26696273/),min,13.0,111892,DB00184,Nicotine
,26696273,time to maximum plasma nicotine concentration (Tmax),"The time to maximum plasma nicotine concentration (Tmax) was longer for the EVP (UF2.0%, 9.0 min; FL2.0%, 10.0 min) and the nicotine inhalator (13.0 min) compared to CC (3.0 min).","A randomised, crossover study on an electronic vapour product, a nicotine inhalator and a conventional cigarette. Part A: Pharmacokinetics. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26696273/),min,3.0,111893,DB00184,Nicotine
,26696273,Cmax,"In Part 2, EVP with 0%, 0.4%, 0.9% and 2.0% nicotine produced Cmax values of 0.6, 1.0, 1.9 and 3.6 ng/mL, respectively.","A randomised, crossover study on an electronic vapour product, a nicotine inhalator and a conventional cigarette. Part A: Pharmacokinetics. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26696273/),[ng] / [ml],0.6,111894,DB00184,Nicotine
,26696273,Cmax,"In Part 2, EVP with 0%, 0.4%, 0.9% and 2.0% nicotine produced Cmax values of 0.6, 1.0, 1.9 and 3.6 ng/mL, respectively.","A randomised, crossover study on an electronic vapour product, a nicotine inhalator and a conventional cigarette. Part A: Pharmacokinetics. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26696273/),[ng] / [ml],1.0,111895,DB00184,Nicotine
,26696273,Cmax,"In Part 2, EVP with 0%, 0.4%, 0.9% and 2.0% nicotine produced Cmax values of 0.6, 1.0, 1.9 and 3.6 ng/mL, respectively.","A randomised, crossover study on an electronic vapour product, a nicotine inhalator and a conventional cigarette. Part A: Pharmacokinetics. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26696273/),[ng] / [ml],1.9,111896,DB00184,Nicotine
,26696273,Cmax,"In Part 2, EVP with 0%, 0.4%, 0.9% and 2.0% nicotine produced Cmax values of 0.6, 1.0, 1.9 and 3.6 ng/mL, respectively.","A randomised, crossover study on an electronic vapour product, a nicotine inhalator and a conventional cigarette. Part A: Pharmacokinetics. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26696273/),[ng] / [ml],3.6,111897,DB00184,Nicotine
,11853935,maximum adsorption,The maximum adsorption of nicotine onto Amberlite IRP69 was 1.071 mg drug per mg resin.,Development of a novel nasal nicotine formulation comprising an optimal pulsatile and sustained plasma nicotine profile for smoking cessation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11853935/),[drug·mg] / [mg],1.071,113380,DB00184,Nicotine
,17716838,amount of,"The mean (+/-S.D.) amount of nicotine retained was 0.126+/-0.167, 0.960+/-0.214, and 1.070+/-0.223mg/cig for Patterns A, B, and C, respectively.",Respiratory retention of nicotine and urinary excretion of nicotine and its five major metabolites in adult male smokers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17716838/),[mg] / [cig],0.126,114044,DB00184,Nicotine
,17716838,amount of,"The mean (+/-S.D.) amount of nicotine retained was 0.126+/-0.167, 0.960+/-0.214, and 1.070+/-0.223mg/cig for Patterns A, B, and C, respectively.",Respiratory retention of nicotine and urinary excretion of nicotine and its five major metabolites in adult male smokers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17716838/),[mg] / [cig],0.960,114045,DB00184,Nicotine
,17716838,amount of,"The mean (+/-S.D.) amount of nicotine retained was 0.126+/-0.167, 0.960+/-0.214, and 1.070+/-0.223mg/cig for Patterns A, B, and C, respectively.",Respiratory retention of nicotine and urinary excretion of nicotine and its five major metabolites in adult male smokers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17716838/),[mg] / [cig],1.070,114046,DB00184,Nicotine
,17716838,relative retention,"The mean (+/-S.D.) relative retention (the amount retained relative to the amount delivered) was 11.2+/-14.7%, 98.0+/-1.6%, and 99.6+/-0.3% for Patterns A, B, and C, respectively.",Respiratory retention of nicotine and urinary excretion of nicotine and its five major metabolites in adult male smokers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17716838/),%,11.2,114047,DB00184,Nicotine
,17716838,relative retention,"The mean (+/-S.D.) relative retention (the amount retained relative to the amount delivered) was 11.2+/-14.7%, 98.0+/-1.6%, and 99.6+/-0.3% for Patterns A, B, and C, respectively.",Respiratory retention of nicotine and urinary excretion of nicotine and its five major metabolites in adult male smokers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17716838/),%,98.0,114048,DB00184,Nicotine
,17716838,relative retention,"The mean (+/-S.D.) relative retention (the amount retained relative to the amount delivered) was 11.2+/-14.7%, 98.0+/-1.6%, and 99.6+/-0.3% for Patterns A, B, and C, respectively.",Respiratory retention of nicotine and urinary excretion of nicotine and its five major metabolites in adult male smokers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17716838/),%,99.6,114049,DB00184,Nicotine
,17716838,elimination half-life,"Based on this model, the elimination half-life of NE was 19.4+/-2.6h, and the NE excretion had reached approximately 96% of the steady state levels by Day 4.",Respiratory retention of nicotine and urinary excretion of nicotine and its five major metabolites in adult male smokers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17716838/),h,19.4,114050,DB00184,Nicotine
,29178785,IC50,"Both compounds are devoid of in vitro agonist activity and are potent inhibitors of epibatidine-induced changes in membrane potential in cells containing α4β2 nAChR, with IC50 values of approximately 10 nM, but are weak agonists in cells containing α3β4 nAChR.",Highly Selective and Potent α4β2 nAChR Antagonist Inhibits Nicotine Self-Administration and Reinstatement in Rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29178785/),nM,10,115204,DB00184,Nicotine
less,29178785,half-life,"The pharmacokinetic data also indicate that 5, via sc administration, is rapidly absorbed into the blood, reaching maximal concentration within 10 min with a half-life of less than 1 h.",Highly Selective and Potent α4β2 nAChR Antagonist Inhibits Nicotine Self-Administration and Reinstatement in Rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29178785/),h,1,115205,DB00184,Nicotine
,1445487,elimination half-lives,The calculated elimination half-lives of nicotine (3.4 +/- 1.8 h after patch A and 3.3 +/- 2.0 h after patch B) were longer than after i.v. application (published values range from 40 to 120 min).,Pharmacokinetics of nicotine and cotinine after application of two different nicotine patches under steady state conditions. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1445487/),h,3.4,118433,DB00184,Nicotine
,1445487,elimination half-lives,The calculated elimination half-lives of nicotine (3.4 +/- 1.8 h after patch A and 3.3 +/- 2.0 h after patch B) were longer than after i.v. application (published values range from 40 to 120 min).,Pharmacokinetics of nicotine and cotinine after application of two different nicotine patches under steady state conditions. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1445487/),h,3.3,118434,DB00184,Nicotine
,1445487,elimination half-lives,The calculated elimination half-lives of nicotine (3.4 +/- 1.8 h after patch A and 3.3 +/- 2.0 h after patch B) were longer than after i.v. application (published values range from 40 to 120 min).,Pharmacokinetics of nicotine and cotinine after application of two different nicotine patches under steady state conditions. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1445487/),min,40 to 120,118435,DB00184,Nicotine
,18477263,t(max),"The median (range) t(max) was 60 min (20-120 min) and 75 min (20-360 min) in the EXU with no exposure and EXU passive exposure groups, respectively.",Acute passive cigarette smoke exposure and inhaled human insulin (Exubera) pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18477263/),min,60,120100,DB00184,Nicotine
,18477263,t(max),"The median (range) t(max) was 60 min (20-120 min) and 75 min (20-360 min) in the EXU with no exposure and EXU passive exposure groups, respectively.",Acute passive cigarette smoke exposure and inhaled human insulin (Exubera) pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18477263/),min,75,120101,DB00184,Nicotine
,20291,half-life,"Independent of dose, the concentration of nicotine declined biexponentially with a mean half-life ranging from 0.92 to 1.10 hr.",Effect of dose on the pharmacokinetics of intravenous nicotine in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20291/),h,0.92 to 1.10,121845,DB00184,Nicotine
,20291,total plasma clearance,"However, the total plasma clearance of nicotine increased (p less than 0.05) from a mean value of 2.53 liter/hr-kg at the 0.08 mg/kg dose to mean values of 3.88 and 4.04 at the 0.4- and 0.8-mg/kg doses, respectively.",Effect of dose on the pharmacokinetics of intravenous nicotine in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20291/),[l] / [hr-kg],2.53,121846,DB00184,Nicotine
,20291,total plasma clearance,"However, the total plasma clearance of nicotine increased (p less than 0.05) from a mean value of 2.53 liter/hr-kg at the 0.08 mg/kg dose to mean values of 3.88 and 4.04 at the 0.4- and 0.8-mg/kg doses, respectively.",Effect of dose on the pharmacokinetics of intravenous nicotine in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20291/),[l] / [hr-kg],3.88,121847,DB00184,Nicotine
,20291,total plasma clearance,"However, the total plasma clearance of nicotine increased (p less than 0.05) from a mean value of 2.53 liter/hr-kg at the 0.08 mg/kg dose to mean values of 3.88 and 4.04 at the 0.4- and 0.8-mg/kg doses, respectively.",Effect of dose on the pharmacokinetics of intravenous nicotine in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20291/),[l] / [hr-kg],4.04,121848,DB00184,Nicotine
,20291,half-life of formation,"There were no dose-related differences in the half-life of formation of the major metabolite, cotinine (range 0.33-0.46 hr) or the half-life of its elimination (range 5.39-6.63 hr).",Effect of dose on the pharmacokinetics of intravenous nicotine in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20291/),h,0.33-0.46,121849,DB00184,Nicotine
,20291,half-life of its elimination,"There were no dose-related differences in the half-life of formation of the major metabolite, cotinine (range 0.33-0.46 hr) or the half-life of its elimination (range 5.39-6.63 hr).",Effect of dose on the pharmacokinetics of intravenous nicotine in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20291/),h,5.39-6.63,121850,DB00184,Nicotine
,17021260,Ki,"The inhibition was potent, as seen in human inhibition studies, with a Ki of 0.32 microM.",Inhibition of nicotine metabolism by methoxysalen: Pharmacokinetic and pharmacological studies in mice. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17021260/),μM,0.32,122240,DB00184,Nicotine
,27613939,maximum concentration,"In the single-dose study, the amount of nicotine released from the 2, 4, and 6mg gums (1.44, 3.36, and 4.94mg) as well as the resulting maximum concentration and area under the curve (5.9, 10.1, and 13.8ng/mL, and 17.1, 30.7, 46.2ng/mL × h, respectively) increased with dose.",Single-Dose and Multiple-Dose Pharmacokinetics of Nicotine 6 mg Gum. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27613939/),[ng] / [ml],5.9,123340,DB00184,Nicotine
,27613939,maximum concentration,"In the single-dose study, the amount of nicotine released from the 2, 4, and 6mg gums (1.44, 3.36, and 4.94mg) as well as the resulting maximum concentration and area under the curve (5.9, 10.1, and 13.8ng/mL, and 17.1, 30.7, 46.2ng/mL × h, respectively) increased with dose.",Single-Dose and Multiple-Dose Pharmacokinetics of Nicotine 6 mg Gum. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27613939/),[ng] / [ml],10.1,123341,DB00184,Nicotine
,27613939,area under the curve,"In the single-dose study, the amount of nicotine released from the 2, 4, and 6mg gums (1.44, 3.36, and 4.94mg) as well as the resulting maximum concentration and area under the curve (5.9, 10.1, and 13.8ng/mL, and 17.1, 30.7, 46.2ng/mL × h, respectively) increased with dose.",Single-Dose and Multiple-Dose Pharmacokinetics of Nicotine 6 mg Gum. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27613939/),[ng] / [ml],13.8,123342,DB00184,Nicotine
,27613939,area under the curve,"In the single-dose study, the amount of nicotine released from the 2, 4, and 6mg gums (1.44, 3.36, and 4.94mg) as well as the resulting maximum concentration and area under the curve (5.9, 10.1, and 13.8ng/mL, and 17.1, 30.7, 46.2ng/mL × h, respectively) increased with dose.",Single-Dose and Multiple-Dose Pharmacokinetics of Nicotine 6 mg Gum. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27613939/),[ng] / [h·ml],17.1,123343,DB00184,Nicotine
,27613939,area under the curve,"In the single-dose study, the amount of nicotine released from the 2, 4, and 6mg gums (1.44, 3.36, and 4.94mg) as well as the resulting maximum concentration and area under the curve (5.9, 10.1, and 13.8ng/mL, and 17.1, 30.7, 46.2ng/mL × h, respectively) increased with dose.",Single-Dose and Multiple-Dose Pharmacokinetics of Nicotine 6 mg Gum. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27613939/),[ng] / [h·ml],30.7,123344,DB00184,Nicotine
,27613939,area under the curve,"In the single-dose study, the amount of nicotine released from the 2, 4, and 6mg gums (1.44, 3.36, and 4.94mg) as well as the resulting maximum concentration and area under the curve (5.9, 10.1, and 13.8ng/mL, and 17.1, 30.7, 46.2ng/mL × h, respectively) increased with dose.",Single-Dose and Multiple-Dose Pharmacokinetics of Nicotine 6 mg Gum. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27613939/),[ng] / [h·ml],46.2,123345,DB00184,Nicotine
,27613939,steady-state average plasma nicotine concentration,"Upon hourly administration, the steady-state average plasma nicotine concentration with 6mg gum (37.4ng/mL) was significantly higher than those for 4mg lozenge (28.3ng/mL) and 4mg gum (27.1ng/mL).",Single-Dose and Multiple-Dose Pharmacokinetics of Nicotine 6 mg Gum. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27613939/),[ng] / [ml],37.4,123346,DB00184,Nicotine
,27613939,steady-state average plasma nicotine concentration,"Upon hourly administration, the steady-state average plasma nicotine concentration with 6mg gum (37.4ng/mL) was significantly higher than those for 4mg lozenge (28.3ng/mL) and 4mg gum (27.1ng/mL).",Single-Dose and Multiple-Dose Pharmacokinetics of Nicotine 6 mg Gum. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27613939/),[ng] / [ml],28.3,123347,DB00184,Nicotine
,27613939,steady-state average plasma nicotine concentration,"Upon hourly administration, the steady-state average plasma nicotine concentration with 6mg gum (37.4ng/mL) was significantly higher than those for 4mg lozenge (28.3ng/mL) and 4mg gum (27.1ng/mL).",Single-Dose and Multiple-Dose Pharmacokinetics of Nicotine 6 mg Gum. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27613939/),[ng] / [ml],27.1,123348,DB00184,Nicotine
,19346511,maximum plasma concentration,"Nicotine administered by an MDI produced a median maximum plasma concentration that was about 50% of that obtained by smoking a cigarette (12.5 vs. 25.9 ng/ml) and took twice the time to reach that concentration, 6 versus 3 min.",A pilot study of nicotine delivery to smokers from a metered-dose inhaler. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19346511/),[ng] / [ml],12.5,128128,DB00184,Nicotine
,19346511,maximum plasma concentration,"Nicotine administered by an MDI produced a median maximum plasma concentration that was about 50% of that obtained by smoking a cigarette (12.5 vs. 25.9 ng/ml) and took twice the time to reach that concentration, 6 versus 3 min.",A pilot study of nicotine delivery to smokers from a metered-dose inhaler. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19346511/),[ng] / [ml],25.9,128129,DB00184,Nicotine
,19346511,time to reach that concentration,"Nicotine administered by an MDI produced a median maximum plasma concentration that was about 50% of that obtained by smoking a cigarette (12.5 vs. 25.9 ng/ml) and took twice the time to reach that concentration, 6 versus 3 min.",A pilot study of nicotine delivery to smokers from a metered-dose inhaler. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19346511/),min,6,128130,DB00184,Nicotine
,19346511,time to reach that concentration,"Nicotine administered by an MDI produced a median maximum plasma concentration that was about 50% of that obtained by smoking a cigarette (12.5 vs. 25.9 ng/ml) and took twice the time to reach that concentration, 6 versus 3 min.",A pilot study of nicotine delivery to smokers from a metered-dose inhaler. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19346511/),min,3,128131,DB00184,Nicotine
,21849415,AUC,"The AUC(10 min) with 2 and 1 mg doses of spray, respectively, was twice and 1.5 times as high as the AUC(10 min) with lozenge or gum.",Single-dose pharmacokinetics of nicotine when given with a novel mouth spray for nicotine replacement therapy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21849415/),min,10,131727,DB00184,Nicotine
,21849415,time to reach C(max),"The maximum baseline-corrected plasma nicotine concentration (cC(max)) with 4 mg spray exceeded that for lozenge and gum by 34% and 20%; the median time to reach C(max) was 10-12.5 min for the 3 doses of spray, 45 min for lozenge, and 30 min for gum.",Single-dose pharmacokinetics of nicotine when given with a novel mouth spray for nicotine replacement therapy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21849415/),min,10-12.5,131728,DB00184,Nicotine
,21849415,time to reach C(max),"The maximum baseline-corrected plasma nicotine concentration (cC(max)) with 4 mg spray exceeded that for lozenge and gum by 34% and 20%; the median time to reach C(max) was 10-12.5 min for the 3 doses of spray, 45 min for lozenge, and 30 min for gum.",Single-dose pharmacokinetics of nicotine when given with a novel mouth spray for nicotine replacement therapy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21849415/),min,45,131729,DB00184,Nicotine
,21849415,time to reach C(max),"The maximum baseline-corrected plasma nicotine concentration (cC(max)) with 4 mg spray exceeded that for lozenge and gum by 34% and 20%; the median time to reach C(max) was 10-12.5 min for the 3 doses of spray, 45 min for lozenge, and 30 min for gum.",Single-dose pharmacokinetics of nicotine when given with a novel mouth spray for nicotine replacement therapy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21849415/),min,30,131730,DB00184,Nicotine
,23239844,LC50,"The acute inhalation toxicity of nicotine: LC50 = 2.3mg/L was determined; it was affected by pH, suggesting that acidification decreases nicotine absorption and/or bioavailability.",Nicotine delivery to rats via lung alveolar region-targeted aerosol technology produces blood pharmacokinetics resembling human smoking. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23239844/),[mg] / [l],2.3,134505,DB00184,Nicotine
,10570026,brain half-lives,"The brain half-lives of nicotine, cotinine, and nornicotine were 52, 333, and 166 min, respectively.",Residence times and half-lives of nicotine metabolites in rat brain after acute peripheral administration of [2'-(14)C]nicotine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10570026/),min,52,134597,DB00184,Nicotine
,10570026,brain half-lives,"The brain half-lives of nicotine, cotinine, and nornicotine were 52, 333, and 166 min, respectively.",Residence times and half-lives of nicotine metabolites in rat brain after acute peripheral administration of [2'-(14)C]nicotine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10570026/),min,333,134598,DB00184,Nicotine
,10570026,brain half-lives,"The brain half-lives of nicotine, cotinine, and nornicotine were 52, 333, and 166 min, respectively.",Residence times and half-lives of nicotine metabolites in rat brain after acute peripheral administration of [2'-(14)C]nicotine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10570026/),min,166,134599,DB00184,Nicotine
,10570026,Peak brain concentrations,"Peak brain concentrations of nicotine metabolites were 300, 70, and 7 nM for cotinine, nornicotine, and norcotinine, respectively.",Residence times and half-lives of nicotine metabolites in rat brain after acute peripheral administration of [2'-(14)C]nicotine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10570026/),nM,300,134600,DB00184,Nicotine
,10570026,Peak brain concentrations,"Peak brain concentrations of nicotine metabolites were 300, 70, and 7 nM for cotinine, nornicotine, and norcotinine, respectively.",Residence times and half-lives of nicotine metabolites in rat brain after acute peripheral administration of [2'-(14)C]nicotine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10570026/),nM,70,134601,DB00184,Nicotine
,10570026,Peak brain concentrations,"Peak brain concentrations of nicotine metabolites were 300, 70, and 7 nM for cotinine, nornicotine, and norcotinine, respectively.",Residence times and half-lives of nicotine metabolites in rat brain after acute peripheral administration of [2'-(14)C]nicotine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10570026/),nM,7,134602,DB00184,Nicotine
,7716176,biological half-life,"Nicotine is oxidized to its major metabolite, cotinine, which has a long biological half-life (19-24 h).","Distribution and retention of nicotine and its metabolite, cotinine, in the rat as a function of time. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7716176/),h,19-24,137606,DB00184,Nicotine
,7716176,half-time,The plasma level of nicotine decreased by 50% within 20 min (half-time) after its intravenous administration.,"Distribution and retention of nicotine and its metabolite, cotinine, in the rat as a function of time. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7716176/),min,20,137607,DB00184,Nicotine
,7716176,half-time,The half-time of nicotine in the brain was about 50 min.,"Distribution and retention of nicotine and its metabolite, cotinine, in the rat as a function of time. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7716176/),min,50,137608,DB00184,Nicotine
,7716176,half-times,The half-times of nicotine for the other organs were about 20-25 min.,"Distribution and retention of nicotine and its metabolite, cotinine, in the rat as a function of time. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7716176/),min,20-25,137609,DB00184,Nicotine
,21053991,elimination half-life,"Consistent with an elimination half-life of ∼24 hours, steady-state conditions are reached within 4 days of repeat dosing.",A review of the clinical pharmacokinetics and pharmacodynamics of varenicline for smoking cessation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21053991/),h,∼24,138379,DB00184,Nicotine
,1412462,Bmax,"The Bmax and KD estimated by model simulations for these tissues were brain, 0.009 and 0.12; lung, 0.039 and 2.0; and heart, 0.039 nmol/tissue and 0.12 nM, respectively.",A physiologically based pharmacokinetic model for nicotine disposition in the Sprague-Dawley rat. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1412462/),,0.009,143287,DB00184,Nicotine
,1412462,Bmax,"The Bmax and KD estimated by model simulations for these tissues were brain, 0.009 and 0.12; lung, 0.039 and 2.0; and heart, 0.039 nmol/tissue and 0.12 nM, respectively.",A physiologically based pharmacokinetic model for nicotine disposition in the Sprague-Dawley rat. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1412462/),,0.12,143288,DB00184,Nicotine
,1412462,Bmax,"The Bmax and KD estimated by model simulations for these tissues were brain, 0.009 and 0.12; lung, 0.039 and 2.0; and heart, 0.039 nmol/tissue and 0.12 nM, respectively.",A physiologically based pharmacokinetic model for nicotine disposition in the Sprague-Dawley rat. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1412462/),[nM] / [tissue],0.039,143289,DB00184,Nicotine
,1412462,KD,"The Bmax and KD estimated by model simulations for these tissues were brain, 0.009 and 0.12; lung, 0.039 and 2.0; and heart, 0.039 nmol/tissue and 0.12 nM, respectively.",A physiologically based pharmacokinetic model for nicotine disposition in the Sprague-Dawley rat. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1412462/),,0.12,143290,DB00184,Nicotine
,1412462,KD,"The Bmax and KD estimated by model simulations for these tissues were brain, 0.009 and 0.12; lung, 0.039 and 2.0; and heart, 0.039 nmol/tissue and 0.12 nM, respectively.",A physiologically based pharmacokinetic model for nicotine disposition in the Sprague-Dawley rat. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1412462/),[nM] / [tissue],0.039,143291,DB00184,Nicotine
,1412462,KD,"The Bmax and KD estimated by model simulations for these tissues were brain, 0.009 and 0.12; lung, 0.039 and 2.0; and heart, 0.039 nmol/tissue and 0.12 nM, respectively.",A physiologically based pharmacokinetic model for nicotine disposition in the Sprague-Dawley rat. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1412462/),[nM] / [tissue],2.0,143292,DB00184,Nicotine
,1412462,KD,"The Bmax and KD estimated by model simulations for these tissues were brain, 0.009 and 0.12; lung, 0.039 and 2.0; and heart, 0.039 nmol/tissue and 0.12 nM, respectively.",A physiologically based pharmacokinetic model for nicotine disposition in the Sprague-Dawley rat. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1412462/),nM,0.12,143293,DB00184,Nicotine
,11699608,Elimination half-life,Elimination half-life was approximately 6 h.,Pharmacodynamics and pharmacokinetics of single nasal (5 mg and 10 mg) and oral (50 mg) doses of ephedrine in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11699608/),h,6,144104,DB00184,Nicotine
,2052530,AUC(0-24),"The nicotine pharmacokinetic parameters for Day 1 and Day 5 were similar: the mean (SD) AUC(0-24) values for Days 1 and 5 were 271.7 (50.7) and 311.7 (55.0) ng.hr/ml, the mean (SD) Cmax values were 16.3 (2.6) and 16.8 (2.9) ng/ml, and the median (range) Tmax values on Days 1 and 5 were 12 (9-24) hr and 12 (0-24) hr, respectively.",Pharmacokinetics of multiple daily transdermal doses of nicotine in healthy smokers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2052530/),[h·ng] / [ml],271.7,146146,DB00184,Nicotine
,2052530,AUC(0-24),"The nicotine pharmacokinetic parameters for Day 1 and Day 5 were similar: the mean (SD) AUC(0-24) values for Days 1 and 5 were 271.7 (50.7) and 311.7 (55.0) ng.hr/ml, the mean (SD) Cmax values were 16.3 (2.6) and 16.8 (2.9) ng/ml, and the median (range) Tmax values on Days 1 and 5 were 12 (9-24) hr and 12 (0-24) hr, respectively.",Pharmacokinetics of multiple daily transdermal doses of nicotine in healthy smokers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2052530/),[h·ng] / [ml],311.7,146147,DB00184,Nicotine
,2052530,Cmax,"The nicotine pharmacokinetic parameters for Day 1 and Day 5 were similar: the mean (SD) AUC(0-24) values for Days 1 and 5 were 271.7 (50.7) and 311.7 (55.0) ng.hr/ml, the mean (SD) Cmax values were 16.3 (2.6) and 16.8 (2.9) ng/ml, and the median (range) Tmax values on Days 1 and 5 were 12 (9-24) hr and 12 (0-24) hr, respectively.",Pharmacokinetics of multiple daily transdermal doses of nicotine in healthy smokers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2052530/),[ng] / [ml],16.3,146148,DB00184,Nicotine
,2052530,Cmax,"The nicotine pharmacokinetic parameters for Day 1 and Day 5 were similar: the mean (SD) AUC(0-24) values for Days 1 and 5 were 271.7 (50.7) and 311.7 (55.0) ng.hr/ml, the mean (SD) Cmax values were 16.3 (2.6) and 16.8 (2.9) ng/ml, and the median (range) Tmax values on Days 1 and 5 were 12 (9-24) hr and 12 (0-24) hr, respectively.",Pharmacokinetics of multiple daily transdermal doses of nicotine in healthy smokers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2052530/),[ng] / [ml],16.8,146149,DB00184,Nicotine
,2052530,Tmax,"The nicotine pharmacokinetic parameters for Day 1 and Day 5 were similar: the mean (SD) AUC(0-24) values for Days 1 and 5 were 271.7 (50.7) and 311.7 (55.0) ng.hr/ml, the mean (SD) Cmax values were 16.3 (2.6) and 16.8 (2.9) ng/ml, and the median (range) Tmax values on Days 1 and 5 were 12 (9-24) hr and 12 (0-24) hr, respectively.",Pharmacokinetics of multiple daily transdermal doses of nicotine in healthy smokers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2052530/),h,12,146150,DB00184,Nicotine
,2052530,Tmax,"The nicotine pharmacokinetic parameters for Day 1 and Day 5 were similar: the mean (SD) AUC(0-24) values for Days 1 and 5 were 271.7 (50.7) and 311.7 (55.0) ng.hr/ml, the mean (SD) Cmax values were 16.3 (2.6) and 16.8 (2.9) ng/ml, and the median (range) Tmax values on Days 1 and 5 were 12 (9-24) hr and 12 (0-24) hr, respectively.",Pharmacokinetics of multiple daily transdermal doses of nicotine in healthy smokers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2052530/),h,12,146151,DB00184,Nicotine
,2052530,AUC,"There was only slight or no accumulation of nicotine after multiple dosing as indicated by the Day 5 to Day 1 AUC and Cmax ratios of 1.15 (0.09) and 0.98 (0.06), respectively.",Pharmacokinetics of multiple daily transdermal doses of nicotine in healthy smokers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2052530/),,1.15,146152,DB00184,Nicotine
,2052530,Cmax ratios,"There was only slight or no accumulation of nicotine after multiple dosing as indicated by the Day 5 to Day 1 AUC and Cmax ratios of 1.15 (0.09) and 0.98 (0.06), respectively.",Pharmacokinetics of multiple daily transdermal doses of nicotine in healthy smokers. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2052530/),,0.98,146153,DB00184,Nicotine
,11733086,AUC,"Compared to NS, NB exhibited higher and sustained plasma nicotine levels, thereby yielding significantly (P<0.05) larger AUC (66.3 vs. 27.7 microg ml/min), MRT (165.7 vs. 58.3 min), T(1/2,beta) (144.2 vs. 51.4 min) and a lower CL (18.3 vs. 46.3 ml/min per kg).",Different pharmacokinetics of nicotine following intravenous administration of nicotine base and nicotine hydrogen tartarate in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11733086/),[ml·μg] / [min],66.3,152293,DB00184,Nicotine
,11733086,AUC,"Compared to NS, NB exhibited higher and sustained plasma nicotine levels, thereby yielding significantly (P<0.05) larger AUC (66.3 vs. 27.7 microg ml/min), MRT (165.7 vs. 58.3 min), T(1/2,beta) (144.2 vs. 51.4 min) and a lower CL (18.3 vs. 46.3 ml/min per kg).",Different pharmacokinetics of nicotine following intravenous administration of nicotine base and nicotine hydrogen tartarate in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11733086/),[ml·μg] / [min],27.7,152294,DB00184,Nicotine
,11733086,MRT,"Compared to NS, NB exhibited higher and sustained plasma nicotine levels, thereby yielding significantly (P<0.05) larger AUC (66.3 vs. 27.7 microg ml/min), MRT (165.7 vs. 58.3 min), T(1/2,beta) (144.2 vs. 51.4 min) and a lower CL (18.3 vs. 46.3 ml/min per kg).",Different pharmacokinetics of nicotine following intravenous administration of nicotine base and nicotine hydrogen tartarate in rats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11733086/),min,165.7,152295,DB00184,Nicotine
,11733086,MRT,"Compared to NS, NB exhibited higher and sustained plasma nicotine levels, thereby yielding significantly (P<0.05) larger AUC (66.3 vs. 27.7 microg ml/min), MRT (165.7 vs. 58.3 min), T(1/2,beta) (144.2 vs. 51.4 min) and a lower CL (18.3 vs. 46.3 ml/min per kg).",Different pharmacokinetics of nicotine following intravenous administration of nicotine base and nicotine hydrogen tartarate in rats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11733086/),min,58.3,152296,DB00184,Nicotine
,11733086,"T(1/2,beta)","Compared to NS, NB exhibited higher and sustained plasma nicotine levels, thereby yielding significantly (P<0.05) larger AUC (66.3 vs. 27.7 microg ml/min), MRT (165.7 vs. 58.3 min), T(1/2,beta) (144.2 vs. 51.4 min) and a lower CL (18.3 vs. 46.3 ml/min per kg).",Different pharmacokinetics of nicotine following intravenous administration of nicotine base and nicotine hydrogen tartarate in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11733086/),min,144.2,152297,DB00184,Nicotine
,11733086,"T(1/2,beta)","Compared to NS, NB exhibited higher and sustained plasma nicotine levels, thereby yielding significantly (P<0.05) larger AUC (66.3 vs. 27.7 microg ml/min), MRT (165.7 vs. 58.3 min), T(1/2,beta) (144.2 vs. 51.4 min) and a lower CL (18.3 vs. 46.3 ml/min per kg).",Different pharmacokinetics of nicotine following intravenous administration of nicotine base and nicotine hydrogen tartarate in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11733086/),min,51.4,152298,DB00184,Nicotine
,11733086,CL,"Compared to NS, NB exhibited higher and sustained plasma nicotine levels, thereby yielding significantly (P<0.05) larger AUC (66.3 vs. 27.7 microg ml/min), MRT (165.7 vs. 58.3 min), T(1/2,beta) (144.2 vs. 51.4 min) and a lower CL (18.3 vs. 46.3 ml/min per kg).",Different pharmacokinetics of nicotine following intravenous administration of nicotine base and nicotine hydrogen tartarate in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11733086/),[ml] / [kg·min],18.3,152299,DB00184,Nicotine
,11733086,CL,"Compared to NS, NB exhibited higher and sustained plasma nicotine levels, thereby yielding significantly (P<0.05) larger AUC (66.3 vs. 27.7 microg ml/min), MRT (165.7 vs. 58.3 min), T(1/2,beta) (144.2 vs. 51.4 min) and a lower CL (18.3 vs. 46.3 ml/min per kg).",Different pharmacokinetics of nicotine following intravenous administration of nicotine base and nicotine hydrogen tartarate in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11733086/),[ml] / [kg·min],46.3,152300,DB00184,Nicotine
,32013640,peak BACs,"Results and Discussion: The estimated peak BACs for these three user profiles were 0.22, 0.22, and 0.30 mg/L for first-generation devices, respectively, and 0.85, 0.58, and 0.34 mg/L for second-generation devices, respectively.",PBPK modeling characterization of potential acute impairment effects from inhalation of ethanol during e-cigarette use. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32013640/),[mg] / [l],0.22,155401,DB00184,Nicotine
,32013640,peak BACs,"Results and Discussion: The estimated peak BACs for these three user profiles were 0.22, 0.22, and 0.30 mg/L for first-generation devices, respectively, and 0.85, 0.58, and 0.34 mg/L for second-generation devices, respectively.",PBPK modeling characterization of potential acute impairment effects from inhalation of ethanol during e-cigarette use. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32013640/),[mg] / [l],0.30,155402,DB00184,Nicotine
,32013640,peak BACs,"Results and Discussion: The estimated peak BACs for these three user profiles were 0.22, 0.22, and 0.30 mg/L for first-generation devices, respectively, and 0.85, 0.58, and 0.34 mg/L for second-generation devices, respectively.",PBPK modeling characterization of potential acute impairment effects from inhalation of ethanol during e-cigarette use. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32013640/),[mg] / [l],0.85,155403,DB00184,Nicotine
,32013640,peak BACs,"Results and Discussion: The estimated peak BACs for these three user profiles were 0.22, 0.22, and 0.30 mg/L for first-generation devices, respectively, and 0.85, 0.58, and 0.34 mg/L for second-generation devices, respectively.",PBPK modeling characterization of potential acute impairment effects from inhalation of ethanol during e-cigarette use. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32013640/),[mg] / [l],0.58,155404,DB00184,Nicotine
,32013640,peak BACs,"Results and Discussion: The estimated peak BACs for these three user profiles were 0.22, 0.22, and 0.30 mg/L for first-generation devices, respectively, and 0.85, 0.58, and 0.34 mg/L for second-generation devices, respectively.",PBPK modeling characterization of potential acute impairment effects from inhalation of ethanol during e-cigarette use. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32013640/),[mg] / [l],0.34,155405,DB00184,Nicotine
,32013640,peak BACs,"Additionally, peak BACs for individual first-generation users with directly measured puffing parameters were estimated to range from 0.06 to 0.67 mg/L.",PBPK modeling characterization of potential acute impairment effects from inhalation of ethanol during e-cigarette use. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32013640/),[mg] / [l],0.06 to 0.67,155406,DB00184,Nicotine
,1815971,bioavailability,"Compared to an intravenous infusion of nicotine, the bioavailability of the nasal administrations was 60 to 75%.",Absolute bioavailability of nicotine applied to different nasal regions. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1815971/),%,60 to 75,155593,DB00184,Nicotine
,10663452,maximum level,"After use of the inhaler, arterial nicotine concentrations rose slowly to a maximum level of 5. 9 +/- 1.5 ng/ml at a mean time to reach peak concentration (t(max)) of 9.0 +/- 1.1 min, whereas jugular venous nicotine levels peaked at 25.4 +/- 5.4 ng/ml at 6.7 +/- 0.3 min.",Site of nicotine absorption from a vapour inhaler--comparison with cigarette smoking. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10663452/),[ng] / [ml],5. 9,164289,DB00184,Nicotine
,10663452,time to reach peak concentration (t(max)),"After use of the inhaler, arterial nicotine concentrations rose slowly to a maximum level of 5. 9 +/- 1.5 ng/ml at a mean time to reach peak concentration (t(max)) of 9.0 +/- 1.1 min, whereas jugular venous nicotine levels peaked at 25.4 +/- 5.4 ng/ml at 6.7 +/- 0.3 min.",Site of nicotine absorption from a vapour inhaler--comparison with cigarette smoking. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10663452/),min,9.0,164290,DB00184,Nicotine
,10663452,maximum level,"In contrast, after smoking a cigarette, arterial nicotine plasma concentrations rose quickly to a maximum level of 49.",Site of nicotine absorption from a vapour inhaler--comparison with cigarette smoking. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10663452/),,49,164291,DB00184,Nicotine
,10663452,maximum concentration,"2 +/- 9.7 ng/ml after 4.0 +/- 0.6 min, while the maximum concentration of nicotine in the jugular vein was 22.4 +/- 3.9 ng/ml after 6.4 +/- 0.4 min, indicating primarily pulmonary absorption of nicotine.",Site of nicotine absorption from a vapour inhaler--comparison with cigarette smoking. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10663452/),[ng] / [ml],22.4,164292,DB00184,Nicotine
,9354194,bioavailabilities,"The mean bioavailabilities of nicotine after ileocolonic nicotine tartrate administration via delayed-release oral capsules at doses 3 mg and 6 mg nicotine were 41% and 42%, respectively.",A dose-ranging pharmacokinetic study of nicotine tartrate following single-dose delayed-release oral and intravenous administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9354194/),%,41,165333,DB00184,Nicotine
,9354194,bioavailabilities,"The mean bioavailabilities of nicotine after ileocolonic nicotine tartrate administration via delayed-release oral capsules at doses 3 mg and 6 mg nicotine were 41% and 42%, respectively.",A dose-ranging pharmacokinetic study of nicotine tartrate following single-dose delayed-release oral and intravenous administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9354194/),%,42,165334,DB00184,Nicotine
,15639444,Recoveries,"Recoveries were 90-115% nicotine, 76-117% cotinine, 88-101% norcotinine, and 67-77% trans-3'-hydroxycotinine.","Simultaneous determination of nicotine, cotinine, norcotinine, and trans-3'-hydroxycotinine in human oral fluid using solid phase extraction and gas chromatography-mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15639444/),%,90-115,167057,DB00184,Nicotine
,15639444,Recoveries,"Recoveries were 90-115% nicotine, 76-117% cotinine, 88-101% norcotinine, and 67-77% trans-3'-hydroxycotinine.","Simultaneous determination of nicotine, cotinine, norcotinine, and trans-3'-hydroxycotinine in human oral fluid using solid phase extraction and gas chromatography-mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15639444/),%,76-117,167058,DB00184,Nicotine
,15639444,Recoveries,"Recoveries were 90-115% nicotine, 76-117% cotinine, 88-101% norcotinine, and 67-77% trans-3'-hydroxycotinine.","Simultaneous determination of nicotine, cotinine, norcotinine, and trans-3'-hydroxycotinine in human oral fluid using solid phase extraction and gas chromatography-mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15639444/),%,88-101,167059,DB00184,Nicotine
,15639444,Recoveries,"Recoveries were 90-115% nicotine, 76-117% cotinine, 88-101% norcotinine, and 67-77% trans-3'-hydroxycotinine.","Simultaneous determination of nicotine, cotinine, norcotinine, and trans-3'-hydroxycotinine in human oral fluid using solid phase extraction and gas chromatography-mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15639444/),%,67-77,167060,DB00184,Nicotine
,21999217,lag times,Their corresponding estimated in vivo lag times for appearance of the drugs in the deeper probes were 1.1 min for diclofenac and 30 min for nicotine.,Convective transport of highly plasma protein bound drugs facilitates direct penetration into deep tissues after topical application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21999217/),min,1.1,169176,DB00184,Nicotine
,21999217,lag times,Their corresponding estimated in vivo lag times for appearance of the drugs in the deeper probes were 1.1 min for diclofenac and 30 min for nicotine.,Convective transport of highly plasma protein bound drugs facilitates direct penetration into deep tissues after topical application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21999217/),min,30,169177,DB00184,Nicotine
,31521954,elimination half-life,"The mean (±SD) nicotine elimination half-life was 136 min (±33.5), clearance was 1237 mL/min (±331), and Vss was 204 L (±66), or 2.6 L/kg (±0.7).",Relationship between skin melanin index and nicotine pharmacokinetics in African American smokers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31521954/),min,136,169781,DB00184,Nicotine
,31521954,clearance,"The mean (±SD) nicotine elimination half-life was 136 min (±33.5), clearance was 1237 mL/min (±331), and Vss was 204 L (±66), or 2.6 L/kg (±0.7).",Relationship between skin melanin index and nicotine pharmacokinetics in African American smokers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31521954/),[ml] / [min],1237,169782,DB00184,Nicotine
,31521954,Vss,"The mean (±SD) nicotine elimination half-life was 136 min (±33.5), clearance was 1237 mL/min (±331), and Vss was 204 L (±66), or 2.6 L/kg (±0.7).",Relationship between skin melanin index and nicotine pharmacokinetics in African American smokers. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31521954/),l,204,169783,DB00184,Nicotine
,31521954,Vss,"The mean (±SD) nicotine elimination half-life was 136 min (±33.5), clearance was 1237 mL/min (±331), and Vss was 204 L (±66), or 2.6 L/kg (±0.7).",Relationship between skin melanin index and nicotine pharmacokinetics in African American smokers. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31521954/),[l] / [kg],2.6,169784,DB00184,Nicotine
,9973205,distribution half-life,"The distribution half-life for NNAL and NNAL-Gluc was 3-4 days, whereas the elimination half-life was 40-45 days.",Quantitation of urinary metabolites of a tobacco-specific lung carcinogen after smoking cessation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9973205/),d,3-4,172559,DB00184,Nicotine
,9973205,elimination half-life,"The distribution half-life for NNAL and NNAL-Gluc was 3-4 days, whereas the elimination half-life was 40-45 days.",Quantitation of urinary metabolites of a tobacco-specific lung carcinogen after smoking cessation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9973205/),d,40-45,172560,DB00184,Nicotine
,9973205,Total body clearance,"Total body clearance of NNAL was estimated to be 61.4 +/- 35.4 ml/min, and volume of distribution in the beta-phase was estimated to be 3800 +/- 2100 liters, indicating substantial distribution into the tissues.",Quantitation of urinary metabolites of a tobacco-specific lung carcinogen after smoking cessation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9973205/),[ml] / [min],61.4,172561,DB00184,Nicotine
,9973205,volume of distribution in the beta-phase,"Total body clearance of NNAL was estimated to be 61.4 +/- 35.4 ml/min, and volume of distribution in the beta-phase was estimated to be 3800 +/- 2100 liters, indicating substantial distribution into the tissues.",Quantitation of urinary metabolites of a tobacco-specific lung carcinogen after smoking cessation. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9973205/),l,3800,172562,DB00184,Nicotine
,1914363,absolute bioavailability,"In 11 subjects with good patch adhesion, an average systemic dose of 19 mg nicotine was delivered, with average absolute bioavailability of 82%.",Stable isotope method for studying transdermal drug absorption: the nicotine patch. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1914363/),%,82,173562,DB00184,Nicotine
,15735610,clearance,"Nicotine clearance was 1000 +/- 315 mL/min and 1047 +/- 271 mL/min in the follicular and luteal phases, respectively (geometric mean ratio, 1.06; 90% confidence interval, 0.87-1.29).",Influence of menstrual cycle on cytochrome P450 2A6 activity and cardiovascular effects of nicotine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15735610/),[ml] / [min],1000,176980,DB00184,Nicotine
,15735610,clearance,"Nicotine clearance was 1000 +/- 315 mL/min and 1047 +/- 271 mL/min in the follicular and luteal phases, respectively (geometric mean ratio, 1.06; 90% confidence interval, 0.87-1.29).",Influence of menstrual cycle on cytochrome P450 2A6 activity and cardiovascular effects of nicotine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15735610/),[ml] / [min],1047,176981,DB00184,Nicotine
,15735610,clearance,"Cotinine clearance was 44 +/- 20 mL/min and 55 +/- 42 mL/min in the follicular and luteal phases, respectively (geometric mean ratio, 1.13; 90% confidence interval, 0.90-1.41).",Influence of menstrual cycle on cytochrome P450 2A6 activity and cardiovascular effects of nicotine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15735610/),[ml] / [min],44,176982,DB00184,Nicotine
,15735610,clearance,"Cotinine clearance was 44 +/- 20 mL/min and 55 +/- 42 mL/min in the follicular and luteal phases, respectively (geometric mean ratio, 1.13; 90% confidence interval, 0.90-1.41).",Influence of menstrual cycle on cytochrome P450 2A6 activity and cardiovascular effects of nicotine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15735610/),[ml] / [min],55,176983,DB00184,Nicotine
,22311961,peak concentrations of nicotine in plasma (C(max)),"Following single-cigarette smoke inhalation, mentholated cigarettes significantly decreased the mean peak concentrations of nicotine in plasma (C(max)) from 27.1 to 9.61 ng/ml and the total area under the plasma concentration-time curves (AUC) from 977 to 391 ng min/ml as compared with those after nonmentholated cigarette smoke inhalation.",Effect of menthol on nicotine pharmacokinetics in rats after cigarette smoke inhalation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22311961/),[ng] / [ml],27.1 to 9.61,178059,DB00184,Nicotine
,22311961,total area under the plasma concentration-time curves (AUC),"Following single-cigarette smoke inhalation, mentholated cigarettes significantly decreased the mean peak concentrations of nicotine in plasma (C(max)) from 27.1 to 9.61 ng/ml and the total area under the plasma concentration-time curves (AUC) from 977 to 391 ng min/ml as compared with those after nonmentholated cigarette smoke inhalation.",Effect of menthol on nicotine pharmacokinetics in rats after cigarette smoke inhalation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22311961/),[min·ng] / [ml],977 to 391,178060,DB00184,Nicotine
,22311961,AUC ratio,"Interestingly, there was a significant increase in the cotinine to nicotine AUC ratio from 13.8 for the nonmentholated to 21.1 for the mentholated cigarette.",Effect of menthol on nicotine pharmacokinetics in rats after cigarette smoke inhalation. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22311961/),,13.8,178061,DB00184,Nicotine
,22311961,AUC ratio,"Interestingly, there was a significant increase in the cotinine to nicotine AUC ratio from 13.8 for the nonmentholated to 21.1 for the mentholated cigarette.",Effect of menthol on nicotine pharmacokinetics in rats after cigarette smoke inhalation. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22311961/),,21.1,178062,DB00184,Nicotine
,17329297,plasma Cmax,PK analysis indicated a plasma Cmax range of 5-25/35 ng/ml ispronicline was associated with the most beneficial effect.,"Effect of ispronicline, a neuronal nicotinic acetylcholine receptor partial agonist, in subjects with age associated memory impairment (AAMI). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17329297/),[ng] / [ml],5-25/35,178541,DB00184,Nicotine
,16130745,flow-rate,"The mobile phase consisted of an acetonitrile-methanol-20 mM monosodium phosphate buffer (55:45:900, v/v/v, pH adjusted to 5.1) with a flow-rate of 1 ml/min.","Simultaneous determination of nicotine and its metabolite, cotinine, in rat blood and brain tissue using microdialysis coupled with liquid chromatography: pharmacokinetic application. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16130745/),[ml] / [min],1,178815,DB00184,Nicotine
,26430813,maximum plasma nicotine concentration (Cmax ),Average maximum plasma nicotine concentration (Cmax ) was 8.4 (5.4-11.5) ng/ml and time of maximal concentration (Tmax ) was 2-5 minutes.,"Nicotine delivery, retention and pharmacokinetics from various electronic cigarettes. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26430813/),[ng] / [ml],8.4,181602,DB00184,Nicotine
,26430813,time of maximal concentration (Tmax ),Average maximum plasma nicotine concentration (Cmax ) was 8.4 (5.4-11.5) ng/ml and time of maximal concentration (Tmax ) was 2-5 minutes.,"Nicotine delivery, retention and pharmacokinetics from various electronic cigarettes. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26430813/),min,2-5,181603,DB00184,Nicotine
,26430813,Tmax,One participant had Tmax of 30 minutes.,"Nicotine delivery, retention and pharmacokinetics from various electronic cigarettes. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26430813/),min,30,181604,DB00184,Nicotine
,25385878,arterial plasma nicotine concentrations,"In Part A, mean arterial plasma nicotine concentrations at 2 min after the start of inhalation were 1.10, 2.06, and 2.59 ng/mL for the 0.22, 0.45, and 0.67 mg doses, respectively.",Evaluation of a novel nicotine inhaler device: part 1--arterial and venous pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25385878/),[ng] / [ml],1.10,184554,DB00184,Nicotine
,25385878,arterial plasma nicotine concentrations,"In Part A, mean arterial plasma nicotine concentrations at 2 min after the start of inhalation were 1.10, 2.06, and 2.59 ng/mL for the 0.22, 0.45, and 0.67 mg doses, respectively.",Evaluation of a novel nicotine inhaler device: part 1--arterial and venous pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25385878/),[ng] / [ml],2.06,184555,DB00184,Nicotine
,25385878,arterial plasma nicotine concentrations,"In Part A, mean arterial plasma nicotine concentrations at 2 min after the start of inhalation were 1.10, 2.06, and 2.59 ng/mL for the 0.22, 0.45, and 0.67 mg doses, respectively.",Evaluation of a novel nicotine inhaler device: part 1--arterial and venous pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25385878/),[ng] / [ml],2.59,184556,DB00184,Nicotine
,25385878,maximum arterial plasma nicotine concentrations (C(max)),"Mean maximum arterial plasma nicotine concentrations (C(max)) were 2.11, 3.73, and 4.38 ng/mL and mean times to C(max) were 10.2, 7.3, and 6.5 min after the start of inhalation for the 0.22, 0.45, and 0.67 mg doses, respectively.",Evaluation of a novel nicotine inhaler device: part 1--arterial and venous pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25385878/),[ng] / [ml],2.11,184557,DB00184,Nicotine
,25385878,maximum arterial plasma nicotine concentrations (C(max)),"Mean maximum arterial plasma nicotine concentrations (C(max)) were 2.11, 3.73, and 4.38 ng/mL and mean times to C(max) were 10.2, 7.3, and 6.5 min after the start of inhalation for the 0.22, 0.45, and 0.67 mg doses, respectively.",Evaluation of a novel nicotine inhaler device: part 1--arterial and venous pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25385878/),[ng] / [ml],3.73,184558,DB00184,Nicotine
,25385878,maximum arterial plasma nicotine concentrations (C(max)),"Mean maximum arterial plasma nicotine concentrations (C(max)) were 2.11, 3.73, and 4.38 ng/mL and mean times to C(max) were 10.2, 7.3, and 6.5 min after the start of inhalation for the 0.22, 0.45, and 0.67 mg doses, respectively.",Evaluation of a novel nicotine inhaler device: part 1--arterial and venous pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25385878/),[ng] / [ml],4.38,184559,DB00184,Nicotine
,25385878,times to C(max),"Mean maximum arterial plasma nicotine concentrations (C(max)) were 2.11, 3.73, and 4.38 ng/mL and mean times to C(max) were 10.2, 7.3, and 6.5 min after the start of inhalation for the 0.22, 0.45, and 0.67 mg doses, respectively.",Evaluation of a novel nicotine inhaler device: part 1--arterial and venous pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25385878/),min,10.2,184560,DB00184,Nicotine
,25385878,times to C(max),"Mean maximum arterial plasma nicotine concentrations (C(max)) were 2.11, 3.73, and 4.38 ng/mL and mean times to C(max) were 10.2, 7.3, and 6.5 min after the start of inhalation for the 0.22, 0.45, and 0.67 mg doses, respectively.",Evaluation of a novel nicotine inhaler device: part 1--arterial and venous pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25385878/),min,7.3,184561,DB00184,Nicotine
,25385878,times to C(max),"Mean maximum arterial plasma nicotine concentrations (C(max)) were 2.11, 3.73, and 4.38 ng/mL and mean times to C(max) were 10.2, 7.3, and 6.5 min after the start of inhalation for the 0.22, 0.45, and 0.67 mg doses, respectively.",Evaluation of a novel nicotine inhaler device: part 1--arterial and venous pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25385878/),min,6.5,184562,DB00184,Nicotine
,3184775,cumulative excretion rates,"After oral administration of 30 mg trans-3'-hydroxycotinine, the cumulative excretion rates of two subjects were 81% and 93% of the unchanged compound, respectively.",Trans-3'-hydroxycotinine--a main metabolite in smokers. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3184775/),%,81,184960,DB00184,Nicotine
,3184775,cumulative excretion rates,"After oral administration of 30 mg trans-3'-hydroxycotinine, the cumulative excretion rates of two subjects were 81% and 93% of the unchanged compound, respectively.",Trans-3'-hydroxycotinine--a main metabolite in smokers. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3184775/),%,93,184961,DB00184,Nicotine
,16758265,clearance,"In vivo pharmacokinetic parameters, such as nicotine clearance (1.32+/-0.37 vs. 1.18+/-0.20 L/min), fractional clearance of nicotine to cotinine (1.02+/-0.36 vs. 0.99+/-0.23 L/min), nicotine half-life (111+/-37 vs. 116+/-29 min), and the trans-3'-hydroxycotinine to cotinine ratio (1.92+/-1.0 vs. 1.55+/-0.58) indicated no substantial differences in nicotine metabolism between those without the variant (CYP2A6*1/*1, n = 163) and those with the variant (CYP2A6*1/*21, n = 9), respectively.",Characterization of the novel CYP2A6*21 allele using in vivo nicotine kinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16758265/),[l] / [min],1.32,185647,DB00184,Nicotine
,16758265,clearance,"In vivo pharmacokinetic parameters, such as nicotine clearance (1.32+/-0.37 vs. 1.18+/-0.20 L/min), fractional clearance of nicotine to cotinine (1.02+/-0.36 vs. 0.99+/-0.23 L/min), nicotine half-life (111+/-37 vs. 116+/-29 min), and the trans-3'-hydroxycotinine to cotinine ratio (1.92+/-1.0 vs. 1.55+/-0.58) indicated no substantial differences in nicotine metabolism between those without the variant (CYP2A6*1/*1, n = 163) and those with the variant (CYP2A6*1/*21, n = 9), respectively.",Characterization of the novel CYP2A6*21 allele using in vivo nicotine kinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16758265/),[l] / [min],1.18,185648,DB00184,Nicotine
,16758265,fractional clearance,"In vivo pharmacokinetic parameters, such as nicotine clearance (1.32+/-0.37 vs. 1.18+/-0.20 L/min), fractional clearance of nicotine to cotinine (1.02+/-0.36 vs. 0.99+/-0.23 L/min), nicotine half-life (111+/-37 vs. 116+/-29 min), and the trans-3'-hydroxycotinine to cotinine ratio (1.92+/-1.0 vs. 1.55+/-0.58) indicated no substantial differences in nicotine metabolism between those without the variant (CYP2A6*1/*1, n = 163) and those with the variant (CYP2A6*1/*21, n = 9), respectively.",Characterization of the novel CYP2A6*21 allele using in vivo nicotine kinetics. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16758265/),[l] / [min],1.02,185649,DB00184,Nicotine
,16758265,fractional clearance,"In vivo pharmacokinetic parameters, such as nicotine clearance (1.32+/-0.37 vs. 1.18+/-0.20 L/min), fractional clearance of nicotine to cotinine (1.02+/-0.36 vs. 0.99+/-0.23 L/min), nicotine half-life (111+/-37 vs. 116+/-29 min), and the trans-3'-hydroxycotinine to cotinine ratio (1.92+/-1.0 vs. 1.55+/-0.58) indicated no substantial differences in nicotine metabolism between those without the variant (CYP2A6*1/*1, n = 163) and those with the variant (CYP2A6*1/*21, n = 9), respectively.",Characterization of the novel CYP2A6*21 allele using in vivo nicotine kinetics. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16758265/),[l] / [min],0.99,185650,DB00184,Nicotine
,16758265,half-life,"In vivo pharmacokinetic parameters, such as nicotine clearance (1.32+/-0.37 vs. 1.18+/-0.20 L/min), fractional clearance of nicotine to cotinine (1.02+/-0.36 vs. 0.99+/-0.23 L/min), nicotine half-life (111+/-37 vs. 116+/-29 min), and the trans-3'-hydroxycotinine to cotinine ratio (1.92+/-1.0 vs. 1.55+/-0.58) indicated no substantial differences in nicotine metabolism between those without the variant (CYP2A6*1/*1, n = 163) and those with the variant (CYP2A6*1/*21, n = 9), respectively.",Characterization of the novel CYP2A6*21 allele using in vivo nicotine kinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16758265/),min,111,185651,DB00184,Nicotine
,16758265,half-life,"In vivo pharmacokinetic parameters, such as nicotine clearance (1.32+/-0.37 vs. 1.18+/-0.20 L/min), fractional clearance of nicotine to cotinine (1.02+/-0.36 vs. 0.99+/-0.23 L/min), nicotine half-life (111+/-37 vs. 116+/-29 min), and the trans-3'-hydroxycotinine to cotinine ratio (1.92+/-1.0 vs. 1.55+/-0.58) indicated no substantial differences in nicotine metabolism between those without the variant (CYP2A6*1/*1, n = 163) and those with the variant (CYP2A6*1/*21, n = 9), respectively.",Characterization of the novel CYP2A6*21 allele using in vivo nicotine kinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16758265/),min,116,185652,DB00184,Nicotine
,16758265,trans-3'-hydroxycotinine to cotinine,"In vivo pharmacokinetic parameters, such as nicotine clearance (1.32+/-0.37 vs. 1.18+/-0.20 L/min), fractional clearance of nicotine to cotinine (1.02+/-0.36 vs. 0.99+/-0.23 L/min), nicotine half-life (111+/-37 vs. 116+/-29 min), and the trans-3'-hydroxycotinine to cotinine ratio (1.92+/-1.0 vs. 1.55+/-0.58) indicated no substantial differences in nicotine metabolism between those without the variant (CYP2A6*1/*1, n = 163) and those with the variant (CYP2A6*1/*21, n = 9), respectively.",Characterization of the novel CYP2A6*21 allele using in vivo nicotine kinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16758265/),,1.92,185653,DB00184,Nicotine
,16758265,ratio,"In vivo pharmacokinetic parameters, such as nicotine clearance (1.32+/-0.37 vs. 1.18+/-0.20 L/min), fractional clearance of nicotine to cotinine (1.02+/-0.36 vs. 0.99+/-0.23 L/min), nicotine half-life (111+/-37 vs. 116+/-29 min), and the trans-3'-hydroxycotinine to cotinine ratio (1.92+/-1.0 vs. 1.55+/-0.58) indicated no substantial differences in nicotine metabolism between those without the variant (CYP2A6*1/*1, n = 163) and those with the variant (CYP2A6*1/*21, n = 9), respectively.",Characterization of the novel CYP2A6*21 allele using in vivo nicotine kinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16758265/),,1.92,185654,DB00184,Nicotine
,16758265,ratio,"In vivo pharmacokinetic parameters, such as nicotine clearance (1.32+/-0.37 vs. 1.18+/-0.20 L/min), fractional clearance of nicotine to cotinine (1.02+/-0.36 vs. 0.99+/-0.23 L/min), nicotine half-life (111+/-37 vs. 116+/-29 min), and the trans-3'-hydroxycotinine to cotinine ratio (1.92+/-1.0 vs. 1.55+/-0.58) indicated no substantial differences in nicotine metabolism between those without the variant (CYP2A6*1/*1, n = 163) and those with the variant (CYP2A6*1/*21, n = 9), respectively.",Characterization of the novel CYP2A6*21 allele using in vivo nicotine kinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16758265/),,1.55,185655,DB00184,Nicotine
,761952,reaching systemic circulation,The extent of unchanged drug reaching systemic circulation (extent of bioavailability) upon sc administration was 83%.,Animal model and pharmacokinetic interpretation of nicotine poisoning in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/761952/),%,83,187408,DB00184,Nicotine
,761952,extent of bioavailability,The extent of unchanged drug reaching systemic circulation (extent of bioavailability) upon sc administration was 83%.,Animal model and pharmacokinetic interpretation of nicotine poisoning in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/761952/),%,83,187409,DB00184,Nicotine
,9513590,hair:urine concentration ratio,"In a similar manner, the hair:urine concentration ratio was significantly higher in children with asthma (0.028 +/- 0.002) than in their controls (0.18 +/- 0.003) (p = 0.0001).",Pharmacokinetic predisposition to nicotine from environmental tobacco smoke: a risk factor for pediatric asthma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9513590/),,0.028,190554,DB00184,Nicotine
,9513590,hair:urine concentration ratio,"In a similar manner, the hair:urine concentration ratio was significantly higher in children with asthma (0.028 +/- 0.002) than in their controls (0.18 +/- 0.003) (p = 0.0001).",Pharmacokinetic predisposition to nicotine from environmental tobacco smoke: a risk factor for pediatric asthma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9513590/),,0.18,190555,DB00184,Nicotine
,461952,"biological half life (t 1/2, beta)","A biological half life (t 1/2, beta) of 0.61 hr we observed in dogs was similar to that in man and one half of that in rats.",Plasma nicotine pharmacokinetics in dogs after intravenous administration: determination by radioimmunoassay. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/461952/),h,0.61,191586,DB00184,Nicotine
,22741472,t1/2,"The configuration process in blood and brain both conforms to 2 compartments model, t1/2 is 29.38 min, t1/2beta is 208.51 min, AUC(0-infinity) is 152 127.10 microg x min x L(-1) in the blood t1/2 is 86.64 min, t1/2beta is 386.00 min, AUC(0-infinity) is 152 820.90 microg x min x L(-1) in the brain.",[Pharmacokinetics of nicotine in blood and brain using microdialysis and stable labelled isotope]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22741472/),min,29.38,195514,DB00184,Nicotine
,22741472,t1/2beta,"The configuration process in blood and brain both conforms to 2 compartments model, t1/2 is 29.38 min, t1/2beta is 208.51 min, AUC(0-infinity) is 152 127.10 microg x min x L(-1) in the blood t1/2 is 86.64 min, t1/2beta is 386.00 min, AUC(0-infinity) is 152 820.90 microg x min x L(-1) in the brain.",[Pharmacokinetics of nicotine in blood and brain using microdialysis and stable labelled isotope]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22741472/),min,208.51,195515,DB00184,Nicotine
,22741472,AUC(0-infinity),"The configuration process in blood and brain both conforms to 2 compartments model, t1/2 is 29.38 min, t1/2beta is 208.51 min, AUC(0-infinity) is 152 127.10 microg x min x L(-1) in the blood t1/2 is 86.64 min, t1/2beta is 386.00 min, AUC(0-infinity) is 152 820.90 microg x min x L(-1) in the brain.",[Pharmacokinetics of nicotine in blood and brain using microdialysis and stable labelled isotope]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22741472/),[min·μg] / [l],152 127.10,195516,DB00184,Nicotine
,22741472,t1/2,"The configuration process in blood and brain both conforms to 2 compartments model, t1/2 is 29.38 min, t1/2beta is 208.51 min, AUC(0-infinity) is 152 127.10 microg x min x L(-1) in the blood t1/2 is 86.64 min, t1/2beta is 386.00 min, AUC(0-infinity) is 152 820.90 microg x min x L(-1) in the brain.",[Pharmacokinetics of nicotine in blood and brain using microdialysis and stable labelled isotope]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22741472/),min,86.64,195517,DB00184,Nicotine
,22741472,t1/2beta,"The configuration process in blood and brain both conforms to 2 compartments model, t1/2 is 29.38 min, t1/2beta is 208.51 min, AUC(0-infinity) is 152 127.10 microg x min x L(-1) in the blood t1/2 is 86.64 min, t1/2beta is 386.00 min, AUC(0-infinity) is 152 820.90 microg x min x L(-1) in the brain.",[Pharmacokinetics of nicotine in blood and brain using microdialysis and stable labelled isotope]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22741472/),min,386.00,195518,DB00184,Nicotine
,22741472,AUC(0-infinity),"The configuration process in blood and brain both conforms to 2 compartments model, t1/2 is 29.38 min, t1/2beta is 208.51 min, AUC(0-infinity) is 152 127.10 microg x min x L(-1) in the blood t1/2 is 86.64 min, t1/2beta is 386.00 min, AUC(0-infinity) is 152 820.90 microg x min x L(-1) in the brain.",[Pharmacokinetics of nicotine in blood and brain using microdialysis and stable labelled isotope]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22741472/),[min·μg] / [l],152 820.90,195519,DB00184,Nicotine
,28479294,relative bioavailability,"The estimated MLE following the use of PNTV product was approximately two-thirds of that obtained following the smoking of CC1, but the relative bioavailability of PNTV product to CC1 was approximately 104%.",Pharmacokinetics of nicotine following the controlled use of a prototype novel tobacco vapor product. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28479294/),%,104,195580,DB00184,Nicotine
,2725116,limit of detection,"The limit of detection of nicotine in plasma was around 1 ng/ml and that of nicotine and cotinine in urine around 20 ng/ml and 10 ng/ml, respectively.","High performance liquid chromatographic determination of nicotine and cotinine in plasma and nicotine and cotinine, simultaneously, in urine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2725116/),[ng] / [ml],1,196638,DB00184,Nicotine
,2725116,limit of detection,"The limit of detection of nicotine in plasma was around 1 ng/ml and that of nicotine and cotinine in urine around 20 ng/ml and 10 ng/ml, respectively.","High performance liquid chromatographic determination of nicotine and cotinine in plasma and nicotine and cotinine, simultaneously, in urine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2725116/),[ng] / [ml],20,196639,DB00184,Nicotine
,2725116,limit of detection,"The limit of detection of nicotine in plasma was around 1 ng/ml and that of nicotine and cotinine in urine around 20 ng/ml and 10 ng/ml, respectively.","High performance liquid chromatographic determination of nicotine and cotinine in plasma and nicotine and cotinine, simultaneously, in urine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2725116/),[ng] / [ml],10,196640,DB00184,Nicotine
,2340848,total plasma clearance,"Mean total plasma clearance was 63.8 ml.h-1.kg-1 and mean renal clearance was 4.7 ml.h-1.kg-1, i.e. only 10% of the dose was excreted unchanged in the urine.",The pharmacokinetics of cotinine in plasma and saliva from non-smoking healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2340848/),[ml] / [h·kg],63.8,200325,DB00184,Nicotine
,2340848,renal clearance,"Mean total plasma clearance was 63.8 ml.h-1.kg-1 and mean renal clearance was 4.7 ml.h-1.kg-1, i.e. only 10% of the dose was excreted unchanged in the urine.",The pharmacokinetics of cotinine in plasma and saliva from non-smoking healthy volunteers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2340848/),[ml] / [h·kg],4.7,200326,DB00184,Nicotine
,2340848,terminal half-life,"As the clearance and distribution values in saliva were directly proportional to the corresponding values in plasma, similar terminal half-life values were obtained in the two body fluids, 15.5 and 16.8 h for plasma and saliva, respectively.",The pharmacokinetics of cotinine in plasma and saliva from non-smoking healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2340848/),h,15.5,200327,DB00184,Nicotine
,2340848,terminal half-life,"As the clearance and distribution values in saliva were directly proportional to the corresponding values in plasma, similar terminal half-life values were obtained in the two body fluids, 15.5 and 16.8 h for plasma and saliva, respectively.",The pharmacokinetics of cotinine in plasma and saliva from non-smoking healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2340848/),h,16.8,200328,DB00184,Nicotine
,10593207,peak arterial levels,These behavioral observations were associated with peak arterial levels of nicotine (approximately 25 ng/ml) no greater than the average venous levels of nicotine commonly maintained by cigarette smokers.,Behavioral sensitization following repeated intravenous nicotine administration: gender differences and gonadal hormones. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10593207/),[ng] / [ml],25,201939,DB00184,Nicotine
,2751025,biological half-life,"The mean biological half-life of cotinine in urine, collected from the nine smokers was 16.5 +/- 1.2 h, in never-smokers exposed to ETS, 27.3 +/- 1.9 h.",Elimination of cotinine from body fluids: disposition in smokers and nonsmokers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2751025/),h,16.5,203913,DB00184,Nicotine
,2751025,biological half-life,"The mean biological half-life of cotinine in urine, collected from the nine smokers was 16.5 +/- 1.2 h, in never-smokers exposed to ETS, 27.3 +/- 1.9 h.",Elimination of cotinine from body fluids: disposition in smokers and nonsmokers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2751025/),h,27.3,203914,DB00184,Nicotine
,28393086,puff,"Average puff duration and interpuff interval were 3.5±1.4 seconds (±SD) and 118±141 seconds, respectively.",Nicotine Delivery and Vaping Behavior During ad Libitum E-cigarette Access. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28393086/),seconds,3.5,204828,DB00184,Nicotine
,28393086,duration,"Average puff duration and interpuff interval were 3.5±1.4 seconds (±SD) and 118±141 seconds, respectively.",Nicotine Delivery and Vaping Behavior During ad Libitum E-cigarette Access. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28393086/),seconds,3.5,204829,DB00184,Nicotine
,28393086,interpuff interval,"Average puff duration and interpuff interval were 3.5±1.4 seconds (±SD) and 118±141 seconds, respectively.",Nicotine Delivery and Vaping Behavior During ad Libitum E-cigarette Access. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28393086/),seconds,118,204830,DB00184,Nicotine
,28393086,maximum plasma nicotine concentration (Cmax),"On average, 4.0±3.3 mg of nicotine was inhaled; the maximum plasma nicotine concentration (Cmax) was 12.8±8.5 ng/mL.",Nicotine Delivery and Vaping Behavior During ad Libitum E-cigarette Access. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28393086/),[ng] / [ml],12.8,204831,DB00184,Nicotine
,9203165,maximum level,The maximum level (5.4 micrograms/kg) was shown after 2 h.,Effects of cigarette smoke inhalation on plasma diltiazem levels in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9203165/),[μg] / [kg],5.4,209753,DB00184,Nicotine
,3450843,tissue-to-blood partition coefficients,"The tissue-to-blood partition coefficients of cotinine were calculated for adipose (0.08), brain (0.48), heart muscle (0.51), following the cotinine infusion.","Constant-rate infusion of nicotine and cotinine. I. A physiological pharmacokinetic analysis of the cotinine disposition, and effects on clearance and distribution in the rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3450843/),,0.08,215614,DB00184,Nicotine
,3450843,tissue-to-blood partition coefficients,"The tissue-to-blood partition coefficients of cotinine were calculated for adipose (0.08), brain (0.48), heart muscle (0.51), following the cotinine infusion.","Constant-rate infusion of nicotine and cotinine. I. A physiological pharmacokinetic analysis of the cotinine disposition, and effects on clearance and distribution in the rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3450843/),,0.48,215615,DB00184,Nicotine
,3450843,tissue-to-blood partition coefficients,"The tissue-to-blood partition coefficients of cotinine were calculated for adipose (0.08), brain (0.48), heart muscle (0.51), following the cotinine infusion.","Constant-rate infusion of nicotine and cotinine. I. A physiological pharmacokinetic analysis of the cotinine disposition, and effects on clearance and distribution in the rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3450843/),,0.51,215616,DB00184,Nicotine
,25122503,peak plasma concentrations,"Compared with the PK profile when using EC for the first time, 4 weeks of practice generated a 24% increase in the peak plasma concentrations (from 4.6 to 5.7 ng/ml; nonsignificant) and a 79% increase in overall nicotine intake (AUC(0 → inf) increased from 115 to 206 ng*min/ml; p < .05).",Nicotine intake from electronic cigarettes on initial use and after 4 weeks of regular use. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25122503/),[ng] / [ml],4,216414,DB00184,Nicotine
,25122503,peak plasma concentrations,"Compared with the PK profile when using EC for the first time, 4 weeks of practice generated a 24% increase in the peak plasma concentrations (from 4.6 to 5.7 ng/ml; nonsignificant) and a 79% increase in overall nicotine intake (AUC(0 → inf) increased from 115 to 206 ng*min/ml; p < .05).",Nicotine intake from electronic cigarettes on initial use and after 4 weeks of regular use. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25122503/),[ng] / [ml],5,216415,DB00184,Nicotine
,25122503,AUC(0 → inf),"Compared with the PK profile when using EC for the first time, 4 weeks of practice generated a 24% increase in the peak plasma concentrations (from 4.6 to 5.7 ng/ml; nonsignificant) and a 79% increase in overall nicotine intake (AUC(0 → inf) increased from 115 to 206 ng*min/ml; p < .05).",Nicotine intake from electronic cigarettes on initial use and after 4 weeks of regular use. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25122503/),[min·ng] / [ml],115,216416,DB00184,Nicotine
,25122503,AUC(0 → inf),"Compared with the PK profile when using EC for the first time, 4 weeks of practice generated a 24% increase in the peak plasma concentrations (from 4.6 to 5.7 ng/ml; nonsignificant) and a 79% increase in overall nicotine intake (AUC(0 → inf) increased from 115 to 206 ng*min/ml; p < .05).",Nicotine intake from electronic cigarettes on initial use and after 4 weeks of regular use. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25122503/),[min·ng] / [ml],206,216417,DB00184,Nicotine
,8440767,Cmax,"After a single application, mean Cmax and tmax for plasma nicotine were 12.2 ng/mL and 4.4 hours, respectively.",Single- and multiple-dose pharmacokinetics of Nicoderm (Nicotine Transdermal System). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8440767/),[ng] / [ml],12.2,216991,DB00184,Nicotine
,8440767,tmax,"After a single application, mean Cmax and tmax for plasma nicotine were 12.2 ng/mL and 4.4 hours, respectively.",Single- and multiple-dose pharmacokinetics of Nicoderm (Nicotine Transdermal System). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8440767/),h,4.4,216992,DB00184,Nicotine
,8440767,apparent ni,The apparent nicotine half-life (t1/2) after system removal was 3.2 hours.,Single- and multiple-dose pharmacokinetics of Nicoderm (Nicotine Transdermal System). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8440767/),h,3.2,216993,DB00184,Nicotine
,17112802,total plasma clearance,"The mean total plasma clearance of nicotine (+/-SD) was 18.8+/-6.0, 15.5+/-4.9, and 11.7+/-5.1 mL.min-1.kg-1 in groups 1, 2, and 3, respectively, and group 1 had significantly faster clearance than group 2 (P<.05) and group 3 (P<.01).",CYP2A6 genotype and the metabolism and disposition kinetics of nicotine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17112802/),[ml] / [kg·min],18.8,217862,DB00184,Nicotine
,17112802,total plasma clearance,"The mean total plasma clearance of nicotine (+/-SD) was 18.8+/-6.0, 15.5+/-4.9, and 11.7+/-5.1 mL.min-1.kg-1 in groups 1, 2, and 3, respectively, and group 1 had significantly faster clearance than group 2 (P<.05) and group 3 (P<.01).",CYP2A6 genotype and the metabolism and disposition kinetics of nicotine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17112802/),[ml] / [kg·min],15.5,217863,DB00184,Nicotine
,17112802,total plasma clearance,"The mean total plasma clearance of nicotine (+/-SD) was 18.8+/-6.0, 15.5+/-4.9, and 11.7+/-5.1 mL.min-1.kg-1 in groups 1, 2, and 3, respectively, and group 1 had significantly faster clearance than group 2 (P<.05) and group 3 (P<.01).",CYP2A6 genotype and the metabolism and disposition kinetics of nicotine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17112802/),[ml] / [kg·min],11.7,217864,DB00184,Nicotine
,15843487,K(d),The effects of antibodies on nicotine distribution to brain were studied using nicotine-specific monoclonal antibodies (NICmAbs) with K(d) values ranging from 60 to 250 nM and a high-affinity polyclonal rabbit antiserum (K(d) = 1.6 nM).,Monoclonal nicotine-specific antibodies reduce nicotine distribution to brain in rats: dose- and affinity-response relationships. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15843487/),nM,60 to 250,220535,DB00184,Nicotine
,15843487,K(d),The effects of antibodies on nicotine distribution to brain were studied using nicotine-specific monoclonal antibodies (NICmAbs) with K(d) values ranging from 60 to 250 nM and a high-affinity polyclonal rabbit antiserum (K(d) = 1.6 nM).,Monoclonal nicotine-specific antibodies reduce nicotine distribution to brain in rats: dose- and affinity-response relationships. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15843487/),nM,1.6,220536,DB00184,Nicotine
,17368006,clearance half-life,"The conventional nasal spray deposited in the posterior nasal cavity in only one instance, with a rapid clearance half-life of 9.2 min.","Nasal residence of insulin containing lyophilised nasal insert formulations, using gamma scintigraphy. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17368006/),min,9.2,222323,DB00184,Nicotine
,17368006,nasal residence time,"The nasal insert formulations did not enhance nasal absorption of insulin, however an extended nasal residence time of 4-5 h was observed for the 2% HPMC formulation.","Nasal residence of insulin containing lyophilised nasal insert formulations, using gamma scintigraphy. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17368006/),h,4-5,222324,DB00184,Nicotine
,2791443,Clearance,"Clearance for passive smokers was 6.01 x 10(-2) L/hr.kg and for nonsmokers, clearance was 4.09 x 10(-2) L/hr.kg (p less than 0.025).",Effects of passive smoking on theophylline clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2791443/),[l] / [h·kg],6.01 x 10(-2),222364,DB00184,Nicotine
,2791443,clearance,"Clearance for passive smokers was 6.01 x 10(-2) L/hr.kg and for nonsmokers, clearance was 4.09 x 10(-2) L/hr.kg (p less than 0.025).",Effects of passive smoking on theophylline clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2791443/),[l] / [h·kg],4.09 x 10(-2),222365,DB00184,Nicotine
,2791443,Terminal elimination half-life,Terminal elimination half-life for passive smokers was 6.93 hours versus 8.69 hours for nonsmokers (p less than 0.05).,Effects of passive smoking on theophylline clearance. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2791443/),h,6.93,222366,DB00184,Nicotine
,2791443,Terminal elimination half-life,Terminal elimination half-life for passive smokers was 6.93 hours versus 8.69 hours for nonsmokers (p less than 0.05).,Effects of passive smoking on theophylline clearance. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2791443/),h,8.69,222367,DB00184,Nicotine
,2791443,mean residence time,The mean residence time for passive smokers was 9.89 hours.,Effects of passive smoking on theophylline clearance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2791443/),h,9.89,222368,DB00184,Nicotine
,2791443,mean residence time,"For nonsmokers, the mean residence time was 13.11 hours (p less than 0.05).",Effects of passive smoking on theophylline clearance. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2791443/),h,13.11,222369,DB00184,Nicotine
,23714690,half-life,"The estimate of half-life using a mixed-effect model was 17.9 h (95% confidence interval: 16.5, 19.3), similar to that reported in adults.",CYP2A6 genotype but not age determines cotinine half-life in infants and children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23714690/),h,17.9,222841,DB00184,Nicotine
,3411460,Fractional conversions,Fractional conversions of both enantiomers of nicotine to cotinine were approximately 50%.,Disposition kinetics of nicotine and cotinine enantiomers in rabbits and beagle dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3411460/),,50,224398,DB00184,Nicotine
,4030985,Overall recoveries,Overall recoveries of NNO were 64-76% from biological media.,Isolation and analysis of N-oxide metabolites of tertiary amines: quantitation of nicotine-1'-N-oxide formation in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4030985/),%,64-76,233815,DB00184,Nicotine
,20097626,total extraction recovery (,The total extraction recovery (%) was concentration dependent and ranged between 52-88% in plasma and 51-118% in urine.,"A novel validated procedure for the determination of nicotine, eight nicotine metabolites and two minor tobacco alkaloids in human plasma or urine by solid-phase extraction coupled with liquid chromatography-electrospray ionization-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20097626/),%,52-88,236218,DB00184,Nicotine
,20097626,total extraction recovery (,The total extraction recovery (%) was concentration dependent and ranged between 52-88% in plasma and 51-118% in urine.,"A novel validated procedure for the determination of nicotine, eight nicotine metabolites and two minor tobacco alkaloids in human plasma or urine by solid-phase extraction coupled with liquid chromatography-electrospray ionization-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20097626/),%,51-118,236219,DB00184,Nicotine
,31496314,initial half-time of absorption,"Results and Discussion: Following exposure, both nicotine formulations had very rapid and similar dissolution and absorption kinetics in both the DissolvIt and IPL exposure models, with an initial half-time of absorption to the single-pass perfusate of 34 and 72 seconds, respectively.","Respirable aerosol exposures of nicotine dry powder formulations to in vitro, ex vivo, and in vivo pre-clinical models demonstrate consistency of pharmacokinetic profiles. ","t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31496314/),seconds,34,236677,DB00184,Nicotine
,31496314,initial half-time of absorption,"Results and Discussion: Following exposure, both nicotine formulations had very rapid and similar dissolution and absorption kinetics in both the DissolvIt and IPL exposure models, with an initial half-time of absorption to the single-pass perfusate of 34 and 72 seconds, respectively.","Respirable aerosol exposures of nicotine dry powder formulations to in vitro, ex vivo, and in vivo pre-clinical models demonstrate consistency of pharmacokinetic profiles. ","t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31496314/),seconds,72,236678,DB00184,Nicotine
,31496314,systemic elimination half-time,"In the intratracheally intubated rat, following a rapid initial equilibration between the lungs and systemic compartments, nicotine had a systemic elimination half-time of 2.3-2.4 hours for both formulations.","Respirable aerosol exposures of nicotine dry powder formulations to in vitro, ex vivo, and in vivo pre-clinical models demonstrate consistency of pharmacokinetic profiles. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31496314/),h,2.3-2.4,236679,DB00184,Nicotine
,31496314,tissue-blood partition coefficient,The rapid pulmonary PK of nicotine was likely close to the theoretical equilibration of a low-binding substance with a tissue-blood partition coefficient close to 1.,"Respirable aerosol exposures of nicotine dry powder formulations to in vitro, ex vivo, and in vivo pre-clinical models demonstrate consistency of pharmacokinetic profiles. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31496314/),,1,236680,DB00184,Nicotine
,10975241,Limits,"Limits of quantitation for mecamylamine, nicotine and cotinine are 2, 1 and 2 ng/ml, respectively.","Simultaneous determination of mecamylamine, nicotine, and cotinine in plasma by gas chromatography-mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10975241/),[ng] / [ml],2,239394,DB00184,Nicotine
,10975241,Limits,"Limits of quantitation for mecamylamine, nicotine and cotinine are 2, 1 and 2 ng/ml, respectively.","Simultaneous determination of mecamylamine, nicotine, and cotinine in plasma by gas chromatography-mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10975241/),[ng] / [ml],1,239395,DB00184,Nicotine
,26438645,time to the maximum nicotine concentration,The time to the maximum nicotine concentration was 8 minutes after single use of the THS 2.1 and CCs.,Comparison of the Pharmacokinetics of Nicotine Following Single and Ad Libitum Use of a Tobacco Heating System or Combustible Cigarettes. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26438645/),min,8,239514,DB00184,Nicotine
,26438645,maximum plasma nicotine concentration,"The maximum plasma nicotine concentration after single use of the THS 2.1 was 8.4 ng/mL, 70.3% of that obtained with CCs.",Comparison of the Pharmacokinetics of Nicotine Following Single and Ad Libitum Use of a Tobacco Heating System or Combustible Cigarettes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26438645/),[ng] / [ml],8.4,239515,DB00184,Nicotine
,26851241,IC50,IC50 values from recombinant enzymes indicated that an interaction is most probable for CYP2A6 (IC50 = 6.1 µM).,Inactivation of CYP2A6 by the Dietary Phenylpropanoid trans-Cinnamic Aldehyde (Cinnamaldehyde) and Estimation of Interactions with Nicotine and Letrozole. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26851241/),μM,6.1,242385,DB00184,Nicotine
,26851241,KS,t-CA is a type I ligand for CYP2A6 (KS = 14.9 µM).,Inactivation of CYP2A6 by the Dietary Phenylpropanoid trans-Cinnamic Aldehyde (Cinnamaldehyde) and Estimation of Interactions with Nicotine and Letrozole. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26851241/),μM,14.9,242386,DB00184,Nicotine
,26851241,K(I),"Using a static model and mechanism-based inhibition parameters (K(I) = 18.0 µM; k(inact) = 0.056 minute(-1)), changes in the area under the concentration-time curve (AUC) for nicotine and letrozole were predicted in the presence of t-CA (0.1 and 1 µM).",Inactivation of CYP2A6 by the Dietary Phenylpropanoid trans-Cinnamic Aldehyde (Cinnamaldehyde) and Estimation of Interactions with Nicotine and Letrozole. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26851241/),μM,18.0,242387,DB00184,Nicotine
,26851241,k(inact),"Using a static model and mechanism-based inhibition parameters (K(I) = 18.0 µM; k(inact) = 0.056 minute(-1)), changes in the area under the concentration-time curve (AUC) for nicotine and letrozole were predicted in the presence of t-CA (0.1 and 1 µM).",Inactivation of CYP2A6 by the Dietary Phenylpropanoid trans-Cinnamic Aldehyde (Cinnamaldehyde) and Estimation of Interactions with Nicotine and Letrozole. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26851241/),1/[minute],0.056,242388,DB00184,Nicotine
,26851241,AUC fold-change,The AUC fold-change ranged from 1.1 to 3.6.,Inactivation of CYP2A6 by the Dietary Phenylpropanoid trans-Cinnamic Aldehyde (Cinnamaldehyde) and Estimation of Interactions with Nicotine and Letrozole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26851241/),,1.1,242389,DB00184,Nicotine
,11489317,area under the nicotine concentration time curve (AUC),Mean area under the nicotine concentration time curve (AUC) in subepidermal layers underneath the application site of the TTS was 70.0+/-55.1 microg/g per h.,Application of the minimal trauma tissue biopsy to transdermal clinical pharmacokinetic studies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11489317/),[μg] / [g·h],70.0,242947,DB00184,Nicotine
,32319528,extracted fractions,The extracted fractions of nicotine for both ZYN products (56% and 59%) were significantly larger than for 8 mg General (32%).,"Pharmacokinetic Comparison of a Novel Non-tobacco-Based Nicotine Pouch (ZYN) With Conventional, Tobacco-Based Swedish Snus and American Moist Snuff. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32319528/),%,56,243729,DB00184,Nicotine
,32319528,extracted fractions,The extracted fractions of nicotine for both ZYN products (56% and 59%) were significantly larger than for 8 mg General (32%).,"Pharmacokinetic Comparison of a Novel Non-tobacco-Based Nicotine Pouch (ZYN) With Conventional, Tobacco-Based Swedish Snus and American Moist Snuff. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32319528/),%,59,243730,DB00184,Nicotine
,32319528,extracted fractions,The extracted fractions of nicotine for both ZYN products (56% and 59%) were significantly larger than for 8 mg General (32%).,"Pharmacokinetic Comparison of a Novel Non-tobacco-Based Nicotine Pouch (ZYN) With Conventional, Tobacco-Based Swedish Snus and American Moist Snuff. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32319528/),%,32,243731,DB00184,Nicotine
,32319528,extracted fraction,The extracted fraction of nicotine for ZYN 8 mg (50%) was larger than for Longhorn Natural (19%) and General 2 × 8 mg snus pouches (33%).,"Pharmacokinetic Comparison of a Novel Non-tobacco-Based Nicotine Pouch (ZYN) With Conventional, Tobacco-Based Swedish Snus and American Moist Snuff. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32319528/),%,50,243732,DB00184,Nicotine
,32319528,extracted fraction,The extracted fraction of nicotine for ZYN 8 mg (50%) was larger than for Longhorn Natural (19%) and General 2 × 8 mg snus pouches (33%).,"Pharmacokinetic Comparison of a Novel Non-tobacco-Based Nicotine Pouch (ZYN) With Conventional, Tobacco-Based Swedish Snus and American Moist Snuff. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32319528/),%,19,243733,DB00184,Nicotine
,32319528,extracted fraction,The extracted fraction of nicotine for ZYN 8 mg (50%) was larger than for Longhorn Natural (19%) and General 2 × 8 mg snus pouches (33%).,"Pharmacokinetic Comparison of a Novel Non-tobacco-Based Nicotine Pouch (ZYN) With Conventional, Tobacco-Based Swedish Snus and American Moist Snuff. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32319528/),%,33,243734,DB00184,Nicotine
,10704023,recoveries,"As a result, the recoveries for nicotine and cotinine were improved to 68 and 65%, respectively.",Simultaneous GC-MS determination of nicotine and cotinine in plasma for the pharmacokinetic characterization of nicotine in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10704023/),%,68,245237,DB00184,Nicotine
,10704023,recoveries,"As a result, the recoveries for nicotine and cotinine were improved to 68 and 65%, respectively.",Simultaneous GC-MS determination of nicotine and cotinine in plasma for the pharmacokinetic characterization of nicotine in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10704023/),%,65,245238,DB00184,Nicotine
,10704023,Cl,"Moment analysis revealed that pharmacokinetic parameters for nicotine (i.e. Cl, 46.30 ml min(-1) kg(-1); Vss, 2.77 1 kg(-1)) was similar to those reported in studies using 14C-nicotine.",Simultaneous GC-MS determination of nicotine and cotinine in plasma for the pharmacokinetic characterization of nicotine in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10704023/),[ml] / [kg·min],46.30,245239,DB00184,Nicotine
,10704023,Vss,"Moment analysis revealed that pharmacokinetic parameters for nicotine (i.e. Cl, 46.30 ml min(-1) kg(-1); Vss, 2.77 1 kg(-1)) was similar to those reported in studies using 14C-nicotine.",Simultaneous GC-MS determination of nicotine and cotinine in plasma for the pharmacokinetic characterization of nicotine in rats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10704023/),[1] / [kg],2.77,245240,DB00184,Nicotine
,10704023,Absolute bioavailabilities,"Absolute bioavailabilities of nicotine for i.p. and oral administration were 87.0 and 80.4%, respectively.",Simultaneous GC-MS determination of nicotine and cotinine in plasma for the pharmacokinetic characterization of nicotine in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10704023/),%,87.0,245241,DB00184,Nicotine
,10704023,Absolute bioavailabilities,"Absolute bioavailabilities of nicotine for i.p. and oral administration were 87.0 and 80.4%, respectively.",Simultaneous GC-MS determination of nicotine and cotinine in plasma for the pharmacokinetic characterization of nicotine in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10704023/),%,80.4,245242,DB00184,Nicotine
,20233178,volume of distribution,Nicotine decreased the volume of distribution (62.6 vs.,Effects of nicotine on cytochrome P450 2A6 and 2E1 activities. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20233178/),,62.6,246804,DB00184,Nicotine
,2612544,Absorption,Absorption of nicotine from the TDS was 80-90% and the rate of delivery was similar during both studies.,Transdermal delivery of nicotine in normal human volunteers: a single dose and multiple dose study. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612544/),%,80-90,247873,DB00184,Nicotine
,1268547,peak levels,"Levels comparable to those resulting from smoking were not obtained with the 2-mg gum, but peak levels on the 4-mg gum averaged 40-1 ng/ml from the third gum onwards compared with 49-2ng/ml after cigarettes.",Plasma nicotine levels after cigarette smoking and chewing nicotine gum. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1268547/),[ng] / [ml],40-1,249153,DB00184,Nicotine
,1268547,peak levels,"Levels comparable to those resulting from smoking were not obtained with the 2-mg gum, but peak levels on the 4-mg gum averaged 40-1 ng/ml from the third gum onwards compared with 49-2ng/ml after cigarettes.",Plasma nicotine levels after cigarette smoking and chewing nicotine gum. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1268547/),[ng] / [ml],49-2,249154,DB00184,Nicotine
,12194535,half-life,"According to this model tolerance developed rapidly with a median half-life of 6.6 min, and median decrease of effect due to tolerance of 31%.",Influence of arterial vs. venous sampling site on nicotine tolerance model selection and parameter estimation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12194535/),min,6.6,250283,DB00184,Nicotine
,26951892,minimum inhibitory concentration,"After lead optimization, one nicotine analogue [3-(5-(3fluorophenyl)nicotinoyl)-1-methylpyrrolidin-2-one] exhibited minimum inhibitory concentration of 1 μg/mL (2.86 nM) against M. tuberculosis (H37Rv strain), a human pathogenic strain of clinically significant importance.",Novel nicotine analogues with potential anti-mycobacterial activity. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26951892/),[μg] / [ml],1,251226,DB00184,Nicotine
,26951892,minimum inhibitory concentration,"After lead optimization, one nicotine analogue [3-(5-(3fluorophenyl)nicotinoyl)-1-methylpyrrolidin-2-one] exhibited minimum inhibitory concentration of 1 μg/mL (2.86 nM) against M. tuberculosis (H37Rv strain), a human pathogenic strain of clinically significant importance.",Novel nicotine analogues with potential anti-mycobacterial activity. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26951892/),nM,2.86,251227,DB00184,Nicotine
,26951892,maximum serum drug concentration (Cmax),"Pharmacokinetic analysis of [3-(5-(3fluorophenyl)nicotinoyl)-1methylpyrrolidin-2-one] with lowest MIC value via oral route in Wistar rats revealed that at a dosage of 5 mg/kg body weight gave a maximum serum drug concentration (Cmax) of 2.86 μg/mL, Tmax of one hour and a half-life (T1/2) of more than 24 h and Volume of distribution (Vd) of 27.36 L.",Novel nicotine analogues with potential anti-mycobacterial activity. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26951892/),[μg] / [ml],2.86,251228,DB00184,Nicotine
,26951892,Tmax,"Pharmacokinetic analysis of [3-(5-(3fluorophenyl)nicotinoyl)-1methylpyrrolidin-2-one] with lowest MIC value via oral route in Wistar rats revealed that at a dosage of 5 mg/kg body weight gave a maximum serum drug concentration (Cmax) of 2.86 μg/mL, Tmax of one hour and a half-life (T1/2) of more than 24 h and Volume of distribution (Vd) of 27.36 L.",Novel nicotine analogues with potential anti-mycobacterial activity. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26951892/),h,one,251229,DB00184,Nicotine
more,26951892,half-life (T1/2),"Pharmacokinetic analysis of [3-(5-(3fluorophenyl)nicotinoyl)-1methylpyrrolidin-2-one] with lowest MIC value via oral route in Wistar rats revealed that at a dosage of 5 mg/kg body weight gave a maximum serum drug concentration (Cmax) of 2.86 μg/mL, Tmax of one hour and a half-life (T1/2) of more than 24 h and Volume of distribution (Vd) of 27.36 L.",Novel nicotine analogues with potential anti-mycobacterial activity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26951892/),h,24,251230,DB00184,Nicotine
,26951892,Volume of distribution (Vd),"Pharmacokinetic analysis of [3-(5-(3fluorophenyl)nicotinoyl)-1methylpyrrolidin-2-one] with lowest MIC value via oral route in Wistar rats revealed that at a dosage of 5 mg/kg body weight gave a maximum serum drug concentration (Cmax) of 2.86 μg/mL, Tmax of one hour and a half-life (T1/2) of more than 24 h and Volume of distribution (Vd) of 27.36 L.",Novel nicotine analogues with potential anti-mycobacterial activity. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26951892/),l,27.36,251231,DB00184,Nicotine
,26951892,Cmax,"Whereas the parenteral (intra venous) route showed a Cmax of 3.37 μg/mL, Tmax of 0.05 h, T1/2 of 24 h and Vd equivalent to 23.18 L.",Novel nicotine analogues with potential anti-mycobacterial activity. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26951892/),[μg] / [ml],3.37,251232,DB00184,Nicotine
,26951892,Tmax,"Whereas the parenteral (intra venous) route showed a Cmax of 3.37 μg/mL, Tmax of 0.05 h, T1/2 of 24 h and Vd equivalent to 23.18 L.",Novel nicotine analogues with potential anti-mycobacterial activity. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26951892/),h,0.05,251233,DB00184,Nicotine
,26951892,T1/2,"Whereas the parenteral (intra venous) route showed a Cmax of 3.37 μg/mL, Tmax of 0.05 h, T1/2 of 24 h and Vd equivalent to 23.18 L.",Novel nicotine analogues with potential anti-mycobacterial activity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26951892/),h,24,251234,DB00184,Nicotine
,26951892,Vd,"Whereas the parenteral (intra venous) route showed a Cmax of 3.37 μg/mL, Tmax of 0.05 h, T1/2 of 24 h and Vd equivalent to 23.18 L.",Novel nicotine analogues with potential anti-mycobacterial activity. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26951892/),l,23.18,251235,DB00184,Nicotine
>,26951892,LD50,The acute oral toxicity and repeated oral toxicity studies in female Wistar rats had an LD50>2000 mg/kg body weight.,Novel nicotine analogues with potential anti-mycobacterial activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26951892/),[mg] / [kg],2000,251236,DB00184,Nicotine
,18065502,AUC,"In mice in vivo, selegiline increased AUC (90.7 +/- 5.8 versus 57.4 +/- 5.3 ng/h/ml, p < 0.05), decreased clearance (4.6 +/- 0.4 versus 7.3 +/- 0.3 ml/min, p < 0.05), and increased elimination half-life (12.5 +/- 6.3 versus 6.6 +/- 1.4 min, p < 0.05) of nicotine.",Selegiline is a mechanism-based inactivator of CYP2A6 inhibiting nicotine metabolism in humans and mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18065502/),[ng] / [h·ml],90.7,258469,DB00184,Nicotine
,18065502,AUC,"In mice in vivo, selegiline increased AUC (90.7 +/- 5.8 versus 57.4 +/- 5.3 ng/h/ml, p < 0.05), decreased clearance (4.6 +/- 0.4 versus 7.3 +/- 0.3 ml/min, p < 0.05), and increased elimination half-life (12.5 +/- 6.3 versus 6.6 +/- 1.4 min, p < 0.05) of nicotine.",Selegiline is a mechanism-based inactivator of CYP2A6 inhibiting nicotine metabolism in humans and mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18065502/),[ng] / [h·ml],57.4,258470,DB00184,Nicotine
,18065502,clearance,"In mice in vivo, selegiline increased AUC (90.7 +/- 5.8 versus 57.4 +/- 5.3 ng/h/ml, p < 0.05), decreased clearance (4.6 +/- 0.4 versus 7.3 +/- 0.3 ml/min, p < 0.05), and increased elimination half-life (12.5 +/- 6.3 versus 6.6 +/- 1.4 min, p < 0.05) of nicotine.",Selegiline is a mechanism-based inactivator of CYP2A6 inhibiting nicotine metabolism in humans and mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18065502/),[ml] / [min],4.6,258471,DB00184,Nicotine
,18065502,clearance,"In mice in vivo, selegiline increased AUC (90.7 +/- 5.8 versus 57.4 +/- 5.3 ng/h/ml, p < 0.05), decreased clearance (4.6 +/- 0.4 versus 7.3 +/- 0.3 ml/min, p < 0.05), and increased elimination half-life (12.5 +/- 6.3 versus 6.6 +/- 1.4 min, p < 0.05) of nicotine.",Selegiline is a mechanism-based inactivator of CYP2A6 inhibiting nicotine metabolism in humans and mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18065502/),[ml] / [min],7.3,258472,DB00184,Nicotine
,18065502,elimination half-life,"In mice in vivo, selegiline increased AUC (90.7 +/- 5.8 versus 57.4 +/- 5.3 ng/h/ml, p < 0.05), decreased clearance (4.6 +/- 0.4 versus 7.3 +/- 0.3 ml/min, p < 0.05), and increased elimination half-life (12.5 +/- 6.3 versus 6.6 +/- 1.4 min, p < 0.05) of nicotine.",Selegiline is a mechanism-based inactivator of CYP2A6 inhibiting nicotine metabolism in humans and mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18065502/),min,12.5,258473,DB00184,Nicotine
,18065502,elimination half-life,"In mice in vivo, selegiline increased AUC (90.7 +/- 5.8 versus 57.4 +/- 5.3 ng/h/ml, p < 0.05), decreased clearance (4.6 +/- 0.4 versus 7.3 +/- 0.3 ml/min, p < 0.05), and increased elimination half-life (12.5 +/- 6.3 versus 6.6 +/- 1.4 min, p < 0.05) of nicotine.",Selegiline is a mechanism-based inactivator of CYP2A6 inhibiting nicotine metabolism in humans and mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18065502/),min,6.6,258474,DB00184,Nicotine
,18065502,K(i),Selegiline preincubation increased inhibition in microsomes (3.7-fold) and CYP2A6 (14.8-fold); the K(i) for CYP2A6 was 4.2 muM.,Selegiline is a mechanism-based inactivator of CYP2A6 inhibiting nicotine metabolism in humans and mice. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18065502/),muM,4.2,258475,DB00184,Nicotine
,18065502,K(i),"Selegiline dose- and time-dependently inhibited nicotine metabolism by CYP2A6 (K(i) = 15.6 +/- 2.7 muM; k(inact) = 0.34 +/- 0.04 min(-1)), and the inhibition was irreversible in the presence of NADPH, indicating that it is a mechanism-based inhibitor of CYP2A6.",Selegiline is a mechanism-based inactivator of CYP2A6 inhibiting nicotine metabolism in humans and mice. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18065502/),muM,15.6,258476,DB00184,Nicotine
,18065502,k(inact),"Selegiline dose- and time-dependently inhibited nicotine metabolism by CYP2A6 (K(i) = 15.6 +/- 2.7 muM; k(inact) = 0.34 +/- 0.04 min(-1)), and the inhibition was irreversible in the presence of NADPH, indicating that it is a mechanism-based inhibitor of CYP2A6.",Selegiline is a mechanism-based inactivator of CYP2A6 inhibiting nicotine metabolism in humans and mice. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18065502/),1/[min],0.34,258477,DB00184,Nicotine
,8827400,steady-state blood nicotine concentrations,Higher steady-state blood nicotine concentrations (16 to 29 micrograms/L) have been reported for ad libitum clinical self-administration with a nicotine nasal spray.,Clinical pharmacokinetics of nasal nicotine delivery. A review and comparison to other nicotine systems. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8827400/),[μg] / [l],16 to 29,258627,DB00184,Nicotine
,8827400,Time to peak plasma concentration (tmax),Time to peak plasma concentration (tmax) with nasal administration is around 11 to 13 minutes for 1 mg doses.,Clinical pharmacokinetics of nasal nicotine delivery. A review and comparison to other nicotine systems. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8827400/),min,11 to 13,258628,DB00184,Nicotine
,3184779,half-life (t1/2 beta),The following means and ranges for the pharmacokinetic parameters were derived from the 3'-hydroxycotinine infusion experiment: half-life (t1/2 beta) = 5.9 (4.2-9.5) h; apparent volume of distribution (Vd) = 0.87 (0.51-1.14) l/kg; total clearance (Cl total) = 1.79 (1.08-2.59) ml/min/kg; renal clearance (Clr) = 1.31 (0.85-1.78) ml/min/kg; percentage of renal clearance (Clr/Cl total) = 75.4 +/- 12.8 (60.3-98.2).,"Pharmacokinetics of nicotine, cotinine, and 3'-hydroxycotinine in cigarette smokers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3184779/),h,5.9,260685,DB00184,Nicotine
,3184779,apparent volume of distribution (Vd),The following means and ranges for the pharmacokinetic parameters were derived from the 3'-hydroxycotinine infusion experiment: half-life (t1/2 beta) = 5.9 (4.2-9.5) h; apparent volume of distribution (Vd) = 0.87 (0.51-1.14) l/kg; total clearance (Cl total) = 1.79 (1.08-2.59) ml/min/kg; renal clearance (Clr) = 1.31 (0.85-1.78) ml/min/kg; percentage of renal clearance (Clr/Cl total) = 75.4 +/- 12.8 (60.3-98.2).,"Pharmacokinetics of nicotine, cotinine, and 3'-hydroxycotinine in cigarette smokers. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3184779/),[l] / [kg],0.87,260686,DB00184,Nicotine
,3184779,total clearance (Cl total),The following means and ranges for the pharmacokinetic parameters were derived from the 3'-hydroxycotinine infusion experiment: half-life (t1/2 beta) = 5.9 (4.2-9.5) h; apparent volume of distribution (Vd) = 0.87 (0.51-1.14) l/kg; total clearance (Cl total) = 1.79 (1.08-2.59) ml/min/kg; renal clearance (Clr) = 1.31 (0.85-1.78) ml/min/kg; percentage of renal clearance (Clr/Cl total) = 75.4 +/- 12.8 (60.3-98.2).,"Pharmacokinetics of nicotine, cotinine, and 3'-hydroxycotinine in cigarette smokers. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3184779/),[ml] / [kg·min],1.79,260687,DB00184,Nicotine
,3184779,renal clearance (Clr),The following means and ranges for the pharmacokinetic parameters were derived from the 3'-hydroxycotinine infusion experiment: half-life (t1/2 beta) = 5.9 (4.2-9.5) h; apparent volume of distribution (Vd) = 0.87 (0.51-1.14) l/kg; total clearance (Cl total) = 1.79 (1.08-2.59) ml/min/kg; renal clearance (Clr) = 1.31 (0.85-1.78) ml/min/kg; percentage of renal clearance (Clr/Cl total) = 75.4 +/- 12.8 (60.3-98.2).,"Pharmacokinetics of nicotine, cotinine, and 3'-hydroxycotinine in cigarette smokers. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3184779/),[ml] / [kg·min],1.31,260688,DB00184,Nicotine
,3184779,percentage of renal clearance (Clr/Cl total),The following means and ranges for the pharmacokinetic parameters were derived from the 3'-hydroxycotinine infusion experiment: half-life (t1/2 beta) = 5.9 (4.2-9.5) h; apparent volume of distribution (Vd) = 0.87 (0.51-1.14) l/kg; total clearance (Cl total) = 1.79 (1.08-2.59) ml/min/kg; renal clearance (Clr) = 1.31 (0.85-1.78) ml/min/kg; percentage of renal clearance (Clr/Cl total) = 75.4 +/- 12.8 (60.3-98.2).,"Pharmacokinetics of nicotine, cotinine, and 3'-hydroxycotinine in cigarette smokers. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3184779/),,75.4,260689,DB00184,Nicotine
,21963483,Extraction recoveries,"Extraction recoveries ranged from 64% to 115%, LC-MS/MS matrix effects were ≤21%, and overall process efficiency ranged from 57% to 93% at low and high quality control concentrations.",Simultaneous quantification of nicotine and metabolites in rat brain by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21963483/),%,64,264120,DB00184,Nicotine
,21963483,Extraction recoveries,"Extraction recoveries ranged from 64% to 115%, LC-MS/MS matrix effects were ≤21%, and overall process efficiency ranged from 57% to 93% at low and high quality control concentrations.",Simultaneous quantification of nicotine and metabolites in rat brain by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21963483/),%,115,264121,DB00184,Nicotine
,21963483,overall process efficiency,"Extraction recoveries ranged from 64% to 115%, LC-MS/MS matrix effects were ≤21%, and overall process efficiency ranged from 57% to 93% at low and high quality control concentrations.",Simultaneous quantification of nicotine and metabolites in rat brain by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21963483/),%,57,264122,DB00184,Nicotine
,21963483,overall process efficiency,"Extraction recoveries ranged from 64% to 115%, LC-MS/MS matrix effects were ≤21%, and overall process efficiency ranged from 57% to 93% at low and high quality control concentrations.",Simultaneous quantification of nicotine and metabolites in rat brain by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21963483/),%,93,264123,DB00184,Nicotine
,21963483,concentrations,"In these tissues, striatal concentrations were 204.8±49.4, 138.2±14.2 and 36.1±6.1 pg/mg of NIC, COT and NNIC, respectively.",Simultaneous quantification of nicotine and metabolites in rat brain by liquid chromatography-tandem mass spectrometry. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21963483/),,204.8,264124,DB00184,Nicotine
,21963483,concentrations,"In these tissues, striatal concentrations were 204.8±49.4, 138.2±14.2 and 36.1±6.1 pg/mg of NIC, COT and NNIC, respectively.",Simultaneous quantification of nicotine and metabolites in rat brain by liquid chromatography-tandem mass spectrometry. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21963483/),,138.2,264125,DB00184,Nicotine
,21963483,concentrations,"In these tissues, striatal concentrations were 204.8±49.4, 138.2±14.2 and 36.1±6.1 pg/mg of NIC, COT and NNIC, respectively.",Simultaneous quantification of nicotine and metabolites in rat brain by liquid chromatography-tandem mass spectrometry. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21963483/),,36.1,264126,DB00184,Nicotine
,21963483,Concentrations,"Concentrations of NIC, COT and NNIC in the remaining whole brain (RWhB) were 183.3±68.0, 130.0±14.1 and 46.7±10.3 pg/mg, respectively.",Simultaneous quantification of nicotine and metabolites in rat brain by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21963483/),p,183.3,264127,DB00184,Nicotine
,21963483,Concentrations,"Concentrations of NIC, COT and NNIC in the remaining whole brain (RWhB) were 183.3±68.0, 130.0±14.1 and 46.7±10.3 pg/mg, respectively.",Simultaneous quantification of nicotine and metabolites in rat brain by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21963483/),p,130.0,264128,DB00184,Nicotine
,21963483,Concentrations,"Concentrations of NIC, COT and NNIC in the remaining whole brain (RWhB) were 183.3±68.0, 130.0±14.1 and 46.7±10.3 pg/mg, respectively.",Simultaneous quantification of nicotine and metabolites in rat brain by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21963483/),p,46.7,264129,DB00184,Nicotine
,21963483,concentrations,"However, and in contrast to brain tissues, COT concentrations in plasma were significantly higher than were those of NIC (194.6±18.6 ng/mL versus 52.7±12.9 ng/mL).",Simultaneous quantification of nicotine and metabolites in rat brain by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21963483/),[ng] / [ml],194.6,264130,DB00184,Nicotine
,21963483,concentrations,"However, and in contrast to brain tissues, COT concentrations in plasma were significantly higher than were those of NIC (194.6±18.6 ng/mL versus 52.7±12.9 ng/mL).",Simultaneous quantification of nicotine and metabolites in rat brain by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21963483/),[ng] / [ml],52.7,264131,DB00184,Nicotine
,16413604,elimination half-life,"The elimination half-life of methamphetamine was approximately 12 h, and selegiline did not alter clearance of methamphetamine.",A comprehensive assessment of the safety of intravenous methamphetamine administration during treatment with selegiline. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16413604/),h,12,265657,DB00184,Nicotine
,28283988,Apparent nicotine clearance,Apparent nicotine clearance was typically 0.407 L/min in males and 26% higher in females (68% inter-individual variability).,Nicotine Population Pharmacokinetics in Healthy Adult Smokers: A Retrospective Analysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28283988/),[l] / [min],0.407,266174,DB00184,Nicotine
,28283988,initial,"The typical initial and terminal half-lives were 1.35 and 17 h, respectively.",Nicotine Population Pharmacokinetics in Healthy Adult Smokers: A Retrospective Analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28283988/),h,1.35,266175,DB00184,Nicotine
,28283988,terminal half-lives,"The typical initial and terminal half-lives were 1.35 and 17 h, respectively.",Nicotine Population Pharmacokinetics in Healthy Adult Smokers: A Retrospective Analysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28283988/),h,17,266176,DB00184,Nicotine
,27940077,Cmax,"When measured up to 4 h in venous blood, the training dose resulted in the following mean pharmacokinetic parameters: nicotine Cmax = 71.7 ng/ml, t1/2 = 116 min, and clearance = 6.25 ml/min/kg; cotinine Cmax = 191 ng/ml; and 3OH-cotinine Cmax = 63 ng/ml.",The discriminative stimulus effects of i.v. nicotine in rhesus monkeys: Pharmacokinetics and apparent pA2 analysis with dihydro-β-erythroidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27940077/),[ng] / [ml],71.7,268712,DB00184,Nicotine
,27940077,t1/2,"When measured up to 4 h in venous blood, the training dose resulted in the following mean pharmacokinetic parameters: nicotine Cmax = 71.7 ng/ml, t1/2 = 116 min, and clearance = 6.25 ml/min/kg; cotinine Cmax = 191 ng/ml; and 3OH-cotinine Cmax = 63 ng/ml.",The discriminative stimulus effects of i.v. nicotine in rhesus monkeys: Pharmacokinetics and apparent pA2 analysis with dihydro-β-erythroidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27940077/),min,116,268713,DB00184,Nicotine
,27940077,clearance,"When measured up to 4 h in venous blood, the training dose resulted in the following mean pharmacokinetic parameters: nicotine Cmax = 71.7 ng/ml, t1/2 = 116 min, and clearance = 6.25 ml/min/kg; cotinine Cmax = 191 ng/ml; and 3OH-cotinine Cmax = 63 ng/ml.",The discriminative stimulus effects of i.v. nicotine in rhesus monkeys: Pharmacokinetics and apparent pA2 analysis with dihydro-β-erythroidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27940077/),[ml] / [kg·min],6.25,268714,DB00184,Nicotine
,27940077,Cmax,"When measured up to 4 h in venous blood, the training dose resulted in the following mean pharmacokinetic parameters: nicotine Cmax = 71.7 ng/ml, t1/2 = 116 min, and clearance = 6.25 ml/min/kg; cotinine Cmax = 191 ng/ml; and 3OH-cotinine Cmax = 63 ng/ml.",The discriminative stimulus effects of i.v. nicotine in rhesus monkeys: Pharmacokinetics and apparent pA2 analysis with dihydro-β-erythroidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27940077/),[ng] / [ml],191,268715,DB00184,Nicotine
,27940077,Cmax,"When measured up to 4 h in venous blood, the training dose resulted in the following mean pharmacokinetic parameters: nicotine Cmax = 71.7 ng/ml, t1/2 = 116 min, and clearance = 6.25 ml/min/kg; cotinine Cmax = 191 ng/ml; and 3OH-cotinine Cmax = 63 ng/ml.",The discriminative stimulus effects of i.v. nicotine in rhesus monkeys: Pharmacokinetics and apparent pA2 analysis with dihydro-β-erythroidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27940077/),[ng] / [ml],63,268716,DB00184,Nicotine
,27940077,ED50,The ED50 value of nicotine to produce discriminative stimulus effects was 0.013 mg/kg.,The discriminative stimulus effects of i.v. nicotine in rhesus monkeys: Pharmacokinetics and apparent pA2 analysis with dihydro-β-erythroidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27940077/),[mg] / [kg],0.013,268717,DB00184,Nicotine
,27940077,ED50,"Epibatidine and varenicline increased drug-lever responding to 97% and 95%, respectively (ED50 values = 0.00015 and 0.031 mg/kg, respectively), whereas cocaine, midazolam, and morphine produced no more than 28% drug-appropriate responding.",The discriminative stimulus effects of i.v. nicotine in rhesus monkeys: Pharmacokinetics and apparent pA2 analysis with dihydro-β-erythroidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27940077/),[mg] / [kg],0.00015,268718,DB00184,Nicotine
,27940077,ED50,"Epibatidine and varenicline increased drug-lever responding to 97% and 95%, respectively (ED50 values = 0.00015 and 0.031 mg/kg, respectively), whereas cocaine, midazolam, and morphine produced no more than 28% drug-appropriate responding.",The discriminative stimulus effects of i.v. nicotine in rhesus monkeys: Pharmacokinetics and apparent pA2 analysis with dihydro-β-erythroidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27940077/),[mg] / [kg],0.031,268719,DB00184,Nicotine
,27940077,apparent pA2,DHβE (0.1 and 0.32) produced rightward shifts of the nicotine and varenicline dose-response functions; Schild plots fitted through individual data resulted in slopes that were not different from unity; the apparent pA2 calculated for DHβE did not significantly differ in the presence of nicotine (6.58) or varenicline (6.45).,The discriminative stimulus effects of i.v. nicotine in rhesus monkeys: Pharmacokinetics and apparent pA2 analysis with dihydro-β-erythroidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27940077/),,6.58,268720,DB00184,Nicotine
,27940077,apparent pA2,DHβE (0.1 and 0.32) produced rightward shifts of the nicotine and varenicline dose-response functions; Schild plots fitted through individual data resulted in slopes that were not different from unity; the apparent pA2 calculated for DHβE did not significantly differ in the presence of nicotine (6.58) or varenicline (6.45).,The discriminative stimulus effects of i.v. nicotine in rhesus monkeys: Pharmacokinetics and apparent pA2 analysis with dihydro-β-erythroidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27940077/),,6.45,268721,DB00184,Nicotine
,9084459,time to reach peak concentration,"With the exception of nicotine time to reach peak concentration, which was longer in patients (median of 60 minutes compared with 45 minutes; p < 0.005), other comparisons between normal subjects and patients showed no statistically significant difference, although there was considerable inter-subject variation.",Pharmacokinetics of nicotine carbomer enemas: a new treatment modality for ulcerative colitis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9084459/),min,60,270129,DB00184,Nicotine
,9084459,time to reach peak concentration,"With the exception of nicotine time to reach peak concentration, which was longer in patients (median of 60 minutes compared with 45 minutes; p < 0.005), other comparisons between normal subjects and patients showed no statistically significant difference, although there was considerable inter-subject variation.",Pharmacokinetics of nicotine carbomer enemas: a new treatment modality for ulcerative colitis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9084459/),min,45,270130,DB00184,Nicotine
,9084459,Maximum concentration,"Maximum concentration of nicotine, 8.1 +/- 3.5 ng/ml, in the 16 subjects occurred after a median of 60 minutes (range, 30 to 180 minutes); maximum cotinine concentrations of 60.4 +/- 11.5 ng/ml occurred after 4 hours.",Pharmacokinetics of nicotine carbomer enemas: a new treatment modality for ulcerative colitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9084459/),[ng] / [ml],8.1,270131,DB00184,Nicotine
,9084459,maximum cotinine concentrations,"Maximum concentration of nicotine, 8.1 +/- 3.5 ng/ml, in the 16 subjects occurred after a median of 60 minutes (range, 30 to 180 minutes); maximum cotinine concentrations of 60.4 +/- 11.5 ng/ml occurred after 4 hours.",Pharmacokinetics of nicotine carbomer enemas: a new treatment modality for ulcerative colitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9084459/),[ng] / [ml],60.4,270132,DB00184,Nicotine
,12607628,elimination half-life,BP is rapidly absorbed after oral administration and demonstrates biphasic elimination with an elimination half-life of 11 - 14 hours.,Bupropion: pharmacological and clinical profile in smoking cessation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12607628/),h,11 - 14,271070,DB00184,Nicotine
,16809797,terminal half-life (t1/2),"Cmax of TC-1734 was reached around 1 to 2 hours postdose, and mean terminal half-life (t1/2) ranged from 3 to 5.3 hours (single doses) and from 2.7 to 8.8 hours (repeated doses).","Pharmacokinetics and safety profile of ispronicline (TC-1734), a new brain nicotinic receptor partial agonist, in young healthy male volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16809797/),h,3 to 5.3,271358,DB00184,Nicotine
,16809797,terminal half-life (t1/2),"Cmax of TC-1734 was reached around 1 to 2 hours postdose, and mean terminal half-life (t1/2) ranged from 3 to 5.3 hours (single doses) and from 2.7 to 8.8 hours (repeated doses).","Pharmacokinetics and safety profile of ispronicline (TC-1734), a new brain nicotinic receptor partial agonist, in young healthy male volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16809797/),h,2.7 to 8.8,271359,DB00184,Nicotine
,9164577,K1-,"GTS-21 bound to human alpha 4 beta 2 nAChR (K1-20 nM) 100-fold more potently than to human alpha 7 nAChR, and was 18- and 2-fold less potent than (-)-nicotine at human alpha 4 beta 2 and alpha 7 nAChR, respectively.",Functional characterization of the novel neuronal nicotinic acetylcholine receptor ligand GTS-21 in vitro and in vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9164577/),nM,20,272379,DB00184,Nicotine
,9164577,EC50,"GTS-21 stimulated [5H]dopamine release from rat striatal slices with an EC50 of 10 +/- 2 microM (250-fold less potent and 70% as efficacious as (-)-nicotine), an effect blocked by the nAChR antagonist dihydro-beta-erythroidine.",Functional characterization of the novel neuronal nicotinic acetylcholine receptor ligand GTS-21 in vitro and in vivo. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9164577/),μM,10,272380,DB00184,Nicotine
